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dipivoxil  (ADV) and pegylated  interferon alpha  (PEG‐ 
for  the  treatment  of  chronic  hepatitis B  (CHB). 
Data sources: Thirteen bibliographic databases 
were  searched  including  MEDLINE,  EMBASE  and 




PEG‐‐2a  and  PEG‐‐2b with  currently  licensed 
treatments  for  CHB,  including  non‐pegylated  interferon 
alpha  (IFN‐) and  lamivudine  (LAM), were  included. 
Outcomes  included  biochemical,  histological  and 
virological  response  to  treatment, drug  resistance  
and adverse effects. A  systematic  review of economic 



























gains  in quality‐adjusted  life expectancy.  In a UK study, 










cost‐effective  of  79%  at  a willingness‐to‐pay  threshold 
of  £20,000  per QALY,  and  86%  at  a willingness‐to‐pay 
threshold  of  £30,000  per  QALY. 
Conclusions: Both ADV and PEG‐are beneficial for 
patients with CHB  in  terms of  suppressing viral  load, 
reducing  liver damage‐associated biochemical  activity, 
inducing  HBeAg  seroconversion,  and  reducing  liver 
fibrosis and necroinflammation. The effects of  long‐ 
term  treatment with ADV are  generally durable, with 
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This short report is an update and extension of a 
technology assessment report published in 2006 on 
the clinical effectiveness and cost-effectiveness of 
adefovir dipivoxil (ADV) and pegylated interferon 
alpha (PEG-) for the treatment of chronic  
hepatitis B (CHB). 
 
Hepatitis B is an infectious disease caused by 
the hepatitis B virus (HBV). If not successfully 
treated, it can lead to progressive liver damage, 
including cirrhosis, hepatocellular carcinoma and 
death. Patients with CHB may be HBeAg positive 
or HBeAg negative, depending on the presence 
or absence of the ‘e’ antigen. It is estimated that 
around 180,000 people (0.3%) in the UK are 
chronically infected, with around 7000 new cases 
each year, primarily from immigrants, most of 
whom are asymptomatic. 
  
Methods 
Assessment of clinical 
effectiveness 
We searched for studies of the clinical effectiveness 
of adefovir dipivoxil, pegylated interferon alpha- 
2a (PEG--2a) and pegylated interferon alpha-2b 
(PEG--2b) (note that the latter was not included 
in the original report). Searches were run from the 
beginning of 2005 to September 2007. Thirteen 
bibliographic databases were searched, including 
MEDLINE, EMBASE and the Cochrane Library.  
All studies were screened against a set of pre- 
specified inclusion criteria. For the clinical 
effectiveness review, we included randomised 
controlled trials (RCTs) which compared  
ADV, PEG--2a, and PEG--2b with currently 
licensed treatments for CHB, including the 
immunomodulatory drug non-pegylated interferon 
alpha (IFN-) and the nucleoside analogue 
lamivudine (LAM).  
Outcomes included biochemical (alanine 
aminotransferase, ALT), histological (liver 
fibrosis and necroinflammation) and virological 
[HBV deoxyribonucleic acid (DNA)] response to 
treatment, drug resistance and adverse effects. 
The trials were reviewed in a narrative synthesis 
but meta-analysis was not undertaken because of 
heterogeneity in the interventions and comparators 
evaluated. 
 
Assessment of cost-effectiveness 
A systematic review of economic evaluations of 
antiviral treatments for CHB was conducted. In 
addition, the economic model devised for our 
previous report was updated using utility values 
based on a recent study eliciting health-state 
valuations from CHB-infected patients. The 
model was also updated to account for changes 
in methodological guidance on discount rates for 
costs and outcomes. Health-state and treatment 
costs were inflated to 2006–7 prices. Evidence for 
the clinical effectiveness of PEG--2b was used 
in the model to estimate the cost-effectiveness of 




Literature searches yielded a total of 735 articles. 
Of these, 653 were excluded on the basis of title 
and, where available, abstract. Eighty-two papers 
were retrieved for detailed screening and eight 
randomised controlled trials (RCTs) were included 
in the systematic review:  
• Three evaluated ADV, one of which was a 
long-term follow-up of a trial included in our 
original assessment report. In two trials ADV 
was compared with placebo, and in a third 
ADV was compared with ADV added to LAM in 
patients with LAM resistance. 
• Four evaluated PEG--2b. In two of these PEG- 
-2b was combined with LAM and compared 
with either PEG--2b monotherapy or LAM 
monotherapy. Another compared three 
staggered regimens of PEG--2b combined 
with LAM. The fourth trial compared PEG-- 
2b monotherapy with IFN-. 
• A further PEG--2b RCT was included from 
our original literature search database (but not 








was not in the scope of the review at that time). 
This RCT compared PEG--2b combined with 
LAM with PEG--2b monotherapy. 
• No RCTs of PEG--2a were identified. 
HBeAg seroconversion, favouring combination 
therapy in one trial. For liver histology either there 
was no significant difference between groups or no 
statistical tests were performed. 
The trials varied in terms of aims, size and design For the comparison between PEG--2b and IFN-
characteristics. Five included only HBeAg-positive and the comparison between different staggered 
patients, with the remaining three including only regimens of the commencement of PEG--2b 
HBeAg-negative patients. and LAM, there were no statistically significant 
  differences between groups across the outcome 
Methodological quality also varied. Some measures where tests were reported. 
trials reported adequate blinding, allocation 
concealment and randomisation methods, while 
other trials either failed to report such details or 
Cost-effectiveness
were judged inadequate. The systematic review of cost-effectiveness studies 
  identified four relevant full economic evaluations, 
ADV  trials  in addition to one full economic evaluation 
In one trial there was a statistically significant identified and partially reviewed in our original 
difference between ADV and placebo in terms of assessment report. Two of the evaluations assessed 
ALT response and HBV DNA levels after 12 weeks, PEG--2a; the remainder assessed ADV. Four of 
favouring ADV. Following withdrawal of ADV after the five economic evaluations used Markov models, 
40 weeks, the proportion of patients exhibiting with lifetime horizons, while the other study used 
HBV DNA and ALT responses declined to levels a decision tree with a 4-year time horizon. State- 
similar to those experienced by patients who had transition diagrams in the evaluations were similar, 
received placebo. There was no viral resistance identifying the treatment aim as inducing HBeAg 
to ADV. The rate of adverse events and dose seroconversion for patients with HBeAg-positive 
discontinuations was low and generally similar CHB and viral suppression for patients with either 
between study groups. HBeAg-positive or HBeAg-negative CHB. 
In the trial that compared switching to ADV Economic evaluations of PEG--2a found that 
versus adding ADV to LAM in patients with LAM it was associated with increased treatment costs 
resistance there was a statistically significant but also gains in quality-adjusted life expectancy. 
difference in favour of the combination treatment In a UK study, the incremental cost-effectiveness 
in terms of zero resistance to ADV. For the other ratio (ICER) for PEG--2a was £10,444 per QALY 
outcomes there were no statistically significant gained compared with LAM. Evaluations of ADV 
differences between groups. found that LAM monotherapy was dominated, 
  while the ICER for ADV monotherapy compared 
A follow-up publication of an RCT included in our with  ‘doing  nothing’  was  $19,731($14,342– 
original assessment report, comparing ADV with $24,224) at 2005 prices. 
placebo in HBeAg-negative patients, reported 
generally sustained HBV DNA and ALT response A review of health-state utility values used in 
rates among those treated with ADV for 5 years. economic evaluations of antiviral treatments for 
Cumulative probabilities of resistance to ADV in CHB showed that widely varying values were used, 
the cohort varied from 11% to 29% depending on many of which were not specific to CHB patients. 
how resistance was defined. A recently published study reporting health- 
  state utilities for patients with CHB infection and 
PEG‐trials  for non-infected general population samples, 
Where statistical testing was reported, there were derived using the standard gamble technique, was 
statistically significant differences favouring PEG- identified and reviewed. 
-2b in combination with LAM compared with 
either one of the drugs given as monotherapy. This The ICERs generated by the update of our 
was the case for HBV DNA and ALT responses economic model were generally less favourable 
in two trials. However, another trial reported no than those reported in the original assessment 
significant differences between groups for these report. However, it appears that much of 







methodological guidance (i.e. discounting costs 
and outcomes at 3.5% rather than 6% and 1.5% 
respectively) rather than from changes in costs or 
health-state utilities.  
The sequential treatment strategies identified as 
optimal in our original report remained optimal 
in the updated model, i.e. interferon (pegylated 
or non-pegylated) followed by LAM, with ADV as 
salvage for patients who develop LAM resistance.  
The results of the updated analysis were generally 
robust to changes in deterministic sensitivity 
analysis. The most notable changes were in the 
ICER for the strategy including ADV as salvage 
therapy for patients who develop resistance to 
LAM, in some cases increasing the ICER beyond 
the threshold conventionally used to indicate 
cost-effectiveness in the context of NHS decision 
making.  
• The most influential structural assumption 
was excluding the possibility of HBeAg 
seroconversion (in HBeAg-positive CHB) in 
patients with compensated cirrhosis, which 
increased the ICER to £40,833 per QALY 
gained. 
• In terms of the baseline characteristics of the 
treated cohort, decreasing the proportion with 
HBeAg-positive CHB and increasing age were 
associated with less favourable ICERs. 
• The most influential parameter values related 
to the gain in utility associated with HBeAg 
seroconversion and loss of the surface antigen 
(HBsAg). This affected the ICERs for all 
strategies, but was most notable for the strategy 
including ADV as salvage for patients who 
develop resistance to LAM. If there is no utility 
gain for HBeAg seroconversion or loss of 
HBsAg, the ICER increases to £31,114.  
In a probabilistic sensitivity analysis the same 
sequence of treatments was identified as optimal. 
However, the strategy including ADV as salvage 
becomes optimal only above a willingness-to-  
pay threshold of £27,000 per QALY. This is at 
the upper limit of the range of ICERs regarded 
as cost-effective from an NHS decision-making 
perspective. Interferon (conventional or pegylated) 
followed by LAM is optimal for a willingness to  
pay of £9000–£26,000, compared with a range 
of £5000–£11,500 in our previous report. As 
discussed, much of this difference arises from 
changes in the practice of discounting rather than 
changes to input values in the model. 
The ICER for PEG--2b, compared with IFN--2b, 
in patients with HBeAg-positive CHB was £9169, 
based on the results of a clinical trial of 24 weeks 
of interferon treatment. The trial did not include a 
placebo arm, so no ICER for PEG--2b compared 
with best supportive care was estimated. Results 
were generally robust to changes in deterministic 
sensitivity analysis.  
• Increasing age of the cohort and lower utility 
gains from HBeAg seroconversion or loss of 
HBsAg were associated with less favourable 
ICERs. 
• Alternative discount rates (6% for costs and 
1.5% for outcomes, as in our previous report, 
or 0% for both costs and outcomes) and a 
reduction in cost for PEG--2b were associated 
with more favourable ICERs. 
• All ICERs in the one-way sensitivity analyses 
were below the threshold conventionally 
deemed as cost-effective.  
In a probabilistic sensitivity analysis, PEG--2b had 
a probability of being cost-effective (compared with 
IFN--2b) of 79% at a willingness-to-pay threshold 
of £20,000 per QALY, and 86% at a willingness-to- 




Overall, the evidence from RCTs suggests that 
the effects of long-term treatment with ADV are 
generally durable, with relatively low rates of 
resistance. It is also apparent that beneficial effects 
are lost once ADV is withdrawn. Furthermore, in 
LAM-resistant HBeAg-negative patients there were 
no significant differences between adding ADV 
to ongoing LAM or switching from LAM to ADV, 
except for viral resistance where the combination 
was more favourable.  
PEG--2a was associated with some benefit in 
terms of virological and biochemical response, 
HBeAg seroconversion and liver histology, relative 
to comparators. However, not all differences were 
statistically significant, and often significance tests 
were not reported at all. Consequently, there are 
uncertainties regarding the clinical effectiveness of 
this drug across different outcomes relevant to the 
control of CHB.  
In terms of cost-effectiveness, optimum treatment 
strategies include IFN-or PEG-followed by 









resistant to LAM. In most cases, cost-effectiveness 
estimates were within acceptable ranges.  
Further high-quality RCTs are required to assess 
the durability of long-term antiviral treatment, 
optimum treatment of patients with LAM 
resistance, and the clinical effectiveness and cost- 
effectiveness of initiating treatment with nucleoside 





















Description of underlying 
health problem 
Hepatitis B is an infectious disease caused by the 
hepatitis B virus (HBV), and was first identified  
in 1965. Key routes of transmission include 
sexual contact (via exposure to blood, saliva and 
other body fluids), injecting drug use, and from 
mother to child (particularly in South-east Asia). 
In health-care workers, needlestick injuries are 
also a relatively rare source of transmission. Some 
patients with haemophilia in the UK have been 
infected via contaminated blood products [as well 
as being infected with the hepatitis C virus (HCV)]. 
 
The virus infects cells in the liver (hepatocytes) 
and the immune system will at some point mount 
a response to try to remove the infection (in some 
cases after several years). If untreated, HBV can 
result in long-term complications such as cirrhosis 
and liver cancer (hepatocellular carcinoma, HCC). 
Carriers of the virus can remain asymptomatic for 
many years before presenting with symptoms of 
chronic liver disease.  
In acute infection, the majority of cases are self- 
limiting within 6 months, with patients developing 
lasting immunity to reinfection as the virus (surface 
antigen) is cleared from the blood and liver, 
although viral DNA can be detected in many cases.  
There may be no or few symptoms (about 70% 
of patients are asymptomatic), and treatment is 
generally not indicated.  
Chronic hepatitis B (CHB) results from an 
inadequate immune response to the primary 
infection, where viral replication continues and 
there is continuing presence of the surface antigen 
(HBsAg). It can follow acute hepatitis or be 
transmitted vertically from mother to baby (in the 
latter case there may be no acute infection). The 





HBeAg-positive CHB (also referred to as ‘wild 
type’ CHB) is, for many, the first stage of chronic 
disease. This form of the disease prevails in  
Europe and North America. The first stage is the 
‘immunotolerant’ phase, during which the immune 
system does not actively fight the virus, and this 
may last for a number of years.1 Those who acquire 
the disease as neonates or in early childhood will 
undergo this phase, but adults and those infected 
during adolescence generally will not. During the 
immunotolerant phase, HBV deoxyribonucleic acid 
(DNA) levels are increased but aminotransferase 
levels remain normal. Treatment is not indicated in 
this phase.2 
 
Progression to the ‘immunoactive’ phase (also 
referred to as the ‘immune clearance phase’) of 
chronic HBeAg-positive disease, whereby the 
immune system is actively fighting the virus, is 
characterised by HBV DNA replication and an 
increase in alanine aminotransferase (ALT) levels 
(ALT being an enzyme that indicates inflammation 
of the liver). Symptoms may appear during 
this phase, and ‘flares’ (short-lived rises in ALT 
levels) of aminotransferases may occur before 
seroconversion from HBeAg to anti-HBe in some 
patients.3 Treatment, the goal of which is to induce 
HBeAg seroconversion in the first instance, is 
indicated in this phase.2  
HBeAg seroconversion results in the disease 
progressing either to an inactive carrier state (also 
referred to as the ‘low-’ or ‘non-replicative state’  
or ‘immune control phase’) or to the HBeAg- 
negative form of the disease. Between 50% and 
70% of patients with elevated aminotransferases 
spontaneously seroconvert within 5–10 years of 
diagnosis, with a mean annual rate of 8–15% in 
Western countries.3 HBeAg seroconversion is more 
likely to occur in older people, females and those 
with high aminotransferase levels. A proportion 
of seroconverted patients will also reacquire the 
e antigen (i.e. become HBeAg positive again), 
effectively reactivating the disease. Although, for 
most patients, HBeAg seroconversion results in 
transition to the inactive carrier state, between 1% 
and 5% of patients progress to the ‘immune escape 
phase’ whereby a pre-core viral mutation emerges.2 
This is characterised by undetectable HBeAg and 
detectable anti-HBe levels, high serum HBV DNA 








The low- or non-replicative state is characterised 
by low HBV DNA levels and normal ALT. Unless 
cirrhosis is present, this stage usually has a benign 
prognosis, but around 3% of patients per annum 




chronic hepatitis B 
HBeAg-negative CHB (also known as ‘pre-core 
mutant’ or ‘variant’ hepatitis B) was identified 
relatively recently. It is a variant HBV strain 
carrying a mutation within the pre-core region of 
the HBV genome that permits viral replication 
but prevents production of HBeAg (or a mutation 
within the core region of the genome that 
diminishes HBeAg expression).4 Although some 
patients acquire HBeAg-negative infection on or 
following HBeAg seroconversion (as mentioned 
above), many develop the variant at an earlier stage 
or from the outset.  
HBeAg-negative infection, common in 
Mediterranean areas and South-east Asia, 
is considered to be the most severe form of 
the disease. It is characterised by raised (but 
fluctuating) ALT and detectable HBV DNA levels.2 
There are three main patterns of ALT activity: 
recurrent flares with normalisation in between; 
recurrent flares with persistently abnormal 
serum aminotransferase levels in between; and 
persistently abnormal ALT without flares.3 
 
HBsAg seroconversion 
Around 0.5–2% of people with CHB (0.05–0.08% 
in Asia) each year lose the surface antigen  
(HBsAg) and develop antibodies (anti-HBs), 
thereby undergoing HBsAg seroconversion. This  
is most common in the year following HBeAg 
seroconversion (although patients can also 
seroconvert from the immunotolerant phase) and 
signifies resolution of chronic infection. Although 
HBsAg seroconversion is believed to be a relatively 
rare occurrence, it has been recommended that 
future clinical trials use it as an outcome measure 
as it represents the ultimate goal of therapy.2 
 
Long-term complications 
People with CHB, in common with chronic 
hepatitis C, are at increased risk of progressing 
to long-term complications, including cirrhosis 
(scarring) of the liver, decompensated liver disease 
and/or HCC. The risk of progression varies with 





Evidence suggests that 2–5.5% of HBeAg-positive 
people and 8–10% of those who are negative 
progress to cirrhosis annually.3 Decompensated 
liver disease occurs when the liver can no longer 
compensate for scarred tissue. It is characterised 
by ascites (fluid in the peritoneal cavity), variceal 
bleeding and hepatic encephalopathy, and is 
associated with irreversible liver failure, requiring 
liver transplantation. Death from liver disease  
and HCC is common in CHB. It is estimated that 
there are more than 1200 new cases of HCC in  
the UK each year, of which 430 are caused by viral 
hepatitis.  
The 5-year mortality rate for CHB without cirrhosis 
is 0–2%, but this increases to 14–20% for those 
with compensated cirrhosis and 70–80% after the 
occurrence of decompensation.3 
  
Incidence and prevalence 
 
Approximately 400 million people worldwide 
are infected with chronic HBV, although levels 
vary geographically.5 In North-western Europe, 
North America and Australia there is a low level of 
endemic HBV, and the virus is usually transmitted 
by needle sharing among intravenous drug users 
(IDUs) and by sexual transmission. High levels 
of infection are found in Africa and Asia, where 
the virus is usually transmitted perinatally or 
during early childhood. The UK is considered 
to be a low prevalence country, with around 
156,000 people in England and Wales infected 
with CHB6 (180,000/0.3% in the UK) and around 
7000 estimated new chronic cases every year 
(mostly from immigration of established HBV 
carriers, many of whom are thought to be HBeAg 
negative and in the immunotolerant phase, and 
thus not currently symptomatic). The Hepatitis B 
Foundation recently estimated that the prevalence 
of CHB in the UK may have increased to 325,000 
and is thought likely to increase further as a 
consequence of increasing rates of immigration 





A safe and effective vaccine for hepatitis B has been 
available since 1982 and many countries operate a 
universal vaccination programme for newborns or 
adolescents. However, the UK has not introduced 
such a policy, instead offering selective vaccination 
to key risk groups (e.g. men who have sex with  






Morbidity and quality of life 
The impact of CHB on quality of life in the early 
stages of disease is not thought to be great. Many 
people do not know that they are infected and 
consequently may not present to health services for 
many years until symptoms of liver disease become 
evident. 
 
However, quality of life becomes significantly 
impaired as the disease progresses to cirrhosis, 
decompensated liver disease and HCC.8 Patients 
who seroconvert into the low- or non-replicative 
state are thought to have a relatively good quality 
of life. There is evidence to suggest that quality of 





There are two modes of antiviral treatment for 
CHB:  
1. Short-term or finite, circumscribed therapy 
with interferon alpha (IFN-). The goal is   
to achieve an immune response in terms of 
HBeAg seroconversion (for patients who are 
HBeAg positive), suppression of HBV DNA 
and, where possible, HBsAg seroconversion. 
This mode of treatment is a first-line attempt 
to ‘switch’ the immune system into clearing 
the infection or into remission. Although 
IFN-appears to be commonly used in this 
scenario, some clinicians may use a nucleotide/ 
nucleoside  analogue. 
2. Long-term maintenance treatment for patients 
who have failed IFN-or for whom disease has 
advanced such that IFN-is contraindicated. 
This would usually involve lamivudine (LAM), 
a nucleoside analogue. This mode of treatment 
may be particularly suitable for those HBeAg- 
negative patients with high levels of HBV 
DNA and ALT. In these patients, long-term 
suppression of HBV replication with either 
nucleoside or nucleotide analogues will be 
necessary until the infected cells have been 
eliminated. The half-life of these cells may be 
10 years or more.11 Reducing levels to ‘normal’ 
will likely limit disease progression. 
 
IFN-was used as first-line treatment of CHB 
for a number of years. Versions available include 
IFN--2a (Roferon-A®; Hoffman–La Roche) and 
IFN--2b (IntronA®, Viraferon®; Schering–Plough). 
In 1998, LAM (Epivir, Zeffix; GlaxoSmithKline),  
an oral nucleoside reverse transcriptase inhibitor, 
was licensed for the treatment of CHB. In the last  
5 years, newer agents have been licensed, such as 
adefovir dipivoxil (ADV) and the pegylated form of 
IFN-(PEG-).  
Adefovir dipivoxil (Hepsera®; Gilead Sciences), 
a prodrug of adefovir, was the first licensed 
nucleotide analogue for the treatment of CHB. It 
is currently licensed in the UK for CHB infection 
with either compensated liver disease with evidence 
of active viral replication, persistently elevated 
serum ALT levels and histological evidence 
of active liver inflammation and fibrosis, or 
decompensated liver disease. The recommended 
dose is 10 mg per day, taken orally. 
 
A newer ‘pegylated’ derivative of IFN-has 
become available recently. Pegylation involves 
the attachment of an inert polyethylene glycol 
polymer to the IFN-molecule to produce a larger 
molecule with a prolonged half-life. Pegylation 
prolongs the biological effect and thus fewer 
injections are necessary.  
Two versions are available: (1) 40 kD PEG--2a 
(Pegasys®; Hoffman–La Roche) and (2) 12 kD PEG-
-2b (PegIntron®, ViraferonPeg®; Schering– 
Plough). Only the former is currently licensed in 
the UK. 
 
Recently licensed drugs for CHB include 
nucleoside analogues entecavir (Baraclude®; 
Bristol–Myers Squibb) and telbivudine (Sebivo®; 
Novartis). These are not within the scope of the 
current report, but have undergone appraisal by 
the National Institute for Health and Clinical 
Excellence (NICE). 
  
Current service provision 
 
In 2006 NICE issued guidance to the health service 
in England and Wales on the use of PEG--2a 
and ADV, based on an independent technology 
assessment report (TAR).12  The guidance 
recommends:  
• PEG--2a as an option for the initial treatment 
of adults with CHB, within its licensed 
indications. 
• ADV as an option for the treatment of adults 
with CHB within its licensed indications if: 
– treatment with IFN-or PEG--2a has 
been unsuccessful, or 
– a relapse occurs after successful initial 
treatment, or 







poorly tolerated or contraindicated. 
 
The guidance also states that ADV should not 
normally be given before treatment with LAM. It 
may be used either alone or in combination with 
LAM when:  
• treatment with LAM has resulted in viral 
resistance, or 
• LAM resistance is likely to occur rapidly (e.g. 
in the presence of highly replicative hepatitis  
B disease) and development of LAM resistance 
is likely to have an adverse outcome (e.g. if 
a flare of the infection is likely to precipitate 





Our previous assessment report, which 
underpinned this guidance, was produced in 
early 2005.12  The current report is an update 
of the assessment for the National Institute for 
Health Research (NIHR) Health Technology 
Assessment (HTA) Programme (and is not intended 
to inform any NICE appraisal). The aim of 
the report is to update the systematic review of 
clinical effectiveness and the economic evaluation 
conducted in the original report. It also expands 
on the original report by including PEG--2b, 
which was not included in NICE’s appraisal 













he methods used in this update are similar  
to those reported in the original assessment12 
(which can be downloaded free of charge from 
www.hta.ac.uk). A protocol outlining the scope 
and methods was published prior to the start of 
the project. This report was commissioned by the 
HTA programme as a ‘short technology assessment 
report’. Consequently the time and resources 
allocated to it were less than those allocated to the 
original report, which was commissioned as a ‘full 




A sensitive search strategy was developed, tested 
and refined by an information scientist. Specific 
searches were conducted to identify studies of 
clinical effectiveness and cost-effectiveness. The 
strategies were the same as those used in our 
previous assessment report;12 please refer to that 
report for further detail. 
 
The strategies were applied to the following 
electronic databases: 
 
• Cochrane Systematic Reviews Database 
• Cochrane Central Register of Controlled Trials 
• NHS Centre for Reviews and Dissemination 
(CRD) (University of York) databases: 
– DARE (Database of Abstracts of Reviews of 
Effects) 
– Health Technology Assessment (HTA) 
database 
– NHS EED (Economic Evaluations 
Database) 
• MEDLINE (Ovid) 
• PREMEDLINE 
• EMBASE (Ovid) 
• EconLit (Silver Platter) 
• National Research Register 
• ISI Web of Science – Science Citation Index 
• ISI Proceedings 
• ISI BIOSIS 
• Clinical trials.gov 
• Current Controlled Trials. 
 
In our original report, searches were carried out 
for the period 1995/1996 to April 2005. In this 
update they were run from the beginning of 2005 
to September 2007. All searches were limited to the 
English language.  
We rescreened our original bibliographic database 
to identify any relevant trials of PEG--2b. 
Although not included in our original report, our 
search strategies were designed to identify studies 
of PEG--2a as well as PEG--2b. 
  
Inclusion and 
exclusion  criteria 
Studies identified by the search strategy were 
assessed for inclusion in two stages. Firstly, the 
titles and abstracts of all identified studies were 
screened for possible inclusion by one reviewer, 
and a random sample of 10% of these were 
checked by a second reviewer. Any differences in 
opinion between reviewers were discussed and 
a final decision was reached. Secondly, full-text 
versions of relevant papers were retrieved, and an 
inclusion worksheet was applied independently 
by two reviewers. Any differences in judgement at 
either stage were resolved through discussion. The 
level of agreement between reviewers on selection 
decisions was not assessed.  
The inclusion criteria, as specified in the study 
protocol, were as follows. (Note that the inclusion 
criteria for this update are the same as for the 
original assessment report with one key difference, 
i.e. studies of PEG--2b were eligible.) 
 
Interventions 
• Interventions (alone and in combination with 




• Comparators (alone and in combination with 














– best supportive care. 
 
Note that † = not indicated for patients with 
decompensated liver disease; * = intervention was 
not compared with itself. 
 
Patients 
• Adults with CHB infection, including HBeAg- 
positive and HBeAg-negative patients, with 
compensated or decompensated liver disease. 
 
Types of studies 
• Randomised controlled trials (RCTs) 
comparing the different drugs with placebo 
or each other or best supportive care. (Note 
that observational follow-up studies of RCTs 
included in our original report, where fully 
published, were eligible.) 
• Unpublished material, including studies 
published as abstracts or conference 
presentations were not included. 
• Full economic evaluations of the specified 
interventions in patients with CHB were 
included in the review of cost-effectiveness. 
 
Outcomes 
• The following outcome measures were 
included, where available: 
– survival 
– health-related quality of life 
– drug resistance 
– time to treatment failure 
– histological response (e.g. inflammation/ 
fibrosis – on biopsy) 
– biochemical response (e.g. liver function – 
aminotransferase) 
– virological response (e.g. seroconversion 
rate and viral replication – HBV DNA) 
– seroconversion (e.g. HBeAg loss/anti-HBe; 
HBsAg loss/anti-HBs) 
– adverse effects of treatment. 
  
Data extraction strategy 
 
Data were extracted from the included clinical 
effectiveness studies using a standardised template. 
Data extraction was undertaken by one reviewer 
and checked by a second, with any disagreements 
resolved through discussion. The level of 
agreement between reviewers was not assessed. The 
full data extraction forms of all the included studies 
can be seen in Appendix 1. 
  
Quality assessment strategy 
 
The methodological quality of RCTs was assessed 
using the CRD (University of York) criteria13 
(Appendix 1). Quality criteria were applied by 
one reviewer and checked by a second, with any 
disagreements resolved through discussion. 
  
Methods of analysis/synthesis 
 
A narrative synthesis was undertaken with the 
main results of the included clinical effectiveness 
and cost-effectiveness studies described 
qualitatively and in tabular form. A meta-analysis 
was not possible because of heterogeneity in the 
interventions and comparators evaluated by the 











Quantity and quality of 
research available 
Appendix 2 illustrates the inclusion and exclusion 
of studies over the various stages of screening, 
adapted from the QUOROM flowchart. The 
literature searches yielded a total of 735 articles. Of 
these, 653 were excluded on the basis of title and, 
where available, abstract. In many cases, studies 
were excluded on the basis of inappropriate study 
design (i.e. they were not RCTs). The remaining 
82 papers were retrieved for detailed screening. Of 
these, 65 were excluded, again primarily because 
of inappropriate study design. The remaining 17 
papers were included, and of these:  
• Four were follow-up publications relating to 
RCTs included in our original report.14–17 
These publications explored different aspects 
of the RCTs, such as predictors of treatment 
effect and subgroup analyses (e.g. based on 
genotype). As they do not report any updated 
findings on the main outcomes of the RCTs 
(e.g. long-term follow-up of HBV DNA, ALT, 
HBeAg seroconversion) they are not discussed 
further in the current report. 
• Thirteen papers described a total of seven 
studies which met the inclusion criteria for the 
review. Of these seven studies: 
– three were RCTs of ADV, one of which was 
a long-term follow-up of an RCT included 
in our original assessment report 
– four were RCTs of PEG--2b (no RCTs of 
PEG--2a were identified in the update 
search). 
• An additional RCT of PEG--2b from our 
original bibliographic database was also 
included in the review, to make a total of eight 
included RCTs.  
In summary, a total of eight RCTs met the inclusion 
criteria as described by 13 publications. These are 
the focus of this report. 
 
Characteristics of included 
studies from the update search 
For details of the RCTs included in our original 
report see Appendix 3. 
The key characteristics of the eight included 
studies, in terms of interventions, patients, 
methods and methodological quality, are described 
in the following sections. 
 
Characteristics of ADV studies 
Three fully published RCTs which evaluated 
treatment with ADV in CHB patients were 
identified and included.18–20  One trial, by Rapti 
and colleagues,18 recruited patients from a long- 
term open-label study of LAM monotherapy 
and evaluated the efficacy of switching to ADV 
monotherapy or adding ADV to LAM.18 Results 
at 12 and 24 months are reported but the study 
is ongoing. The second trial, by Zeng and 
colleagues,19 had three arms, with participants 
receiving either ADV or placebo for 12 weeks, ADV 
for 28 weeks and ADV or placebo for a further 12 






The rationale of both these studies was based 
upon the need for well-tolerated efficacious drugs 
that have a high barrier to the development 
of resistance, given that many CHB patients 
develop resistance to first-line LAM therapy. 
In the Rapti and colleagues study,18  this was 
investigated by evaluating long-term therapy for 
LAM-resistant patients by adding ADV to LAM, 
compared with switching to ADV. The trial by Zeng 
and colleagues19   tested the long-term antiviral 
efficacy and safety of ADV monotherapy, and also 
investigated the impact of cessation of therapy 
(placebo  phases).  
The third trial, by Hadziyannis and colleagues,20 
was a long-term follow-up of Study 438,21,22 an  
RCT that was included in our original assessment 
report.12 The trial compared ADV with placebo for 
48 weeks, at which point patients who had received 
ADV were re-randomised to ADV for a further 
48 weeks (n = 80, the ADV–ADV group) or to 
placebo (n = 40, the ADV–placebo group). Patients 
originally randomised to placebo switched to ADV 
(n = 60, the placebo–ADV group). At week 97, the 
ADV–placebo group discontinued treatment and all 







long-term safety and efficacy study until week 240. 
In the ADV–ADV group, 70 patients were analysed, 
while in the placebo–ADV group 55 patients were 
analysed. (Note that a 2005 publication reported 
interim results at week 144 for the ADV–ADV 
group, and results at week 96 for the ADV–placebo 
and placebo–ADV groups; these results are 
reported in our original assessment report,12  and 
can also be found in Appendix 1 of the current 
report). In all studies, the dose of ADV was 10 mg 
once daily.  
The key characteristics of the trials and the 
participants involved are shown in Table 1. The 
Rapti and colleagues trial18 was a relatively small, 
single-centre, open-label study carried out in 
Greece. The source of funding was not reported 
by the authors but the ADV capsules used in 
the study were supplied on a ‘compassionate 
basis’ by Gilead Sciences. In contrast, the trial by 
Zeng and colleagues19 was a larger, multicentre 
study incorporating both double-blind and open-
label phases, and was carried out across seven 
cities in China. The trial was supported by 
GlaxoSmithKline. The study by Hadziyannis and 
colleagues20 was supported by Gilead Sciences.  
The primary outcome measure in the Zeng and 
colleagues trial19 was the reduction in serum 
HBV DNA after 12 weeks’ treatment. The main 
secondary efficacy end point was the proportion 
of patients with ALT normalisation in week 12. 
Other secondary outcome measures included HBV 
DNA change from baseline at end of treatment, 
the proportion of subjects with HBV DNA < 105 
copies/ml and with undetectable HBV DNA, ALT 
normalisation at end of treatment, HBeAg loss  
and seroconversion, and health-related quality of 
life. Rapti and colleagues18 did not specify which  
of their outcomes were primary and secondary 
measures, but reported median HBV DNA levels 
and non-detectability of HBV DNA at 6, 12 and 24 
months. Biochemical measures reported included 
ALT change from baseline and ALT normalisation. 
Both studies reported adverse effects. The 
outcomes reported by Hadziyannis and colleagues20 
were HBV DNA, ALT, histological response, HBsAg 
seroconversion and resistance to ADV.  
Both trials included only adult patients, although 
the median age reported varied between trials 
[median 56 years (range 39–76)18 versus median 
30 years (range 17–61)19]. Participants were 
predominantly male in both trials, with the 
proportion ranging from 83% to 93%. Patients 






negative while those in the Zeng and colleagues 
trial19 were HBeAg positive. In terms of ethnicity, 
one trial included 100% white Europeans,18 in 
another all patients were Chinese,19 and in the 
third around two-thirds were described as white, 
with the remaining patients being Asian or black.20  
The majority of patients across the two trials had 
received previous antiviral therapy for CHB. All 
patients in the Rapti and colleagues trial18 had 
previously received LAM [for a median duration 
of 32 months (range 12–84)] and exhibited 
genotypical LAM resistance with virological and 
clinical breakthroughs. Prior to enrolment in the 
long-term LAM study, none had received any other 
antiviral drug other than IFN-.  
In the Zeng and colleagues trial,19 approximately 
one-third of patients had previously received 
treatment with LAM, one-third had previously 
received treatment with traditional Chinese 
medicines and one-third were treatment naïve. All 
patients in the included trials had compensated 
liver disease. In the Zeng and colleagues trial,19  
no patients had cirrhosis, while in the Rapti and 
colleagues trial18 about one-third of patients had 
histological evidence of cirrhosis. None of the 
patients had co-infection with hepatitis C, hepatitis 
D or HIV, or any co-morbidities.  
Table 2 provides an overview of the methodological 
quality of two of the ADV RCTs. The third, the 
open-label follow-up study, is discussed below.  
The two RCTs varied in terms of methodological 
quality. The trial by Zeng and colleagues19 
generally appeared to be of better quality than 
the trial by Rapti and colleagues18. It provided 
an adequate description of the method of 
randomisation; baseline characteristics were similar 
across the trial arms; the reporting of the primary 
outcome was adequate; and the study comprised 
both blinded and open-label phases (hence judged 
‘partial’). However, concealment of allocation 
was only partially met. The level of reporting in  
the trial by Rapti and colleagues was poor, and 
prohibited a full assessment of its methodological 
quality. Importantly, the methods of randomisation 
and concealment are unknown, although there 
were no reported statistically significant differences 
between study groups at baseline, suggesting that 
selection bias was unlikely. 
 
The third study, the long-term open-label 
study by Hadziyannis and colleagues,20 became 



















No. of participants (n), 
duration of trial (T ), d 
Study and HBeAg additional follow-up (F ) 
d 
methods status and total duration (total) Patient characteristics Group A Group B Group C Outcomes 
Zeng et al., 200619     Positive  n = 480  Detectable HBsAg and HBeAg  PAA  AAA  AAP  Primary  outcomes: 
Design: Multicentre,  T  = 52 weeks  Serum HBV DNA 106 copies/ml  Placebo (12  ADV 10 mg/  ADV 10 mg/  Change from baselinef 
d 
double‐blind/open‐  F = ongoinge  Serum ALT level > 1 ULN (and  weeks)  day (12  day (12  of serum HBV DNA at 
label RCTd    d      weeks)  weeks)  week 12 
Total = ongoinge  > 2 ULN sometime within the  ADV 10 mg/ Number of centres:  previous 6 months)  day (28  ADV 10 mg/  ADV 10 mg/  Secondary  outcomes: 
7  Compensated liver disease  weeks)  day (28  day (28  Virological response: 
Sponsor:  Chinese population  ADV 10 mg/  weeks)  weeks)  HBV DNA  change  from
GlaxoSmithKline  Average age: 32 years  day (12  ADV 10mg/  Placebo (12  baselinef  at weeks 40 Country: China  weeks)  day (12  weeks)  and 52 
Sex: 83% male  (Total ADV  weeks)  (Total ADV  HBV  DNA  < 105 
No LAM therapy within 3 months  duration: 40  (Total ADV  duration: 40  copies/ml prior to screening, or ADV (or other  weeks)  duration: 52  weeks) 
anti‐HBV therapy) in previous 6  (n = 120)  weeks)  (n = 120)  Undetectable HBV 

























No. of participants (n), 
duration of trial (T ), 
additional follow-up (F ) 




















































Hadziyannis et  Negative  n = 125  HBeAg negative  AA  PA  –  Virological response:
al., 200620 T = 240 weeks











(192 weeks for PAA group)  Compensated  liver  disease  































































No. of participants (n), 
duration of trial (T ), d 
Study and HBeAg additional follow-up (F ) 
d 



















g    Patients were originally  randomised  to ADV  (n = 123) or placebo  (n = 62). The cohort  reported  in  this observational  study  includes 70 patients who  received ADV  in double‐blind 
phase one  (for 48 weeks), double‐blind phase  two  (from week 49  to week 96) and  the observational phase  (from week 97  to week 240)  (the AAA group); and 55 patients who 








  Zeng et al., 200619 Rapti et al., 200718 
Randomisation  Adequate  Unknown 
Concealment  of  allocation  Partial  Unknown 










weeks’ randomised double-blind treatment (the arms differing in the commencement of 
assessment of methodological quality of the LAM. One group received PEG--2b for 32 
original RCT is available in our earlier assessment weeks and LAM for 104 weeks concurrently. A 
report12). Results for most of the outcomes are second group received PEG--2b for 32 weeks, 
presented for all 125 patients in the observational beginning 8 weeks before commencing LAM 
cohort, regardless of study group. The authors for 96 weeks. The third group received PEG- 
report two types of intention-to-treat (ITT) analysis -2b for 32 weeks, beginning 8 weeks after 
for the analysis of HBV DNA and ALT. In the ‘ITT commencing LAM, which they received for 104 
missing equals failure’ analysis (ITT; M = F), all weeks. The rationale for this pilot study was to 
patients who discontinued were considered to establish if staggered commencement would 
have failed treatment. In the ‘ITT missing equals have a more potent HBV DNA suppression 
failure for resistance or HCC’ analysis (ITT; M than simultaneous commencement of PEG-- 
= F R/HCC), patients were considered failures if 2b plus LAM, with an extended LAM treatment 
they (1) harboured HBV with an ADV-resistance of up to 2 years. 
mutation and either terminated the study or had • Chan and colleagues (2005)24  compared 
LAM added (if a patient had HBV with a resistance combined treatment with LAM alone. A 
mutation and remained in the study on ADV separate publication reported long-term 
monotherapy, his or her serum HBV DNA and ALT sustained virological response outcomes.28 
values were included in analyses rather than being The rationale was to ascertain if combination 
deemed failures), or (2) were diagnosed with HCC. therapy increased HBeAg seroconversion rates 
Missing values from patients who left the study for and improved antiviral efficacy more than did 
other reasons were excluded. The ITT; M = F R/ LAM  monotherapy. 
HCC analysis was considered to provide a more • Kaymakoglu and colleagues25 compared 
realistic view of efficacy as drop-outs unrelated to PEG--2b and LAM with PEG--2b alone. 
efficacy are expected in a 5-year trial. The rationale of this trial was to discover if 
  combination therapy could lead to an increased 
Characteristics of PEG‐‐2b studies  rate of sustained response. 
Five published RCTs evaluating PEG--2b were • Janssen and colleagues26 evaluated combined 
included, all using similar inclusion and exclusion PEG--2b and LAM with PEG--2b plus 
criteria. Four RCTs evaluated combined treatment placebo. Separate publications report long- 
of PEG--2b plus LAM,23–26 while one compared term histology,29 safety results,30 and subgroup 
PEG--2b with IFN--2b.27 The studies had varied analyses (e.g. advanced fibrosis versus 
regimens and differing aims, as follows: no advanced fibrosis;31 genotypes,32 early 
  responders33). The aim was to assess whether 
• Chan and colleagues (2007)23  included three combination therapy was associated with 







increased rates of sustained response in CHB 
compared with PEG--2b monotherapy. 
• Zhao and colleagues27 compared PEG--2b  
with IFN--2b. The authors aimed to establish 
factors predicting sustained combined response 
and adverse effects for a lower dose in patients 
with different genotypes (B versus C), in order 
to determine the most cost-effective treatment 
for developing countries with high HBV 
infection rates.  
The key characteristics of the trials are shown in 
Table 3. Two trials were single-centre RCTs23,24  and 
three were multicentre studies,25–27 of which only 
one trial appeared to take place in more than 
one country.26 Two of the RCTs received funding 
(the Research Fund for the Control of Infections 
Diseases, Health, Welfare and Food Bureau;23 
the Rotterdam Foundation for Liver Research26). 
Schering–Plough supplied PEG--2b to three 
studies and the same studies also received LAM 
from  GlaxoSmithKline.23,24,26 
 
Outcome measures employed by the RCTs were 
similar, with differences in relation to participants’ 
HBeAg status, such as HBeAg seroconversion 
rates. Primary outcomes were changes from 
baseline in rate of serum HBV DNA,27 HBeAg 
seroconversion,24 loss of HBeAg at end of 
treatment,26 reduction of HBV DNA23 and levels  
of HBV DNA.25 Secondary outcome measures 
included ALT normalisation, development 
of genotypic LAM resistance, histological 
improvement (necroinflammatory and fibrosis 
score) using the Knodell score, adverse events and 
LAM-resistant mutations, as well as assessment of 
HBsAg and HBV genotypes.  
All trials defined CHB by the presence of 
detectable HBsAg for a minimum of 6 months 
prior to enrolment. Serum HBV DNA levels were  
at least 105 copies/ml (106 in one study27) and ALT 
levels ranged between 1.3 and 10 times the upper 
limit of the normal range (ULN), although not all 
of the RCTs stated higher ALT limits.25,26  Three of 
the PEG--2b studies required participants to be 
HBeAg positive,23,24,27  one included both HBeAg- 
positive and HBeAg-negative patients,27 and one 
included HBeAg-negative patients only.25 The trials 
generally excluded patients with decompensated/ 
advanced liver disease. A small proportion of 
participants with cirrhosis were included in two 
of the studies (4%;25  8%26). Comorbidities and co-
infections were specifically excluded by three 
RCTs23,24,26  and were not remarked upon by the 
others.25,27 
Trial size varied considerably, ranging from 30 
participants23  to 307.26  Duration of treatment also 
varied from 24 to 104 weeks, with an average 
24-week follow-up. All trials were carried out on 
adult patients. While Chan and colleagues23,24 
recruited only treatment-naive participants, two 
studies included participants with a mixture of 
prior and no prior treatment.26,27  Kaymakoglu 
and colleagues failed to mention prior treatment 
history.25 Previous IFN therapy was recorded for 
13%27 and about 20%26of participants, while 33% of 
participants had previous LAM therapy.26 However, 
no LAM resistance was reported.  
Details of ethnicity were sparse. Chan and 
colleagues included Chinese participants,23 while 
the Kaymakoglu and colleagues trial primarily 
included white participants (74%) along with 20% 
Asian and 6% mixed.25 The mean age of study 
participants was between 30 and 43 years, and 
entailed a higher proportion of male participants 
(range 63–82%).  
The methodological quality of the five PEG--2b 
trials was assessed using CRD criteria,13 and is 
shown in Table 4. Four of the five trials adequately 
reported the method of randomisation,23,24,26,27  and 
three of these adequately reported the concealment 
of allocation to treatment groups.23,24,26  The 
allocation process was unclear in the remaining two 
studies. All of the included RCTs reported patients’ 
baseline characteristics. Four of these reported 
that study groups were similar at baseline, with  
only Zhao and colleagues reporting a difference in 
previous treatment with interferon therapy between 
study groups, which was statistically significant 
(p < 0.05).27 
 
Only one of the studies adequately described all 
aspects of blinding,26  stating, for example, that  
the placebo was similar in appearance to the study 
drug and that HBV markers were assessed at a 
central laboratory, with staff unaware of treatment 
allocation. Each of the remaining trials was open 
label. Two of these23,24  did report some blinding 
of outcome assessors. For example, in one of the 
studies, histological specimens were assessed by 
a single histopathologist who was unaware of the 
treatment assignments or the times at which the 
specimens were obtained.23  
Reporting of primary outcomes was variable across 
the five studies, with only two adequately reporting 
point estimates and measures of variability.25,26 
Three studies adequately described an ITT 




   No. of participants,  duration of trial (T ),
d
Study and HBeAg additional follow-up (F )d Patients’
methods status and total duration (total) characteristics GroupA Group B Group C Outcomes
Chan et al., 200723 Positive  n = 30  No co‐infection  PEG‐‐2ba  PEG‐‐2ba  PEG‐‐2ba  Primary  outcomes: 
Design:  Open‐label 
RCT  (pilot study) 














































































































































No. of participants, 
duration of trial (T ), d 
Study and HBeAg additional follow-up (F ) Patients’ 
d 







Janssen et al., Positive  n = 266  No co‐infection  PEG‐‐2bd  PEG‐‐2bd  Primary  outcomes: 
200526 with hepatitis C, D 
Td = 52 weeks  or HIV  Dose 1: 100  Dose 1: 100  Loss of HBeAg Design: Double‐  g/week  g/week 
blind, RCT  Fd = 26 weeks  74% white; 20%  Secondary  outcomes: Duration: 32  Duration: 32 
Number of centres:  Total = 78 weeks  Asian; 6% other/  weeks  weeks  Concentration of HBV DNA below 
42  mixed  200,000  copies/ml 
Sex: 77% male  Dose 2: 50 g/  Dose 2: 50 g/  Concentrations of HBV DNA below  level 
Country: 15  week  week 
(including Europe,  21% had  of detection 
Israel, Canada and  previously used  Duration: 20  Duration: 20  Return to normal of ALT concentrations 
Asia)  PEG‐ weeks (weeks  weeks (weeks 32–52)  32–52)  Presence of mutations in YMDD motif of 
< 15% had  HBV polymerase 
previously used  + LAM  + Placebo 













No. of participants, 
duration of trial (T ), d 
Study and HBeAg additional follow-up (F ) Patients’ 
d 
methods status and total duration (total) characteristics Group A Group B Group C Outcomes 
Kaymakoglu et  Negative  n= 48  No information  PEG‐‐2b  PEG‐‐2b  Outcomes: 
al., 200725 given on co‐ 
Td = 48 weeks  infection  1.5 g/kg body  1.5 g/kg body  HBV DNA  level Design: Open‐label,  weight/week  weight/week 
RCT  Fd = 24 weeks  Patients with any      ALT level normalisation 
(n = 19)  + LAM 








Zhao et al., Positive  n = 230  No information  PEG‐‐2b  IFN‐‐2b  Primary  outcomes: 
200727 given on co‐ Td  = 24 weeks  infection  1.0 g/kg/week  3 MIU three  Rate of serum HBV DNA < 10   copies/ml 5 
Design: RCT  F  = 24 weeks  subcutaneously  times/week  and < 10 copies/ml 3   
Number of centres: 6    d  No information  (n = 115)  subcutaneously  Mean                    reduction of serum HBV DNA 
level Total = 48 weeks  provided on ethnic 
Country: China  groups  (n = 115)  (from baseline) 



































Randomisation  Adequate Adequate Adequate Unknown Adequate
Concealment  of 
allocation 




Adequate  Adequate  Adequate  Adequate  Partial 
Blinding of 
assessors 
Partial  Partial  Adequate  Inadequate  Inadequate 
Care provider 
blinding 
Unknown  Unknown  Adequate  Inadequate  Inadequate 
Patient blinding  Inadequate  Inadequate  Adequate  Inadequate  Inadequate 
Reporting 
outcomes 
Inadequate  Partial  Adequate  Adequate  Partial 
Intention‐to‐treat 
analysis 
Inadequate  Adequate  Inadequate  Adequate  Adequate 
Withdrawals 
explained 
Adequate  Adequate  Partial  Inadequate  Partial 
     
reported a ‘modified’ ITT analysis. For example, 
in Janssen and colleagues’ study, 41 (13%) of the 
307 randomised patients were excluded from the 
modified ITT. Of these, 24 patients from one 
study centre (12 from each arm) were excluded 
because of ‘misconduct’; 10 lost HBeAg before the 
start of the study; and seven did not receive any 
study medication. It is unclear whether all of those 
excluded received at least one dose of the study 
medication, therefore it is recorded as ‘inadequate’ 
in the table.26  
Withdrawals were fully described in two of the five 
studies. One study reported early withdrawals, with 
no other details given. Studies are described in 
Table 4 as partially explaining withdrawals where 
early attrition or withdrawals due to adverse events 
were reported, but where later losses to follow-up 
are  not  fully  explained.26,34 
 
Assessment of effectiveness 
Virological  response 
Proportion of patients achieving an 
HBV DNA response – ADV studies 
 
Table 5 presents the proportion of patients 
achieving a defined threshold of HBV DNA 
response in the two trials. In the trial by Zeng and 
colleagues,19   the proportion of patients whose HBV 
DNA level dropped below 105  copies/ml reached 
67% by week 52 in patients treated continuously 
with ADV [the adefovir–adefovir–adefovir 
(AAA) group]. For the group who commenced 
open-label ADV after 12 weeks of placebo [the 
placebo–adefovir–adefovir (PAA) group], the 
proportion reached 70% at week 52. For the 
group who initially received ADV and were then 
re-randomised to placebo at week 40 [the adefovir– 
adefovir–placebo (AAP) group], the proportion fell 
to 11% at week 52, having previously reached 59%. 
Zeng and colleagues19 also reported the proportion 
of patients whose HBV DNA was undetectable, 
defined as HBV DNA < 300 copies/ml. At week 
52, the proportions were similar in the AAA and 
the PAA groups (28% and 30% respectively). In the 
AAP group, the proportion fell from 59% at week 
40 to 11% by week 52, following the withdrawal of 
ADV. No statistical tests were reported for any of 
these comparisons.  
In the trial by Rapti and colleagues,18   the 
proportion of patients with HBV DNA 1000 
copies/ml after 24 months of therapy was higher 
in the group treated with ADV and LAM than in 
the group treated with ADV monotherapy (82.6% 
versus 75% respectively). However, this difference 










Study, patient type, outcome Treatment group       p-value 
Zeng et al., 200619 PAA AAA   AAP  
HBeAg +ve           
HBV DNA < 105 copies/ml, week  4/115 (3)  113/227 (50) 55/116 (47)  NR
12, n/N (%)     
HBV DNA < 105 copies/ml, week  75/115 (65) 147/231 (64) 68/115 (59)  NR
40, n/N (%)     
HBV DNA < 105 copies/ml, week  81/115 (70) 155/231 (67) 13/115 (11)  NR
52, n/N (%)     
HBV DNA undetectable, week 0/119 (0)  11/232 (5) 7/120 (6)  NR
12, n/N (%)a     
HBV DNA undetectable, week 23/119 (19) 42/236 (18) 23/119 (19)  NR
40, n/N (%)a     
HBV DNA undetectable, week 36/119 (30) 67/236 (28) 1/119 (1)  NR
52, n/N (%)a           
Rapti et al., 200718 ADV   ADV + LAM  
HBeAg –ve           
HBV DNA 1000  copies/ml at 6  45.5  57.1  0.723 
months, %     
HBV DNA 1000  copies/ml at 12  78.6  68  0.713 
months, %     
HBV DNA 1000  copies/ml at 24  75  82.6  0.670 
months, %           
a  HBV DNA < 300 copies/ml.
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
 
 
Table 6 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to 
the ADV–ADV group as the placebo–ADV group 
commenced ADV only after week 48.)  
In the ‘ITT missing data = failure for resistance 
or HCC’ analysis (i.e. missing values from patients 
who left the study for other reasons were excluded), 
the proportion of patients whose HBV DNA levels 
were < 1000 copies/ml peaked after 96 weeks, 
after which they gradually fell to 67%. In the ‘ITT 
missing data = failure’ analysis, the proportion 
peaked after 144 weeks, and fell to 53% after 240 
weeks.  
In summary, a greater proportion of ADV-treated 
patients experienced an HBV DNA response 
relative to comparators, although this was 
not confirmed statistically. The proportion of 
responders was generally maintained during long- 
term  treatment. 
Proportion of patients achieving an 
HBV DNA response – PEG--2b studies 
Table 7 shows the proportion of patients achieving 
an HBV DNA response as reported in four of the 
five studies. Response was measured by reductions 
in HBV DNA levels to a given threshold. Each of 
the studies of PEG--2b used differing thresholds  
of HBV DNA response. These proportions also vary 
across the studies. 
 
Chan and colleagues23 report HBV DNA response 
for three groups of patients, receiving staggered 
regimens of PEG--2b and LAM. At week 52, 
Group A had a higher proportion of patients  
(44%) with negative HBV DNA than either Group 
B (22%) or Group C (10%). Neither of these 
differences was statistically significant (p = 0.62 and 
p = 0.24). At end of treatment (week 104) Group B 
had the highest proportion of patients (56%) with 
negative HBV DNA, compared with Group A (33%) 
and Group C (40%). Baseline HBV DNA had been 




Study, patient type, outcome Treatment group p-value 
  Group A Group B Group C 
  PEG--2b PEG--2b PEG--2b 
Chan et al., 200723 +LAM + LAM +LAM
HBeAg +ve     
Negative HBV DNA at week 52, n/N (%)  4/9 (44)  2/9 (22)  1/10 (10)  Group B vs Group A: 0.62 
    Group C vs Group A: 0.24 
Negative HBV DNA at week 104, n/N (%)  3/9 (33)  5/9 (56)  4/10 (40)  NR 
Undetectable HBV DNA at follow‐up (week  2/9 (22) 1/9 (11) 2/10 (20) NR 
128), n/N (%)     
  Group A Group B  
Janssen et al., 200526 PEG--2b + LAM PEG- -2b + placebo 
HBeAg +ve     
HBV DNA < 200,000 copies/ml, EOT (week  96/130 (74) 40/136 (29) < 0.0001 
52), n/N (%)   
HBV DNA < 200,000 copies/ml (week 78),  41/130 (32) 37/136 (27) 0.44 
n/N (%)   
HBV DNA < 400 copies/ml (week 52), n/N  43/130 (33) 13/136 (10) < 0.0001 
(%)   
HBV DNA < 400 copies/ml (week 78), n/N  12/130 (9) 9/136 (7) 0.43 
(%)     
  Group A Group B  
Kaymakoglu et al., 200725 PEG--2b PEG--2b +LAM  
HBeAg –ve     
HBV DNA < 4 pg/ml, EOT (week 48), n/N  12/19 (63) 23/29 (79) > 0.05 
(%)   
HBV DNA < 4 pg/ml, EOF‐U (week 72), n/N  7/19(37) 10/29 (34) > 0.05 
(%)   








  Weeks of ADV treatment    
Study, patient type, outcome 48 96 144 192 240a 
Hadziyannis et al., 200620        
HBeAg –ve         
HBV DNA < 1000 copies/ml, %of enrolled  72 80 77 73 67 
patientsb     
HBV DNA < 1000 copies/ml, %of enrolled  71 71 73 62 53 
patientsc         
HCC, hepatocellular carcinoma; ITT, intention to treat.


















Study, patient type, outcome Treatment group   p-value 
  Group A Group B  
Zhao et al., 200727 PEG--2b IFN  
HBeAg +ve       
HBV DNA level < 5 log   copies/ml, EOF‐U  34/115 (29.6) 22/115 (19.1) 0.06 
(week 48), n/N (%)   
HBV DNA level < 3 log   copies/ml, EOF‐U  14/115 (12.2) 14/115 (12.2) 1.00 
(week 48), n/N (%)       
EOF‐U, end of follow‐up; EOT, end of treatment; NR, not reported; pg, picograms. 
  
up (week 128), Group A had a slightly higher 
proportion of patients reaching ‘undetectable’ HBV 
DNA of 22%, compared with Group B at 11% and 
Group C at 20%. Statistical significance was not 
given for these results. Definitions of ‘negative’ and 
‘undetectable’ are not reported, and so it is unclear 
how these differ. 
In summary, the results of these studies show 
that there was no significant difference between 
concurrent and staggered commencement of 
PEG--2b and LAM; and no consistent statistically 
significant differences between the combination 
of PEG--2b and LAM versus PEG--2b 
monotherapy, or between PEG--2b and IFN-. 
The trial by Janssen and colleagues26 compares Changes in HBV DNA 
a group receiving PEG--2b and LAM (Group levels – ADV studies 
A), and a group receiving PEG--2b and placebo Table 8 reports the median changes in HBV DNA 
(Group B). At end of treatment (week 52) the from baseline in the trial by Zeng and colleagues.27 
proportion of patients in Group A reaching 
< 200,000 copies/ml was 74%, compared with 29% At week 12 there was a statistically significant 
in Group B (p < 0.0001). At end of follow-up this difference between the patients randomised to ADV 
had fallen in Group A to 32% and in Group B to (the AAA group) and those randomised to placebo 
27% (p = 0.44). Thirty-three per cent of patients in (the PAA group) (p < 0.001). At week 40, median 
Group A at end of treatment reached < 400 copies/ reductions in HBV DNA appeared to be similar for 
ml, compared with 10% in Group B (p < 0.0001). all three groups (all three had been receiving open- 
This, again, fell by end of follow-up to 9% in Group label ADV since week 12). At week 52, median HBV 
A and 7% in Group B (p = 0.43). DNA reductions appeared to be similar for the 
  patients who had received ADV continuously (the 
In the trial by Kaymakoglu and colleagues,25 a AAA group) and those who had switched to ADV 
higher proportion of patients receiving PEG- from placebo after week 12 (the PAA group) (–4.5 
-2b and LAM achieved HBV DNA < 4 pg/ml 
(picograms per millilitre; in this paper defined as 
and –5.0 log10 copies/ml respectively). However, 
those who had received ADV until week 40 and 
the ‘lower limit of detection’) at end of treatment were then re-randomised to placebo had a smaller 
(week 48) than of those receiving PEG--2b 
alone: 79% versus 63% respectively. At end of 
reduction (–0.2 log10 copies/ml). 
follow-up, the proportions reaching 400 copies/ Changes in HBV DNA levels 
ml were similar for both groups: 24% versus 26%. – PEG--2b studies 
However, none of these differences was statistically Changes in HBV DNA levels are shown in Table 9. 
significant. 
  Chan and colleagues (2007)23  report the median 
Zhao and colleagues27 compared patients receiving log HBV DNA reduction from baseline at weeks 
PEG--2b (Group A) with those taking IFN- 4, 8, 52 and 104. The median difference between 
(Group B). A higher proportion of patients in Group A and Group B was 3.59 (95% CI 1.49–5.65, 
Group A (29.6%) reached < 5 log10 copies/ml at end 
of follow-up (week 48), compared with 19.1% in 
p < 0.0001) at week 4 (at this stage, because of 
the staggered regimen, Group A was receiving 
Group B (p = 0.06). In both groups, 12.2% reached PEG--2b and LAM, Group B was receiving PEG- 
20 < 3 log  copies/ml (p = 1.00). 








Study, patient type, outcome Treatment group     p-value 
Zeng et al., 200619 PAA AAA AAP  
HBeAg +ve         
HBV DNA change (log  copies/ml) from  –0.1, –5.2 to 3.1 –3.4, –7.7 to 0.5 –3.3, –6.8 to –1.0  < 0.001a 
baseline to week 12, median range [25%, 75%  (–0.7 to 0.3) (–4.6 to –2.6) (–4.3 to –2.7) 
(interquartile  values)]     
HBV DNA change (log  copies/ml) from  –4.6, –7.7 to 2.0 –4.2, –8.0 to 0.5 –4.0, –8.6 to 0.7  NR 
baseline to week 40, median range [25%, 75%  (–5.6 to –3.1) (–5.5 to –3.0) (–5.3 to –3.0) 
(interquartile  values)]     
HBV DNA change (log  copies/ml) from  –5.0, –8.0 to 2.1 –4.5, –8.0 to 0.7 –0.2, –6.1 to  NR 
baseline to week 52, median range [25%, 75%  (–6.0 to –3.3) (–5.8 to –3.1) 2.1(–1.6 to 0.3) 
(interquartile  values)]         
NR, not reported. 
a   For AAA vs PAA. 
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
   
monotherapy). At week 52, the point at which the 
primary outcome was measured, the difference 
between Groups A and B was significant (6.38 
versus 3.43, p = 0.030), but the difference between 
Groups A and C was not (p = 0.06). By end of 
treatment, week 104, there were no significant 
differences in median log HBV DNA reduction 
between any of the groups.  
In the trial by Chan and colleagues (2005),24 
there were greater reductions in HBV DNA for 
combination treatment than for monotherapy. 
The median difference between groups at end of 
treatment was reported as 1.24 copies/ml (95% 
CI 0.78–1.66); however, no statistical tests were 
reported for this outcome.  
The HBV DNA change from baseline in Janssen 
and colleagues26 was estimated by the reviewers 
from a figure in the paper, and showed a similar 
reduction in mean log HBV DNA copies/ml of 2.3 
for Group A and 2.2 for Group B at end of follow- 
up.  
Zhao and colleagues27 reported the HBV DNA 
mean reduction from baseline, log10 copies/ml 
at end of treatment and end of follow-up. The 
difference was significant at week 24 (end of 
treatment) (Group A 2.22 versus Group B 1.66, 
p = 0.03), but again was not statistically significant 
by end of follow-up (p = 0.34). At end of follow-up, 
the ‘mean reduction’ in Group A was –1.4 ± 2.2, 
and in Group B it was –1.1 ± 2.1, indicating that 
overall there had been an increase in the HBV 
DNA level in both groups from baseline. 
In summary, the results of the trials show that PEG- 
-2b is generally associated with greater reductions 
in HBV DNA levels than are comparators. This was 
the case when PEG--2b was added to LAM, or  
vice versa, and for PEG--2b versus IFN. However, 
there were no consistent statistically significant 
differences between treatments. The results 
suggested a greater reduction in HBV DNA for 
those who received concurrent commencement of 
PEG--2b and LAM, but by the end of treatment 
there were no statistically significant differences 
between this and the staggered regimens. 
 
Biochemical response (ALT) 
ALT normalisation – ADV studies 
Table 10 reports the proportion of patients with 
normal ALT levels in two of the studies. 
 
Four of the trials reported changes in HBV 
DNA. In the trial by Zeng and colleagues,19 the 
proportion of patients with normal ALT appeared 
similar at week 12 in the groups randomised to 
receive ADV (42% and 44% in the AAA and AAP 
groups respectively). There was a statistically 
significant difference between the AAA and AAP 
groups combined compared with the group 
randomised to placebo (the PAA group). The 
proportion of responders in the AAA and AAP 
groups remained similar to each other at week 40 
after 28 weeks of open-label ADV (73% and 74% 
respectively). At week 40, in the group randomised 
to placebo in the first 12 weeks and who had 
subsequently received open-label ADV for 28 weeks 
(the PAA group), the proportion of ALT responders 










Study, patient type, outcome Treatment group p-value 
Group A Group B Group C 
PEG--2b PEG--2b PEG--2b + 
Chan et al., 200723 +LAM +LAM LAM 
HBeAg +ve 
Median log HBV DNA reduction, week 4a,b  4.21  1.39  2.95  < 0.0001 (Groups A and B)
0.027 (Groups A and C) 
Median log HBV DNA reduction, week 8b,c  5.46  1.55  3.14  < 0.0001 (Groups A and B)
0.004 (Groups A and C) 
Median log HBV DNA reduction, week 52d  6.38  3.43  4.44  0.030 (Groups A and B) 
0.060 (Groups A and C) 
Median log HBV DNA reduction, EOT, week 104e  6.13  5.24  5.15  0.20 (Groups A and B) 
0.46 (Groups A and C) 
 
Group A Group B 
Chan et al., 200524 PEG--2b + LAM LAM 
HBeAg +ve 
HBV DNA median log   reduction, copies/ml  3.89 (1.59–6.35)  2.74 (–0.10 to  NR 
10 
(range), EOTf  5.68) 




Janssen et al., 200526 Group A PEG--2b + 
HBeAg +ve  PEG--2b + LAM placebo 
HBV DNA change from baseline: mean log HBV  2.3h  2.2h  NR 
DNA, copies/ml (estimated from paper), EOF‐U 
 
Group A Group B 
Zhao et al., 200727 PEG--2b IFN 
HBeAg +ve 
Mean reduction of HBV DNA level from baseline,  2.22  1.66   0.03 
log    copies/ml week 24 (EOT) 
10 




















  Weeks of ADV treatment    
Study, patient type, outcome 48 96 144 192 240a 
Hadziyannis et al., 200620        
HBeAg –ve         
ALT normalisation, % of enrolled  75  74 71 73 69 
patientsb     
ALT normalisation, % of enrolled  75  65 68 63 59 
patientsc         
ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; ITT, intention to treat.








Study, patient type, outcome Treatment group     p-value 
Zeng et al., 200619 PAA AAA AAP  
HBeAg +vea,b         
ALT normalisation at week 12, n/N (%)  15/108 (14)  92/220 (42)  48/110 (44)  0.001c 
ALT normalisation at week 40, n/N (%)  69/106 (65)  163/223 (73)  81/109 (74)  NR 
ALT normalisation at week 52, n/N (%)  74/107 (69)  176/224 (79)  23/109 (21)  NR 
Rapti et al., 200718 ADV ADV + LAM  
HBeAg –ve         
% of patients with ALT 49 IU/l (ULN) at 24 months  72.7  91    0.304 
ALT, alanine aminotransferase; IU/l = international units per litre; NR, not reported; ULN, upper limit of normal. 
a   ULN was 49 IU/l. 
b  Subjects with elevated serum ALT at baseline. 
c   For the AAA and AAP groups combined compared with the PAA group.
PAA, placebo–ADV–ADV; AAA = ADV–ADV–ADV;AAP = ADV–ADV–placebo.
   
(65%). At week 52, the proportion of responders 
in the PAA group had increased to 69%, while 
the proportion of responders of those who had 
received ADV continuously (the AAA group) had 
increased to 79%. The proportion of responders 
fell to 21% in the group re-randomised at week 40 
to placebo (the AAP group). No statistical tests were 
reported for these comparisons.  
In the trial by Rapti and colleagues, there was a 
higher proportion of responders in the group who 
received ADV and LAM compared with the group 
that received ADV monotherapy (91% versus 72.7% 
respectively). However, the difference was not 
statistically significant. 
Table 11 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to 
the ADV–ADV group as the placebo–ADV group 
commenced ADV only after week 48.)  
The proportion of patients with normal ALT values 
declined from 75% after 48 weeks to 69% and 59% 
at week 240 for the ‘ITT missing data = failure 
for resistance or HCC’ and ‘ITT missing data = 
failure’ analyses respectively.  
In summary, a greater proportion of ADV-treated 
patients experienced ALT normalisation relative 












statistically significant. The proportion of ALT 
responders was generally maintained during long- 
term treatment. 
-2b versus 34.8% in Group B receiving IFN-; 
p = 0.93). 
 
In summary, the proportion of patients with 
ALT normalisation – PEG--2b studies normalised ALT tended to be greater for the 
Table 12 reports the proportions of patients with combination of PEG--2b and LAM compared 
ALT normalisation in the PEG--2b studies. with either as monotherapy. The proportions 
  were generally similar when comparing different 
All five of the PEG--2b trials reported commencement regimens of PEG and LAM, or 
results of the proportion of patients with ALT PEG--2b with IFN-. Rates of normalisation 
normalisation.23–27  All reported ALT normalisation usually fell between end of treatment and follow- 
at end of follow-up, and four also reported up. Few statistically significant differences between 
results at end of treatment.23–26  None stated the treatments were reported. 
‘normalisation’ threshold used. 
  Changes in ALT levels – ADV studies 
In the trial by Chan and colleagues (2007),23 Table 13 presents median ALT levels in the two 
three groups of patients on staggered regimens ADV trials which reported this outcome. 
of PEG--2b and LAM had similar rates of ALT 
normalisation at end of treatment [Group A 9 In the trial by Zeng and colleagues,19 median ALT 
(100%), Group B 9 (100%), Group C 9 (90%)]. At was similar at week 12 in the groups randomised 
end of follow-up these numbers had decreased to receive ADV (1.1 ULN, in both the AAA and 
to Group A 4/9 (44%), Group B 5/9 (56%) and AAP groups). Median ALT remained similar in the 
Group C 4/9 (40%). There were no statistical tests AAA and AAP groups at week 40, after 28 weeks of 
reported. open-label ADV (0.7 and 0.9 ULN respectively). 
  At week 40, in the group randomised to placebo 
In the study by Chan and colleagues (2005),24 a in the first 12 weeks and who had subsequently 
slightly higher proportion (90%) of Group A (PEG- received open-label ADV for 28 weeks (the PAA 
-2b and LAM), had normal ALT levels compared group), median ALT was similar to the other two 
with 78% of Group B (LAM alone) at end of groups (0.9 ULN). At week 52, median ALT 
treatment. This was similar at follow-up (Group A levels remained similar in the PAA and AAA 
50% versus Group B 30%). No statistical tests were groups, but increased to 3.0 ULN in the group 
reported for these differences. who were re-randomised to placebo at week 40 (the 
  AAP group). No statistical tests were reported for 
The trial by Janssen and colleagues26 found a these comparisons. 
significant difference between Group A (PEG--2b 
and LAM) and Group B (PEG--2b and placebo) In the trial by Rapti and colleagues,18  median ALT 
in ALT normalisation at end of treatment (51% fell to around 24 IU/l in both treatment groups 
and 34% respectively, p = 0.005). By end of follow- at 24 months of treatment, with no statistically 
up, the difference between groups was no longer significant difference between groups. 
significant (35% and 32% respectively, p = 0.60). 
  Changes in ALT levels – 
There were no significant differences in the PEG--2b studies 
proportions of patients reaching normal ALT levels Only one of the PEG--2b studies reported this 
at end of treatment or end of follow-up in the trial outcome (Table 14). In the trial by Chan and 
by Kaymakoglu and colleagues.25 The proportions colleagues,24 medial ALT fell to around 60–70 IU/l 
of patients with normal ALT at these points were at 24 weeks’ post-treatment follow-up. 
slightly higher in Group B (PEG--2b and LAM) 
(p > 0.05). Again, these proportions had decreased HBeAg loss/seroconversion 
between end of treatment and end of follow-up, HBeAg loss/seroconversion 
e.g. 53% of patients in Group A (PEG--2b) at end – ADV studies 
of treatment and 42% at end of follow-up. Table 15 presents rates of HBeAg loss and 
  seroconversion for the Zeng and colleagues trial.19 
The proportion of patients reaching ALT (This outcome was not reported in the study by 
normalisation in the trial by Zhao and colleagues27 Rapti and colleagues,18 and was not applicable to 
was very similar at end of follow-up for the two the study of HBeAg-negative patients in the study 
study groups (33.9% in Group A receiving PEG- 
24 







Study, patient type, outcome Treatment group p-value 
Group A Group B Group C 
PEG--2b + PEG--2b + PEG--2b + LAM 
Chan et al., 200723 LAM LAM 
HBeAg +ve 
Normal ALT  levels, EOT (week 104),a  n/N (%)  9/9 (100)  9/9 (100)  9/10 (90)  NR 
Normal ALT levels at follow‐up (week 128),a  4/9 (44)  59 (56)  4/10 (40)  NR 
n/N (%) 
 
Group A Group B 
Chan et al., 200524 PEG--2b + LAM LAM 
HBeAg +ve 
Normalisation of ALT levels, EOT, n/N (%)b  45/50 (90)  39/50 (78)  NR 
Normalisation of ALT levels at follow‐up (24  25/50 (50)  15/50 (30)  NR 
weeks after treatment), n/N (%)c 
 
Group A Group B 
Janssen et al., 200526 PEG--2b + LAM PEG--2b + placebo 
HBeAg +ve 
ALT returned to normal, EOT (week 52), n/N  66/130 (51)  46/136 (34)  0.005 
(%) 
ALT returned to normal, EOF‐U (week 78),  46/130 (35)  44/136 (32)  0.60 
n/N (%) 
 
Group A Group B 
Kaymakoglu et al., 200725 PEG--2b PEG--2b + LAM 
HBeAg –ve 
ALT normalisation EOT, n/N (%)  10/19 (53)  19/29 (66)  > 0.05 
ALT normalisation EOF‐U, n/N (%)  8/19 (42)  14/29 (48)  > 0.05 
Group A Group B 
Zhao et al., 200727 PEG--2b IFN 
HBeAg +ve 







At week 52, rates of HBeAg loss and seroconversion 
were highest for patients randomised to placebo 
in the first 12 weeks and who then received open- 
label ADV until week 52 (the PAA group). The 
authors attribute this to the six cases of HBeAg  
loss in this group within the first 12 weeks (actual 
date not recorded) which, it is suggested, represent 
spontaneous cases. At week 40, 16 of the 114 
patients (14%) in the AAP group lost HBeAg. 
Following re-randomisation to placebo at week 40, 
nine of them regained HBeAg between week 40 
and week 52. The higher rate of seroconversion in 
the PAA group at week 52 compared with the AAA 
group is again attributed by the study authors to 
the six patients who spontaneously seroconverted 
on placebo in the first 12 weeks. The authors also 
acknowledged that the seroconversion rate in 
the AAA group was lower than achieved in other 
trials. In summary, the results of this study suggest 
that HBeAg seroconversion rates are generally 
maintained with continued ADV treatment, and are 






Study, patient type, outcome 
Group A 





Chan et al., 200524      
HBeAg +ve       
Median ALT at baseline, IU/l (range)  144 (48–1179)  119 (36–461)  NR 
Median ALT at 24 weeks’ follow‐up, IU/l (range)a  60  70  NR 
IU/l,  international units per  litre; NR, not  reported.






Study, patient type, outcome Treatment group   p-value 
Zeng et al., 200619 PAA AAA AAP  
HBeAg +ve       
Median (range) ALT (ULN), week 12  2.4 (0.1–14.4)  1.1 (0.3–9.1)  1.1 (0.2–5.9)  NR 
Median (range) ALT (ULN), week 40  0.8 (0.2–4.1)  0.7 (0.1–4.4)  0.9 (0.3–30)   
Median (range) ALT (ULN), week 52  0.7 (0.2–4.0)  0.6 (0.2–5.1)  3.0 (0.2–36.4)   
Rapti et al., 200718 ADV ADV + LAM  
HBeAg –ve       
Median ALT at baseline, IU/l (range)  135 (74–608)  108 (52–1004)  0.088 
Median ALT at 24 months,  IU/l  (range)  24 (15–55)  24.5 (12–69)  0.863 
ALT, alanine aminotransferase; IU/l = internationalunitsper litre;NR,notreported;ULN=upper limit of normal. 
PAA, placebo–ADV–ADV; AAA = ADV–ADV–ADV;AAP = ADV–ADV–placebo.
 
HBeAg loss/seroconversion 
– PEG--2b studies 
Table 16 reports the results for HBeAg loss and 
seroconversion in four of the PEG--2b studies. 
This outcome was not applicable in the trial  
of HBeAg-negative patients by Kaymakoglu 
and colleagues.25 All four trials reports HBeAg 
seroconversion at end of follow-up; three of these 
report rates at end of treatment. 
 
Chan and colleagues (2007)23  compared three 
groups who received staggered regimens of PEG- 
-2b and LAM as described above. At end of 
treatment (week 104) 56% of patients in Group A, 
33% of patients in Group B and 60% of patients 
in Group C had seroconverted. At week 128, 
these figures remained the same in Groups A and 
B and had fallen in Group C to 40%. None of 
the between-group differences were statistically 
significant. 
Chan and colleagues (2005)24 report the rate of 
seroconversion at end of treatment in Group A 
receiving PEG--2b and LAM (8 weeks of PEG- 
-2b only, followed by 24 weeks of combination 
and then 28 weeks of LAM only) compared with 
Group B receiving LAM alone. In Group A, 60% 
of patients had seroconverted during the last 28 
weeks of LAM therapy; in Group B this figure was 
28%. No statistical tests were reported for these 
results. 
 
Janssen and colleagues26 reported HBeAg loss and 
HBeAg seroconversion at end of treatment (week 
52) and end of follow-up (week 78). At week 52, 
44% of patients in Group A (PEG--2b and LAM) 
lost HBeAg compared with 29% in Group B (PEG- 
-2b and placebo) (p = 0.01). Also at this time,  
25% of patients in Group A and 22% of patients in 
Group B had seroconverted (p = 0.52). At week 78, 
35% of patients in Group A and 36% of patients in 











Study, patient type, outcome Treatment group 
Zeng et al., 200619 PAA AAA AAP 
HBeAg +ve       
HBeAg loss at week 12, n/N (%)  6/119 (5)  14/239 (6)  6/115 (5) 
HBeAg loss at week 40, n/N (%)  22/118 (18)  25/233 (11)  16/114 (14) 
HBeAg loss at week 52, n/N (%)  24/118 (20)  30/233 (13)  10/114 (9) 
HBeAg seroconversion at week 12, n/N (%)  6/119 (5)  14/229 (6)  6/115 (5) 
HBeAg seroconversion at week 40, n/N (%)  22/118 (18)  23/233 (10)  13/114 (11) 




38 patients (29%) in Group A and 29 patients 
(29%) in Group B had seroconverted (p = 0.92).  
Zhao and colleagues27 reported that the difference 
between groups in the rate of HBeAg loss at end 
of treatment (week 24) was not significant: Group 
A (PEG--2b monotherapy) 22.6% versus Group   
B (IFN-monotherapy) 17.4% (actual p-value 
not reported). At end of follow-up (week 48) this 
number had decreased in Group B (i.e. some of the 
patients re-acquired HBeAg; Group A 24.4% versus 
Group B 13.9%) and the difference was statistically 
significant (p = 0.04). HBeAg seroconversion rates 
at end of follow-up were 21.7% in Group A and 
13.9% in Group B (p = 0.92).  
In summary, the results for HBeAg seroconversion 
and loss were mixed. In one trial, higher rates 
of HBeAg seroconversion were reported for the 
combination of PEG--2b and LAM compared 
with LAM monotherapy, although these were not 
confirmed statistically. In another trial, HBeAg 
seroconversion rates were similar for PEG--2b 
and LAM compared with PEG--2b monotherapy. 
There were higher rates of seroconversion for 
PEG--2b compared with IFN-, but the difference 
was not statistically significant. There was also 
no significant difference between staggered 




– ADV studies 
This outcome was reported in only one of the three 
ADV studies, the long-term open-label follow-up 
study by Hadziyannis and colleagues.20 
 
Six patients (5%) had HBsAg loss after a median 
of 196 weeks (range 20–260) of ADV. Five of these 
patients developed antibody to hepatitis B surface 
antigen (anti-HBs) at their last measurement. 
 
HBsAg loss/seroconversion 
– PEG--2b studies 
Table 17 reports HBsAg loss or seroconversion as 
reported in three of the PEG--2b studies.24,26,27 
 
Chan and colleagues24 reported that five patients 
in Group A (staggered regimen of PEG--2b   
and LAM) and seven in Group B (LAM alone) 
underwent HBsAg clearance. No statistical test was 
reported.  
Janssen and colleagues26 reported results for 
HBsAg loss and seroconversion at both end 
of treatment (week 52) and end of follow-  
up (week 78). The results show very similar, 
small proportions of patients from each group 
undergoing HBsAg loss or seroconversion. For 
example, HBsAg loss at end of treatment had 
occurred in nine patients (7%) in Group A and in 
seven (5%) in Group B (p = 0.54). By end of follow- 
up this was nine (7%) in both groups (p = 0.92).  
In the trial by Zhao and colleagues,27 none of the 
patients in Group A (receiving PEG--2b alone) 
had experienced HBsAg seroconversion, compared 
with two (1.7%) in Group B (receiving IFN 
therapy alone). This difference was not statistically 
significant (p = 0.50).  
In summary, rates of HBsAg loss/seroconversion 
were comparatively low (< 15%) and there were 
no consistent statistically significant differences 
between treatment groups. However, statistical 
differences are less likely to be reported for a 










Study, patient type, outcome Treatment group p-value 
  
 
Chan et al., 200723 
  
Group A 
Group B Group C
       
0.35 (Groups A
PEG--2b + PEG--2b + 
PEG--2b+LAM LAM LAM
HBeAg +ve     




Rate of HBeAg seroconversion, EOT  5/9 (56) 3/9 (33) 6/10 (60) 0.64 (Groups A
(week 104), n/N (%)    and B) 
    1.00 (Groups A
    and C) 
Rate of HBeAg seroconversion at follow‐  5/9 (56) 3/9 (33) 4/10 (40) 0.64 (Groups A
up (week 128), n/N (%)    and B) 
    0.83 (Groups A
      and C) 
  Group A Group B  
Chan et al., 200524 PEG--2b + LAM LAM  
HBeAg +ve       
Rate of HBeAg seroconversion, week 8  9/50 (18) 0/50 NR 
(before commencement of LAM in Group 
A), n/N (%)     
Rate of HBeAg seroconversion, week 32  20/50 (40) 11/50 (22) NR 
(after 24 weeks of LAM in both groups), 
n/N (%)     
Rate of HBeAg seroconversion, last 28  30/50 (60) 14/50 (28) NR 
weeks of extended LAM, n/N (%)       
  Group A Group B  
Janssen et al., 200526 PEG--2b + LAM PEG--2b + placebo  
HBeAg +ve       
HBeAg loss, EOT (week 52), n/N (%)  57/130 (44)  40/136 (29)  0.01 
HBeAg loss, EOF‐U (week 78), n/N (%)  46/130 (35)  49/136 (36)  0.91 
HBeAg seroconversion, EOT (week 52),  33/130 (25) 30/136 (22) 0.52 
n/N (%)     
HBeAg  seroconversion, EOF‐U (week 78),  38/130 (29) 39/136 (29) 0.92 
n/N (%)       
  Group A Group B  
Zhao et al., 200727 PEG--2b IFN  
HBeAg +ve       
HBeAg loss, EOT (week 24), n/N (%)  26/115 (22.6)  20/115 (17.4)  NS 
HBeAg loss, EOF‐U (week 48), n/N (%)  28/115 (24.4)  16/115 (13.9)  0.04 











Of the three ADV trials, only the long-term open- 
label ADV study20 reported this outcome. Table 
18 presents histological results for a subset of 45 
patients who had a liver biopsy at the end of the 
study. (Note that there is a discrepancy in the 
journal publication for this study, such that the 
total number of patients is reported as being 45 as 
well as 44.)  
Compared with pre-treatment biopsy, there were 
improvements in necroinflammation in the range 
of 83–86% of patients, and in improvements 
in fibrosis in the range of 73–75% of patients. 
There were similar reductions in median Knodell 
necroinflammation scores (in the range –5.0 to –4.5 
points) and in median Ishak fibrosis scores. 
 
Liver histological response 
– PEG--2b studies 
Liver histological response, as reported in three of 
the PEG--2b studies,23,24,26 is shown in Table 19. 
One of these trials reported using both the Ishak 
and the Knodell classification systems,24   another 
used the Ishak system26  and the third trial did not 
state which system was used.23 
 
 
Chan and colleagues (2007)23  reported no 
significant differences across their three groups 
receiving staggered regimens of PEG--2b and 
LAM (described above), although group B had 
a slightly lower proportion of patients for each 
change: six (75%) for both necroinflammation 
improvement and fibrosis change, compared 
with eight (89%) in Group A for both results, 
and eight (89%) and nine (100%) in Group C for 
necroinflammation and fibrosis change respectively.  
In the trial by Chan and colleagues (2005),24  the 
results across groups were again broadly similar, 
for both improvements and worsening in the 
necroinflammatory score; e.g. four (10%) in Group 
A (PEG--2b) versus four (9%) in Group B (LAM) 
for a 2-point decrease in this score. For both 
improvement and worsening in fibrosis scores, 
Group A had the highest proportion of patients: six 
(15%) versus four (9%) for a 2-point decrease, for 
example. No p-values are reported for these results.  
Janssen and colleagues26  reported improvement, 
no change and deterioration for both fibrosis  
and inflammation. A higher proportion in Group 
A (PEG--2b and LAM) improved their fibrosis 
scores: 33% versus 22% in Group B (PEG--2b 
and placebo). A higher proportion in Group B 
experienced no change, and the proportions were 
equal for deterioration (38% in each group). There 
was no statistically significant difference between 
groups for improvement or no change versus 
worsening (p = 0.22).  
This pattern was reversed for the inflammation 
results, with Group B having a higher proportion 
of patients with improvement. The groups were 
again equal for the proportion that deteriorated. 
Again, the differences between groups for 
improvement and no change versus worsening 
were not statistically significant. The authors of 
this study advise caution with these results as post- 
treatment biopsies were optional and selection bias 
may have occurred.26  
A follow-up paper to this study29 reported the 
improvements in necroinflammatory and fibrosis 
scores (mean ± SD, range) and these are presented 
in Table 19. Results show that Group B had a 
smaller reduction in necroinflammatory score than 
Group A (–1.5 and –1.7 respectively). While the 
improvements in these scores within groups were 
significant, no p-value is given for the difference 
between groups. This is repeated for the changes in 
fibrosis score, where again improvements within the 
groups were significant, but the difference between 
groups in improvements was not (p = 0.59).  
In summary, there were mixed results for liver 
histology. In some instances, differences between 
treatments in necroinflammation and fibrosis 
favoured PEG--2b and LAM combination 
therapy, while in other instances, PEG--2b or 
LAM monotherapy appeared more favourable. 
Where statistical tests were reported there were no 
significant differences between treatments. 
 
Combined outcomes 
Combined outcomes – ADV studies 
None of the ADV studies reported combined 
outcome measures. 
 
Combined outcomes – PEG--
2b studies 
Table 20 reports results for the two PEG--2b trials 
that reported combined outcome measures. In 
the trial by Chan and colleagues,24 a virological 
response was defined as HBeAg seroconversion, 
detection of antibody to HBeAg and HBV DNA 
level < 500,000 copies/ml and normalisation of 
ALT. In a follow-up study,28 sustained virological 











Study, patient type, outcome Treatment group   p-value 
  Group A Group B  
Chan et al., 200524  PEG‐‐2b + LAM  LAM   
HBeAg +ve       
HBsAg clearance, n/N  5/50  7/50  NR 
  Group A Group B  
Janssen et al., 200526 PEG--2b + LAM PEG- -2b + placebo 
HBeAg +ve       
HBsAg loss, EOT (week 52), n/N (%)  9/130 (7)  7/136 (5)  0.54 
HBsAg loss, EOF‐U (week 78), n/N (%)  9/130 (7)  9/136 (7)  0.92 
HBsAg seroconversion, EOT (week 52),  8/130 (6) 6/136 (4) 0.53 
n/N (%)   
HBsAg  seroconversion,  EOF‐U (week  9/130 (7) 7/136 (5) 0.54 
78), n/N (%)       
  Group A Group B  
Zhao et al., 200727 PEG--2b IFN  
HBeAg +ve       






240 weeks, ADV–ADV 192 weeks, placebo–ADV 
Study, patient type, outcome (n=24) (n = 22) 





Median change  in Knodell necroinflammation score from baseline  –5.0  points  –4.5 points 
Median change in Ishak fibrosis score  –1.0  points  –1.0 points 
% improvement in Ishak fibrosis scorea  71  55 









Study, patient type, outcome Treatment group p-value 
Group B Group C 
Group A PEG--2b + PEG--2b 
Chan et al., 200723 PEG--2b + LAM LAM + LAM 
HBeAg +ve 
Necroinflammatory score, 2‐point  8/9 (89)  6/8 (75)  8/9 (89)  Group A vs Group B: 0.91 
improvement, week 104, n/N (%)        Group A vs Group C: 1.00
Fibrosis score, 1‐point change, week  8/9 (89)  6/8 (75)  9/9 (100)  Group A vs Group B: 0.91 
104, n/N  (%)        Group A vs Group C: 1.00
Group A Group B 
Chan et al., 200524 PEG--2b + LAM LAM 
HBeAg +ve 
2‐point increase in necroinflammatory  24/40 (60)  26/44 (59)  NR 
score,  EOT,  n/N   (%)a 
2‐point decrease in necroinflammatory  4/40 (10)  4/44 (9)  NR 
score,  EOT,  n/N  (%) 
2‐point increase in fibrosis scores,  6/40 (15)  4/44 (9)  NR 
EOT,   n/N   (%)b 
2‐point decrease in fibrosis scores,  4/40 (10)  2/44 (5)  NR 
EOT,  n/N  (%)c 
 
Group A Group B 
Janssen et al., 200526 PEG--2b + LAM PEG--2b + placebo 
HBeAg +ve 
Fibrosisf 
Improvement, EOT (week 52), n/N  17/52 (33)  13/58 (22)  0.22          for 




Improvement, EOT (week 52), n/N  25/52 (48)  31/58 (53)  0.57 for improvement or 





Pre‐treatment, mean ± SD (range)  5.4 ± 2.0 (2–9)  5.6 ± 2.2 (1–10)  <0.001 for pre‐treatment 














Study, patient type, outcome Treatment group p-value 
Fibrosis score, EOT  (week 52)f 
Pre‐treatment, mean ± SD (range)  2.6 ± 1.5 (0–6)  2.3 ± 1.6 (0–6)  Group A: 0.23 for 










d Improvement  in histology was defined as a decrease of 2 points  for  the necroinflammatory score  (range 0–18) and 1 
point  for  the  fibrosis  score  (range 0–6); worsening was defined as an  increase of 2 points  for  the necroinflammatory 
score and 1 point  for  the  fibrosis score. 
e Overall mean necroinflammatory  score  improved by 1.6 points, a  significant  improvement  in both groups  (p < 0.001). 
Largest  improvements were  in  focal  inflammation  (mean 0.7 points) and  interface hepatitis  (mean 0.6 points). 
Necroinflammation score improved in 51% of patients (decrease 2 points) and only 10% showed worsening (increase 2 points). Inflammation improved in 48% of patients in Group A and 53% of patients in Group B (p = 0.57). 




loss and HBV DNA < 100,000 copies/ml from 
treatment cessation until the end of follow-up (up 
to 124 weeks). In the Zhao and colleagues trial,27 
a ‘sustained combined response’ was defined as 
No participants in the trial by Zeng and 
colleagues19 developed a resistance to ADV during 
the course of the study. Those included in analysis 
for resistance were patients with an increase in 
serum HBV DNA level < 105 copies/ml, HBeAg loss serum HBV DNA of at least 1 log10 copies/ml while 
and normal ALT levels. 
 
In the study by Chan and colleagues,24  60% of 
patients taking the combination of PEG--2b and 
LAM (Group A) achieved the virological response 
at week 52, compared with 28% in the LAM group 
(Group B) (p = 0.001). Results are also given for 
SVR at both follow-up and long-term follow-up. A 
higher proportion of patients in Group A (18/50, 
36%) achieved an SVR at 24 weeks’ follow-up than 
of those in Group B (7/50, 14%) (p = 0.011). At end 
of long-term follow-up, these numbers decreased 
in Groups A and B (29% and 8% respectively). No 
statistical test is reported for this difference.  
In the trial by Zhao and colleagues,27 a slightly 
higher proportion of patients receiving PEG--2b 
(17.4%) achieved the sustained combined response 
than of those receiving IFN-(10.4%). This 
difference was not statistically significant. 
 
Viral  resistance 
Viral resistance – ADV studies 
Table 21 presents rates of viral resistance in two of 
the ADV studies. 
32 
on ADV from their lowest point during treatment 
and therefore had isolates analysed for the 
presence of ADV associated-mutations at week 52. 
These totalled 45 in the study, and are distributed 
among treatment groups as shown Table 21. 
 
In the trial by Rapti and colleagues,18  a higher 
proportion of patients (21%) developed resistance 
in the group receiving ADV alone, compared with 
0% of patients in the groups receiving ADV and 
LAM combination therapy. This difference was 
statistically significant (p = 0.0182).  
Table 22 presents HBV DNA response rates for all 
125 patients in the long-term open-label study.20 
(Note that results after 240 weeks apply only to the 
ADV–ADV group as the placebo–ADV group only 
commenced ADV after week 48.)  
The incidence of three definitions of resistance 
was measured: (1) ADV resistance mutations 
(N236T or A181V); (2) ADV-resistant mutations 
with HBV DNA increased from nadir by at least 1 
log10 copies/ml (confirmed or last measurement) 






(‘virological resistance’); and (3) ADV resistance 
mutations with virological resistance and 
ALT elevations (ALT greater than ULN after 
normalising ALT; ‘clinical resistance’). At 240 weeks 
of ADV treatment, the cumulative probabilities of 
ADV resistance were 29%, 20% and 11% for the 
three definitions of resistance respectively.  
In summary, rates of ADV reported in these studies 
were relatively low and tended to remain so over 
long-term treatment. 
 
Viral resistance – PEG--2b studies 
Table 23 presents rates of LAM resistance rates in 
three of the four PEG--2b trials that included 
LAM.23–26 
 
Chan and colleagues (2007)23 reported low rates 
of LAM resistance. In Group C there were two 
patients with LAM resistance, compared with one 
patient in each of Groups A and B at week 104 
(end of treatment).  
In the trial by Chan and colleagues (2005),24 
a higher proportion of patients exhibited 
LAM resistance in the group receiving LAM 
monotherapy than in the group receiving PEG-- 
2b and LAM (40% versus 21%). No statistical test 
was reported for these results. 
In the trial by Janssen and colleagues,26  14 patients 
(11%) in Group A (PEG--2b and LAM) exhibited 
LAM resistance at the end of treatment. The 
comparison group in this trial did not receive 
LAM. Seven of the 14 had previously been treated 
with LAM and had a mutant from the start of 
therapy.  
In summary, the addition of LAM to PEG--2b 
was associated with lower rates of LAM resistance, 
although this was not confirmed statistically. 
 
Adverse events 
Adverse events – ADV studies 
Table 24 reports dose discontinuations, reductions 
and incidence of serious adverse events in the ADV 
studies. 
 
Zeng and colleagues19 reported that two patients in 
the AAA group and one patient in the AAP group 
discontinued the study drug because of adverse 
events. The authors state that adverse events were 
similar in nature and severity between treatment 
groups. No patients died during the trial. The 
authors stated that adverse events rarely occurred 
at a frequency of 5% or greater in any treatment 
group. The incidence of CHB-related adverse 
events was reported, with 9% in the AAP group, 




Study, patient type, outcome Treatment group   p-value 
  Group A Group B  
Chan et al., 200524 PEG--2b + LAM LAM  
HBeAg +ve       
HBV DNA virological response, EOT  30/50 (60) 14/50 (28) 0.001 
(week 52), n/N (%)   
HBV DNA virological response,week 48,  25/50 (50) 14/50 (28) NR 
n/N (%)   
SVR at follow‐up (24 weeks after 18/50 (36) 7/50 (14) 0.011 
treatment), n/N (%)   
SVR at long‐term follow‐up, n/N (%)  14/48 (29)  4/47 (8)  NR 
  Group A Group B  
Zhao et al., 200727 PEG--2b IFN  
HBeAg +ve       
Sustained combined  response at week 48  20/115 (17.4) 12/115 (10.4) 0.13 












Study, patient type, outcome Treatment group p-value 
Zeng et al., 200619 PAA AAA   AAP 
HBeAg +vea         
Viral resistance at week 52, N236T or A181V  0/11 0/28 0/6
mutation, n/N         
Rapti et al., 200718 ADV   ADV + LAM 
HBeAg –ve         







The authors report that these events all occurred 
after patients in the AAP group were randomised to 
placebo at week 40. 
 
There were no dose discontinuations in the trial 
by Rapti and colleagues,18 but two patients in the 
group receiving ADV and LAM had their ADV 
dose reduced, compared with zero reductions 
in the ADV monotherapy group. Three patients 
experienced HCC during the course of the trial, 
all in the ADV and LAM group. There was no 
statistically significant difference between groups 
(p = 0.545). Only serious adverse events were 
reported.  
In summary, the incidence of adverse events was 
low and generally similar between treatment 
groups. 
 
Adverse events – PEG--2b studies 
Table 25 reports dose discontinuations, reductions 
and incidence of serious adverse events in the PEG-
-2b studies. 
Chan and colleagues (2007)23  compared three 
groups receiving staggered regimens of PEG--2b 
and LAM as described above. Two patients in both 
Group A and Group C had their dose of PEG--2b 
halved owing to neutropenia (0.7–0.9 109/ml) at 
doses 6–19. While no patients in Group B had a 
dose reduction, one experienced a serious adverse 
event (hysterectomy for menorraghia). The authors 
state that this was unrelated to the study drug, 
and the study medication was uninterrupted. No 
patients in this study died. Each of the groups in 
this trial experienced generally similar numbers  
of adverse events; however, Group B (receiving 
PEG--2b for 8 weeks prior to commencing LAM) 
experienced the fewest adverse events. The largest 
apparent difference was in upper respiratory tract 
symptoms, where one incident occurred in Group 
B, compared with five (50%) in Group A and seven 
(70%) in Group C (not shown in Table 25; for more 
information refer to Appendix 1).  
In the trial by Chan and colleagues (2005),24  Group 




Weeks of ADV treatment 
Study, patient type, outcome 48 96 144 192 240 
 
Hadziyannis et al., 200620 
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Study, patient type, outcome Treatment group   p-value 
  Group A Group B Group C  
Chan et al., 200723 PEG--2b +LAM PEG--2b +LAM PEG--2b +LA M 
HBeAg +ve       
Resistance to LAM at week 104, 1/9  1/8 1/9 NR
rtM204V,  n/N     
Resistance to LAM at week 104, 0  0 1/9 NR
rtL108M and  rtM205I, n/N       
  Group A Group B  
Chan et al., 200524 PEG--2b + LAM LAM  
HBeAg +ve       
LAM‐resistant mutants, EOT, n/N (%)a  10/48 (21)  19/48 (40)  NR 
  Group A Group B  
Janssen et al., 200526 PEG--2b + LAM PEG--2b + placebo  
HBeAg +ve       
YMDD mutation (resistance to LAM),  14/130 (11) Not applicable  






Study, patient type, outcome Treatment group       p-value 
Zeng et al., 200619 PAA AAA   AAP  
HBeAg +ve           
Dose discontinuation  for any adverse event, n/N    2/240    1/120  NR 
Incidence of hepatitis B‐related adverse events, %  < 1  < 1    9a  NR 
Rapti et al., 200718 ADV   ADV + LAM  
HBeAg –ve           
Dose discontinuation  for any adverse event, n/N  0/14    0/28    NR 
Dose reduction for any adverse event, n/N  0/14    2/28b    NR 
a  All events occurred after re‐randomisation to placebo at week 40.
b  ADV dose reduced to 10 mg every other day. 
PAA = placebo–ADV–ADV; AAA = ADV–ADV–ADV; AAP = ADV–ADV–placebo.
  
than Group B (LAM monotherapy) of patients 
discontinuing the study drug (4 versus 0), dose 
reduction (5 versus 0) and serious adverse events 
(4 versus 0). The authors report that most adverse 
events were transient and related to the use of 
PEG--2b. No patient died or required liver 
transplantation. Reduction of the PEG--2b dose 
to 50 g/week (if body weight > 65 kg) or 1.0 g/ 
kg/week if < 65kg) was due to anaemia (n = 1), 
neutropenia (n = 3) and/or thrombocytopenia 
(n = 4). PEG--2b was discontinued in all four  
cases of serious adverse events, which were: bipolar 
disorder, pulmonary tuberculosis, thyrotoxicosis 
and severe local reaction at injection sites. Three 
patients continued with LAM through to week 60, 
while the fourth patient withdrew from the study 
and was considered a treatment failure. 
 
The most common adverse events in Groups A and 







Study, patient type, outcome Treatment group     p-value 
  Group A Group B Group C  
  PEG--2b + PEG--2b + PEG--2b + 
Chan et al., 200723 LAM LAM LAM  
HBeAg +ve         
Dose reduction for any adverse event, n/N  2/9  0/8  2/9  NR 
Serious adverse event, n/N  0/9  1/8  0/9  NR 
Total number of adverse events, n  42  34  45   
  Group A Group B    
Chan et al., 200524 PEG--2b + LAM LAM    
HBeAg +ve         
Dose discontinuation  (PEG‐‐2b)  for  any  adverse  4/40 (8)  0/44  NR 
event, n/N (%)   
Dose reduction (PEG‐‐2b) for any adverse event, 5/40 (10)  0/44  NR 
n/N (%)   
Serious adverse events, n/N (%)  4/40 (8)  0/44    NR 
Total number of adverse events, n  429  55    NR 
  Group A Group B    
Janssen et al., 200526 PEG--2b + LAM PEG--2b + placebo  
HBeAg +ve         
Dose reduction (PEG‐‐2b) for any adverse event, 37/148 (54)  32/152 (47) NS 
n/N (%)   
Blinded drug reduction  –  0     
Blinded drug discontinuation  –  24     
Incidents of common adverse events, n  557  539     
  Group A Group B    
Kaymakoglu et al., 200725 PEG--2 PEG--2b + LAM  
HBeAg –ve         
Dose discontinuation  for any adverse event, n/N  0/19  0/29     
Dose reduction for any adverse event, n/N  0/19  0/29     
  Group A Group B    
Zhao et al., 200727 PEG--2b IFN    
HBeAg +ve         
Dose discontinuation  for any adverse event, n/N  0/115  4/115    NR 
Dose reduction for any adverse event, n/N (%)  0/115  0/115     









included cough, running nose and sore throat. 
Group A had a higher proportion of patients 
experiencing adverse events across all types, and 
all of these differences between the two groups 
were statistically significant, apart from vomiting 
and diarrhoea, weight loss > 10% and abdominal 
discomfort (not shown in Table 25, for more 
information refer to Appendix 1).  
A follow-up publication30 of the trial by Janssen 
and colleagues26 reported that a slightly higher 
percentage of patients in Group A (PEG--2b and 
LAM) than Group B (PEG--2b and placebo) had 
the dose of PEG--2b reduced for any adverse 
event: 37 (54%) and 32 (47%) respectively. There 
was no significant difference between treatment 
groups, for these and for all side effects. The 
authors of this study reported discontinuations of 
PEG--2b across the two groups of patients (28, 
9%) but not how these were distributed between 
groups. Neutropenia was the most common reason 
for dose reduction in this trial (n = 36, 52%). The 
most common reason for early discontinuation was 
local reaction (n = 10, 36%). There were no dose 
reductions of LAM or placebo. Fifty per cent of  
the dose reductions occurred within the first 10 
weeks, with numbers of dose reductions decreasing 
thereafter and only two reported after week 32, 
when the scheduled dose reduction took place. 
Discontinuation of therapy was reported more 
frequently before the scheduled dose reduction of 
PEG--2b at week 32. 
There were 33 serious adverse events in the trial by 
Janssen and colleagues;26  the authors state that 17 
(53%) were probably related to therapy, and that all 
were reversible after treatment had stopped. The 
frequency of all side effects is reported as not being 
statistically significant between groups. 
 
Kaymakoglu and colleagues25 reported that no 
patients from either treatment group had their 
dose reduced or discontinued for any adverse 
event. Of the adverse events experienced, 71%  
were of flu-like symptoms. The authors do not 
comment on severity or likelihood of relation to the 
study drug.  
The study drug was discontinued in four patients 
in the group receiving IFN-, and in no patients in 
the group receiving PEG--2b in the trial by Zhao 
and colleagues.27 There were no dose reductions 
in either group. The authors report that 75% of 
patients in each group experienced ‘various forms’ 
of drug-related adverse events, the most common 
of which, again, were flu-like symptoms and fever.  
In summary, there were mixed findings for adverse 
events. In some trials, the incidence of events 
and dose discontinuations was generally similar 
between treatments. In at least one trial, there was 
a higher incidence of events and discontinuations 
for PEG--2b and LAM compared with LAM. 
Common adverse events included flu-like 













Methods for economic 
analysis 
The aim of this section is to provide an update of 
the cost-effectiveness assessment of PEG-and  
ADV in our original report.12 The economic analysis 
comprises:  
• a systematic review of the 2005–7 publications 
on the cost-effectiveness of PEG-and ADV 
• an update of our previously published 
economic model.12 
 
Systematic review of 
economic evaluations 
Search     strategy 
This review was guided by the general principles 
for conducting a systematic review outlined in 
the CRD Report 4.13  Details on the literature 
search methods to identify published economic 
evaluations are described in Chapter 2. 
 
Titles and abstracts of studies identified by the 
search strategy were independently assessed for 
potential eligibility by two health economists. Full 
economic evaluations were eligible for inclusion if 
they reported on the cost-effectiveness of PEG-   
(2a and 2b) and/or ADV versus the specified 
comparators (IFN-and LAM or best supportive 
care) in adults with CHB. Studies reporting the 
economic evaluation of  comparator treatments  
were also identified. In addition, recently published 
studies on health-related quality of life in patients 
with CHB were considered for potential use in 
the update of our economic model (see below). 
Health-related quality of life literature searches 
were run in MEDLINE, PREMEDLINE, EMBASE 
and PsycINFO Ovid databases. The searches were 




Data were extracted from the included cost- 
effectiveness studies using a standardised template. 
Data extraction was undertaken by one reviewer 
and checked by a second, with any disagreements 
resolved through discussion. Full data extraction 
forms of all the included studies can be found in 
Appendix 4. 
Quality assessment strategy 
Economic evaluations were assessed using  
the critical appraisal checklist for economic 
evaluations. The checklist was consistent with 
methodology proposed by Drummond and 
colleagues36 and Philips and colleagues37 for 
assessing good practice in decision-analytic 
modelling in published economic evaluations. See 
Appendix 4 for details.  
Results of the systematic 
review: cost‐effectiveness 
Our previously published assessment report12 
included:  
• one fully published economic evaluation 
of treatments for CHB, including ADV as 
monotherapy and as a salvage strategy for 
LAM-resistant patients38 
• six fully published economic evaluations of 
antiviral treatments for CHB (IFN-and 
LAM)8,39–43 
• two unpublished drug manufacturers’ 
submissions to NICE – the Roche submission 
evaluating PEG--2a versus IFN-, LAM,    
ADV and best supportive care; and the Gilead 
Sciences submission evaluating ADV as first- 
and second-line treatment versus LAM as first- 
or second-line treatment. 
 
The characteristics and results of these studies 
are not presented in the current report. However, 
where appropriate, two of these evaluations, 
Kanwal and colleagues38 and the Roche submission, 
are discussed. For clarity of presentation, the 
outcomes reported by Kanwal and colleagues38 
are presented separately for HBeAg-positive and 
HBeAg-negative patients. The original model used 
in the Roche submission remains unpublished and 
is not reviewed here. A description is available in 
our previous report.12 
 
A total of 67 publications of the cost-effectiveness of 
PEG-and/or ADV in CHB were identified through 
our updated searches. Four fully published 
economic evaluations met the inclusion criteria  
and were included.44–47   In addition, one systematic 
review of economic evidence of cost-effectiveness  
of antiviral therapies in CHB patients (Sun and 







The studies by Veenstra and colleagues44 
and Sullivan and colleagues45 estimated cost- 
effectiveness of PEG--2a compared with LAM  
in HBeAg-positive patients. The same model was 
used in both studies; however, the perspective in 
Veenstra and colleagues44  was that of the UK NHS, 
while in Sullivan and colleagues45  the perspective 
was of the Taiwan Bureau of National Health 
Insurance. The newly identified study by Kanwal 
and colleagues (2006)46   used the model first 
presented in Kanwal and colleagues (2005)38   to 
estimate cost-effectiveness of alternative treatments 
for CHB in the subgroup of patients with cirrhosis 
(both compensated and decompensated). Buti and 
colleagues47   conducted an economic evaluation 
comparing ADV with LAM in HBeAg-negative 
patients. 
 
A systematic review of cost-effectiveness of antiviral 
therapies (Sun and colleagues48) described studies 
published from 2000 to 2007, including three 
studies described here (Kanwal and colleagues38, 
Buti and colleagues47   and Sullivan and colleagues45) 
and some of the studies identified in our previous 
review.12  Sun and colleagues48  also reviewed other 
cost studies based on randomised, non-randomised 
and retrospective cohort data that did not meet 
the inclusion criteria of the present or previous 
reviews and were generally assessed by Sun and 
colleagues48 as being of moderate or poor quality. 
These studies are therefore not discussed any 
further in the present review.  
Description of  the published 
economic  evaluations 
Table 26 provides a summary of characteristics of 
the identified economic evaluations reporting the 





Four of the five economic evaluations presented in 
Table 26 employed a Markov state-transition model; 
Buti and colleagues 47 used a decision tree analysis. 
All modelled economic evaluations incorporate 
health states that correspond to the natural history 
of the disease. The model presented in Buti and 
colleagues47 has a 4-year time horizon; other 
models have a lifetime horizon as appropriate for 
the chronic nature of the disease.  
The state-transition diagrams presented in 
each of these evaluations are broadly similar. 
Typically, patients enter the model in the ‘chronic 
HBV’ health state and receive the evaluated 
intervention, one of the comparator treatments 
or best supporting care. In accordance with the 
natural history of the disease, patients may then 
remain in this state, achieve treatment-induced 
response (HBeAg seroconversion in HBeAg- 
positive patients or viral suppression that can be 
achieved by both HBeAg-positive and -negative 
patients) or experience treatment relapse (return 
to CHB). Patients could also develop resistance to 
the active treatment (a virological breakthrough). 
Patients who do not achieve a response can also 
enter more progressive stages of liver disease (such 
as compensated or decompensated cirrhosis or 
hepatocellular carcinoma). Patients in the study 
by Kanwal and colleagues46 enter the model at the 
cirrhotic stage, which can be either compensated or 
decompensated. The best outcome in this subgroup 
of CHB patients is to remain in the compensated 
cirrhosis stage or revert from decompensated 
to compensated cirrhosis either as a result of 
treatment or spontaneously.  
With the exception of the model reported by Buti 




  Veenstra et  al., 
200744 
Sullivan et al., 





Type of model Adapted from Adapted from Anewdecision‐analytic A new hybrid Adapted from
Crowley42 and  Crowley42 and model modela   consisting  Kanwal et al.38 
Crowley et al.43  Crowley et al.43  of two submodels  for the subgroup
and Pwu and  and Pwu and of patients with
Chan.49 Two Chan49. Two cirrhosis
additional health  additional health  
states – ‘liver  states – ‘liver
transplantation’  transplantation’
and  ‘post‐liver  and  ‘post‐liver










Veenstra et al., Sullivan et al.,  Kanwal et al., Kanwal et al., 
200744 200745 Buti et al., 200647 200538 200646 
Health states/  Seroconversion  Seroconversion  Over 4 years patients  Chronic HBV  Compensated 
stages of      may progress though  infection  cirrhosis 
treatment  Chronic hepatitis  Chronic  the following stages: 
pathway  B  hepatitis B    Virological  Decompensated 
Compensated  Compensated  Receiving initial  response (either  cirrhosis 
cirrhosis  cirrhosis  active treatment with  spontaneously or  Successful liver 
response  due to treatment)  transplant Decompensated  Decompensated  Continuing initial  Virological  relapse 
cirrhosis  cirrhosis  active treatment with    Hepatocellular 
Hepatocellular  Hepatocellular  response  Developing viral  carcinoma resistance 
carcinoma  carcinoma  Developing   resistance    Death 
Liver  Liver  to initial active  Compensated 
transplantation  transplantation  treatment  cirrhosis 
Post‐liver  Post‐liver  Receiving ADV  Decompensated 
transplant  transplant  treatment and  cirrhosis 
continuing with  Liver  transplant 











Characteristics  32 years old  32 years of age  Mean age of patients  40 years of age  50 years of age 
of baseline      varied  from 45 to 49 
cohort  78% male  78% male  years  Elevated ALT,  50% with no evidence of  compensated 
87% Asian  87% Asian  Proportion of males  cirrhosis and no  cirrhosis  and 
17% with  17% with  varied from 74% to  previous CHB  50%  with 
compensated  compensated  83%  treatment  decompensated 
cirrhosis or  cirrhosis or  Proportion of patients  55% of the cohort  cirrhosis 






Cycle length  1 year  1 year  1 year  1 year  1 year 
Time horizon  Lifetime  Not reported,  4 years  Lifetime  Lifetime 
appears to be 
lif i
a Patient progression  through pre‐cirrhotic health  states  is analysed with decision‐analytic model. Progression  through 
cirrhotic health states  is analysed by means of a Markov model. 
b Although not clearly  identified,  ‘progressing to decompensated  liver disease’  is used as an  implicit outcome that only 














  Kanwal et al., 200538     Kanwal et al., 200646 
Veenstra et al., Sullivanetal., CHB patients with  200744 200745 Buti et al., 200647 HBeAg +ve cohorta HBeAg –ve cohorta   cirrhosis
Perspective  UK National Health  Taiwan Bureau of Spanish Public US third‐party payers US third‐party payers US third‐party payers
Service National Health Health System
    Insurance          
Study  type  CEA and CUA  CEA and CUA CEA (incremental CUA CUA   CUA
cost per additional
patient with
      response)        
HBeAg status  +ve  +ve  –ve  +ve  –ve    Not differentiated 
Intervention(s)/  PEG‐‐2a 180 mg  PEG‐‐2a 180mg LAM monotherapy  Strategy 1: no pharmacological  Strategy 1: no pharmacological   Strategy 1: no pharmacological

















































































Kanwal et al., 200538 Kanwal et al., 200646 
Veenstra et al., Sullivan et al., CHB patients with 
200744 200745 Buti et al., 200647 HBeAg +ve cohorta HBeAg –ve cohorta cirrhosis 
Treatment  HBeAg  HBeAg  ‘Response to  Virological response is defined  Virological response is defined  The following clinical 
effect(s) modelled     seroconversion  seroconversion  treatment’ is  as HBeAg seroconversion.  as ‘fully suppressed HBV  outcomes were included 
defined as a  In addition the following  replication while maintaining  in  the model: progression 
(32% PEG‐‐2a vs  (32% PEG‐‐2a vs  ‘decrease in serum  outcomes are used in the  normal ALT’. In addition  from  compensated 19% LAM; Lau et  19% LAM; Lau et  HBV DNA to  model: developing resistance  the following outcomes  to  decompensated 
al., 200550)  al., 200550)  undetectable levels  to active treatment; relapsing  are used in the model:  cirrhosis;  regression 
by polymerase  from virological response;  developing resistance to  from decompensated to 
chain reaction  progression to compensated  active treatment; relapsing  compensated  cirrhosis; 
assay; ‘resistance  cirrhosis; progression  from virological response;  progression from cirrhosis 
to treatment  from compensated  progression to compensated  to  hepatocellular  carcinoma; 
is defined  as                                to decompensated                                cirrhosis; progression                               developing  resistance  to  initial 
‘reappearance                 cirrhosis; regression                           from compensated                          pharmacotherapy; progression
of HBV DNA in              from decompensated to                   to decompensated                              to liver transplantation; 
serum due to the  compensated cirrhosis;  cirrhosis; regression  progression  to  cirrhosis 
emergence of  progression to hepatocellular  from decompensated to  following  liver  transplantation. 




trials. A weighted mean                    estimated by  collecting data                    across  relevant outcomes was 
across  relevant  outcomes  was  across  149  studies  and  clinical  calculated  using  a  sample  size 
calculated using a sample size        trials. A weighted mean                   as the weight 
as  the  weight                                            across  relevant  outcomes  was 











Kanwal et al., 200538 Kanwal et al., 200646 
Veenstra et al., Sullivan et al., CHB patients with 
200744 200745 Buti et al., 200647 HBeAg +ve cohorta HBeAg –ve cohorta cirrhosis 
Currency base  2005 UK£  2004 NTD  2004   2004 US$  2004 US$  2005 US$ 
 
Base‐case results  A 32‐year‐old with  A 32‐year‐old  An incremental  ADV salvage is a dominant  ICER of IFN monotherapy vs  ICER of ADV monotherapy 
HBeAg +ve CHB  with HBeAg +ve  cost (discounted  strategy  ‘doing nothing’ is $2280  vs ‘doing nothing’ is 
gains 0.39 life‐years  CHB gains 0.33  at 3%) of an      $19,731($14,342– $24,224) 
and 0.30 QALYs  life‐years and  additional HBeAg  Both costs and QALYs were  ICER of ADV monotherapy vs 
(both discounted  0.41 QALYs (both  –ve patient with  discounted at 3%  IFN monotherapy is $16,693  ICER of ADV monotherapy 
at 1.5%) with  discounted at 3%)  response is about    ICER of ADV monotherapy vs  vs entecavir monotherapy is 
incremental  with incremental   280,000  ADV salvage is $90,983  $25,626 ($19,637 –$31,184) 
lifetime cost of  lifetime cost of  ADV  salvage, entecavir  salvage
£3100 (discounted  NTD 156,000  LAM monotherapy was  and LAM monotherapy are all 
at 6%) for PEG‐  (discounted at  dominated  dominated ‐2a treatment  3%) for PEG‐  Both costs and QALYs were 
compared with  ‐2a treatment  discounted at 3%  Both costs and QALYs were 




a    For clarity of presentation,  the outcomes of economic evaluations  reported  in Kanwal et al.38  are presented separately  for HBeAg +ve and HBeAg –ve  subgroups of patients.  In 
the base‐case  analysis,  ICER of  IFN monotherapy  vs  ‘doing nothing’  is  $6337;  ICER of ADV monotherapy  vs  interferon monotherapy  is  $8446. Both ADV monotherapy  and  LAM 





the possibility of patients with progressive liver 
disease to undergo liver transplantation. Kanwal 
and colleagues (2006)46  specified that patients in 
decompensated cirrhosis health states (ascites, 
variceal haemorrhage and hepatic encephalopathy) 
and HCC could undergo liver transplantation. 
According to the assumptions of the model 
reported in Veenstra and colleagues44 and Sullivan 
and colleagues,45 patients with HCC do not receive 
a liver transplant. Table 27 presents further details 
of the included economic evaluations including 
base-case results.  
Details of economic evaluations 
based on the Roche model 
As noted earlier, two economic evaluations 
(Veenstra and colleagues44 and Sullivan and 
colleagues45) use the same model to evaluate PEG- 
-2a versus LAM in HBeAg-positive patients. This 
model uses the structure and some of the transition 
probabilities presented in 2005 in the Roche 
submission to NICE for their appraisal of PEG-- 
2a. The model evaluated a 48-week course of PEG- 
-2a versus comparators IFN-, LAM, ADV and 
best supportive care. (For a fuller description see 
our previous report.12) However, unlike the Roche 
model, economic evaluations reported in Veenstra 
and colleagues44 and Sullivan and colleagues45 
apply exclusively to an HBeAg-positive population.  
The 48-week outcomes of the RCT of PEG--2a 
versus LAM reported by Lau and colleagues50 
provided short-term clinical effectiveness data for 
the base-case analysis in all three of these models. 
Long-term clinical effectiveness data (rates of 
seroconversion, relapse and LAM resistance) were 
taken from previously published studies (Liaw and 
colleagues,51   Leung and colleagues 52   and Lok  
and  colleagues53).  The  Roche  model  estimated 
cost-effectiveness of a 48-week course of PEG- 
-2a versus two LAM treatment alternatives: 
treatment for 48 weeks and for 4 years. Veenstra 
and colleagues44   estimated cost-effectiveness of a 
48-week course of PEG--2a versus up to 4 years of 
LAM treatment (i.e. patients who do not achieve a 
sustained seroconversion after 48 weeks continue 
LAM treatment for up to 4 years or until they 
achieve seroconversion). Sullivan and colleagues45 
assumed that a 48-week course duration is applied 
to both PEG--2a and the comparator, LAM.  
Demographic and clinical characteristics of the 
hypothetical cohort of patients in Veenstra and 
colleagues44 and Sullivan and colleagues45 mirrored 
the baseline characteristics of patients enrolled 
in the RCT reported by Lau and colleagues.50 
Of note, 87% of patients in the modelled cohort 
of CHB patients were Asian. This population 
may not be representative of the general 
population in England and Wales, which may 
limit generalisability of the outcomes of the cost- 
effectiveness analysis.  
All three studies use a Markov model 
consisting of the following health states 
(CHB, HBeAg seroconversion, compensated 
cirrhosis, decompensated cirrhosis, HCC, liver 
transplantation, post-liver transplantation and 
death). A health state not included in these studies 
is HBsAg seroconversion, a state which has been 
included in other economic evaluations (e.g. 
Crowley42   and Crowley and colleagues43). The 
outcomes are expressed as incremental cost per 
quality-adjusted life-year (QALY) in these studies. 
Sensitivity analysis is performed in all three studies.  
As in the model presented in the Roche submission 
to NICE, Veenstra and colleagues44 and Sullivan 
and colleagues45 did not include the short-term 
effect of antiviral therapy on progression to 
compensated cirrhosis, such as that estimated in 
recent economic evaluations of LAM (Orlewska,41 
Crowley42 and Crowley and colleagues43 The base- 
case analyses in Veenstra and colleagues44 and 
Sullivan and colleagues45 did not include the effect 
of LAM resistance. Drug resistance was explored 
in the scenario analysis reported in Veenstra and 
colleagues44 but not in Sullivan and colleagues45 
In the base-case analysis of these models, it was 
assumed that by taking HBeAg seroconversion 
rates from long-term follow-up (which show 
reducing denominators over time), some of the 
effects of drug resistance, as indicated by reduced 
seroconversion rates, will have been captured.  
Drug acquisition costs were taken from the most 
recent (at the time of writing) British National 
Formulary in Veenstra and colleagues44 and in  
the Roche model, and from the 2004 Taiwan Fee 
Schedule for Medical Service in Sullivan and 
colleagues45  
As stated in our previous review,12 in the Roche 
model the health-state costs were developed by 
means of a combination of methods, including 
assumption, bottom-up costing using protocols 
based on expert opinion and extrapolation from 
costs developed for previous submissions. These 
costs were not adjusted for the differences in the 
intensity of medical management between the 
treatment groups. We previously12 also noted that 








health state has zero costs and does not correspond 
with current clinical guidelines that suggest that 
seroconverted patients should be reviewed every 
method of cost estimation and the difference in the 
population cohort. 
6–12 months, during which time their serological 
status/HBV DNA should be assessed and a screen 
Details of economic evaluations based 
on the Kanwal and colleagues38 model 
for HCC should be undertaken. The original model was published in 2005 (Kanwal 
  and colleagues38) and assessed in our earlier 
In the recent publication by Veenstra and report.12 Kanwal and colleagues concluded that 
colleagues,44 estimates of the costs of management in the base-case analysis (with 55% of patients 
of patients in different health states were taken being HBeAg negative at baseline), neither LAM 
directly from the economic evaluation in our nor ADV monotherapy is cost-effective in chronic 
previous report.12 Health-state costs used in our HBV infection. However, depending on financial 
previous economic evaluation were estimated restrictions, either IFN or a hybrid strategy that 
specifically for the assessment. The costs were reserves ADV as a salvage therapy only for LAM- 
a combination of values from published cost resistant patients may be cost-effective. The 
estimates for the progressive stages of liver disease objective of the more recent publication of Kanwal 
and estimates based on treatment protocols and colleagues46  was to estimate cost-effectiveness 
developed with expert advisors to the project. Unit of alternative therapies in the subgroup of the CHB 
costs for health-care resources were obtained from population with cirrhosis, and, in particular, to 
the finance department at Southampton University test whether the newer and more expensive agents 
Hospitals Trust. such as ADV and entecavir become cost-effective 
  in this subgroup. The structure and transition 
Sullivan and colleagues45 obtained cost estimates probabilities in the model reported by Kanwal and 
for the disease states of CHB and compensated colleagues38 were adjusted for the subgroup of CHB 
and decompensated cirrhosis by applying the 2004 patients with cirrhosis. 
Taiwan Fee Schedule for Medical Service unit costs 
to the resource use reported by treating clinicians At baseline, 50% of patients in the cohort 
(no further details are provided). Cost estimates have compensated cirrhosis and 50% have 
for HCC were taken from the published literature decompensated cirrhosis, and in each treatment 
(Wang and Kowdley54). Liver transplantation and arm separate transition probabilities are assigned 
post-transplantation costs were obtained from the to patients in the compensated and decompensated 
Chang Gung Memorial Hospital in 2004. cirrhosis groups as they progress through the stages 
  of the disease. The baseline ratio of patients with 
Veenstra and colleagues44 and the Roche compensated versus decompensated cirrhosis was 
submission used the same approach to estimating tested in the sensitivity analysis. 
utility values. This was based principally on values 
reported by Wong and colleagues.8 Sullivan and As noted earlier, in the study by Kanwal and 
colleagues45 used higher estimates of utility in four colleagues,46 the best outcome in the subgroup 
health states (seroconversion, CHB, compensated of cirrhotic patients is either to remain in the 
cirrhosis and HCC), based on Pwu and Chan49 and compensated cirrhosis stage or to revert from 
Bennett and colleagues55  (see Table 28 below). decompensated to compensated cirrhosis as a 
  result of treatment or spontaneously. Patients 
Sullivan and colleagues45 concluded that treatment reverting to compensated cirrhosis were eligible 
with PEG--2a compared with LAM results in to decompensate a second time. The rate of 
higher total cost but longer quality-adjusted life subsequent decompensation was higher than 
expectancy, yielding an ICER of NTD381,000 the initial rate. Hepatocellular carcinoma 
or US$12,000 at 2004 prices). As in the Roche could develop at any stage and all patients with 
submission, Veenstra and colleagues44 confirmed decompensated cirrhosis or HCC were eligible for 
that PEG--2a is associated with higher discounted a liver transplant. 
total health-care cost but also with additional 
discounted QALYs compared with long-term (up The study evaluated cost-effectiveness of six 
to 4 years) LAM treatment. The estimated ICER strategies in treatment of cirrhosis in CHB patients: 
of £10,444 is almost twice as high as the ICER of 
£5948 reported in the Roche original submission. • strategy 1: no pharmacological treatment of 







• strategy 2: LAM monotherapy 100 mg once 
daily for an indefinite period 
• strategy 3: ADV monotherapy 10 mg once daily 
for an indefinite period 
• strategy 4: LAM with crossover to ADV on 
development of resistance (‘ADV salvage’ 
strategy) 
• strategy 5: entecavir monotherapy 0.5 mg once 
daily for an indefinite period 
• strategy 6: LAM with crossover to entecavir on 
development of resistance (‘entecavir salvage’ 
strategy).  
The first four strategies are relevant to the scope of 
this report.  
Unlike the 2005 study by Kanwal and colleagues,38 
the 2006 study46  did not include a treatment 
strategy based on IFN-, as this is not approved 
for patients with decompensated cirrhosis. In both 
studies, the perspective is of a US third-party payer. 
 
In both studies38,46 estimates of costs of health-care 
resources were obtained by (1) calculating direct 
cost estimates by multiplying unit prices for the 
drugs and medical services by the estimated use of 
these resources in natural units, and (2) combining 
these costs with other cost estimates (e.g. costs of 
complications) obtained from the literature. In 
particular, in Kanwal and colleagues,46 costs of 
physician services and procedures were obtained 
from the 2005 American Medical Association 
Current Procedural Terminology codebook and the 
2005 Medicare Fee Schedule. Pharmaceutical costs 
were obtained from the average wholesale prices 
(AWPs) listed in the 2006 Red Book. Cost estimates 
for cirrhosis and related health states were obtained 
from a published study of detailed, itemised 
inpatient and outpatient direct costs incurred by 
patients with cirrhosis (Bennett and colleagues55). 
While the model first presented in the Roche 
submission has only one health state corresponding 
to decompensated cirrhosis, the structure of the 
model in Kanwal and colleagues38,46 differentiates 
between different types of decompensation (i.e. 
variceal haemorrhage, ascites and encephalopathy), 
which allowed for a more precise estimation of the 
associated costs in the first and subsequent years.  
In both studies,38,46 transition probabilities were 
obtained from a systematic review of the literature. 
Appendix 5 compares transition probabilities used 
in studies assessed in our previous report12 and 
those in the present report (the study by Buti and 
colleagues47 is not included in this appendix, as 
explained below). 
The model reported in Kanwal and colleagues38,46 
used utility values obtained from the literature 
that reported utilities for chronic liver disease 
associated with hepatitis C. Kanwal and colleagues 
argue that both hepatitis C and hepatitis B lead 
to cirrhosis and related complications and there is 
no a priori reason to believe that the quality of life 
decrements assigned to the corresponding health 
states would depend on the underlying aetiology. 
(The same approach was used in the economic 
evaluation conducted in our previous report.12  
Table 28 compares utility values used in studies 
assessed in our previous report12 and in the present 
report, with the exception of the study by Buti and 
colleagues47).  
The result of economic modelling in Kanwal and 
colleagues (2006)46  indicated that: 
 
• LAM monotherapy is dominated. 
• The ICER of ADV monotherapy versus ‘doing 
nothing’ is $19,731($14,342–$24,224) at 2005 
prices. 
• The ICER of ADV monotherapy versus 
entecavir monotherapy is $25,626 ($19,637– 
$31,184) at 2005 prices. 
• ADV salvage strategy is dominated. 
• Entecavir salvage strategy is dominated. 
 
The sensitivity analysis showed that the model 
outcomes were sensitive to the cost of ADV and 
entecavir; the annual rate of progression from 
compensated to decompensated cirrhosis with 
LAM resistance; the annual rate of progression 
from compensated to decompensated cirrhosis 
with entecavir (no resistance); the annual rate of 
progression from compensated to decompensated 
cirrhosis with ADV (no resistance); and the  
annual rate of progression from compensated to 
decompensated cirrhosis with ADV resistance. 
For example, if the incidence of progression from 
compensated to decompensated cirrhosis in LAM- 
resistant patients is less than the threshold of 3.5% 
(8% in the base-case analysis), than LAM becomes 
cost-effective. The results were robust with respect 
to the baseline ratio of patients with compensated 
versus decompensated cirrhosis.  
Details of economic evaluation 
reported by Buti and colleagues47 
Buti and colleagues47   estimate cost-effectiveness  
of a 4-year LAM with ADV as a salvage therapy 
strategy for LAM-resistant patients compared with 










In the decision tree model, different health states 
in two treatment groups are assigned to describe 
patient progression:  
• In the LAM arm, these are: receiving LAM 
treatment with response; continuing LAM 
treatment with response; developing resistance 
to LAM, followed by receiving ADV as a 
salvage therapy; receiving ADV treatment with 
response; and developing resistance and no 
response to ADV treatment, in which case no 
other active treatment is received. 
• In the ADV arm, these are: receiving ADV 
treatment with response; continuing ADV 
treatment with response; and developing 
resistance to ADV, in which case no other active 
treatment is received. 
rather than a lifetime horizon, as is appropriate  
in a chronic disease. A discounting factor is 
applied only to costs and not to the outcomes. The 
outcome of cost-effectiveness analysis is expressed 
in terms of additional cost per patient with 
response [defined as decrease of serum HBV DNA 
to undetectable levels by polymerase chain 
reaction (PCR) assay] instead of the conventional 
incremental cost per incremental QALY. Another 
methodological shortcoming is that clinical 
effectiveness data used in the two treatment 
groups come from different clinical trials and may 
therefore involve patient populations with different 
baseline characteristics. These shortcomings may 
potentially introduce a bias to the cost-effectiveness 
estimates, which may compromise the outcomes of 
the cost-effectiveness analysis. 
 
Other health states that characterise disease 
progression (e.g. compensated and decompensated 
cirrhosis, HCC, liver transplant) are not 
explicitly included in the model. Nevertheless,  
a certain proportion of patients who do not 
receive treatment are assumed to develop a 
‘decompensated CHB’, which includes cirrhosis, 
hepatic encephalopathy, varicose haemorrhage, 
ascites and hepatocarcinoma, and is associated 
Buti and colleagues47   estimated an incremental 
cost of ADV per additional patient with response 
at   27,872  at  2003  prices.  Notwithstanding  the 
shortcomings listed above, the results expressed 
in units other than QALYs renders the study 
outcomes of limited use for decision making in the 
area of allocating the limited health-care resources 
across the treatment alternatives. 
with the aggregated ‘cost of decompensation’ of Health‐related quality of life  in 
 172.50. Buti and colleagues47  do not provide patients with chronic hepatitis B 
a clear explanation of either the proportion of The models reported in Kanwal and 
patients with decompensation or the monetary colleagues,38,46  Veenstra and colleagues 44  and 
value of health-care resources associated with Sullivan and colleagues45 assume that health 
treatment of decompensated CHB. In particular, states corresponding to the stages of natural 
it is not clear what proportion of patients (if any) disease progression (CHB, response, resistance, 
start at the compensated cirrhosis state from which compensated cirrhosis, decompensated cirrhosis, 
decompensated cirrhosis is later developed. It does HCC, liver transplantation and post-liver 
not appear that a systematic review of the clinical transplantation) determine the patients’ quality 
evidence used in the model was undertaken. of life. This is consistent with approaches used in 
The probability of response, non-response and previous published economic evaluations of CHB 
resistance seem to have been derived from treatments (Wong and colleagues8, Shepherd and 
averaging the response rate across a few selected colleagues12). The study by Buti and colleagues47 
studies, including non-randomised observational does not include outcomes assessed in terms of 
studies (see Appendix 4 for details). It assumed QALYs. 
that patients receiving an active treatment, 
including those with compensated cirrhosis at A recent study by Levy and colleagues56  was 
baseline, do not develop decompensated CHB. identified during the literature search. In this 
This assumption is not consistent with assumptions study, standard gamble utilities were elicited 
used in other economic evaluations.12,38,44–46 using an interviewer-administered survey from 
  populations in six countries, with a total of 534 
Although the systematic review by Sun and HBV-infected patients and a total of 600 uninfected 
colleagues48 assessed the economic evaluation respondents. The study aimed to recruit 100 HBV- 
reported in Buti and colleagues 47 as being of infected and 100 uninfected respondents from each 
high quality in comparison with the other models country. Chronic hepatitis B was not differentiated 
discussed above, it is characterised by a number with respect to its variants (i.e. HBeAg positive or 
of shortcomings, in addition to the issues outlined negative). Utility values were obtained in relation 
earlier. It has a short time horizon of just 4 years 
48 






decompensated cirrhosis, liver transplantation, 
post-liver transplantation and HCC. Utility values 
for other health states that are typically included in 
the models (e.g. response to treatment or resistance 
to treatment) were not elicited.  
Although the study by Levy and colleagues56 
included a representative sample of the population 
from six countries, it is uncertain whether the UK 
sample consisting of 100 HBV-infected patients 
and 100 uninfected respondents is representative 
of the UK population. Levy and colleagues56 
observed that uninfected respondents had higher 
mean utility values than infected respondents for 
most of the health states.  
Table 28 presents the age- and sex-adjusted utility 
values elicited from 100 HBV-infected patients and 
100 uninfected respondents in the UK study by 
Levy and colleagues,56 alongside the baseline values 
used in the economic evaluation presented in our 
original report.12  
The utility weights, reported by Levy and 
colleagues,56 elicited from the compensated 
cirrhosis state, liver transplant and post-liver 
transplant health states are markedly higher than 
the utility weights used in our previous economic 
evaluation.12 Another observation is that, according 
to Levy and colleagues,56 there is a substantial 
decrease in utility in patients in transition from 
compensated to decompensated cirrhosis. In 
our economic model,12  the largest decrease in 
utility occurs in patients in transition from CHB 
to compensated cirrhosis. The effect of these 
differences on the cost-effectiveness analysis of 
alternative treatments for CHB is explored in the 
update of our economic model, below. 
Comparison of estimates of 
health-related quality of life 
Table 29 compares health-state utilities used 
in different economic evaluations of antiviral 
treatment for patients with CHB. For completeness, 
the methodologically robust studies that used utility 
weights and were assessed in our previous report12 
are included, along with the economic evaluations 
identified in our update search.  
Economic evaluations by Wong and colleagues,8 
Crowley,42 Crowley and colleagues43 and Dusheiko 
and Roberts39 applied health-state utility estimates 
derived from clinicians’ opinion rather than 
from patients’ preferences. These estimates 
are characterised by a large variation. Some  
of these estimates were subsequently reused in 
our previous model,12 and in models by Kanwal 
and colleagues38,46  Veenstra and colleagues44 
and Sullivan and colleagues,45 along with utility 
weights elicited from patients with hepatitis C (see 
Appendix 4 for details). The utility values elicited 
by Levy and colleagues56 from the HBV population 
generally fall within this broad range of estimates 
used in different economic evaluations. 
 
Summary 
We identified four recently published economic 
evaluations in our update search. The studies 
assessed the cost-effectiveness of PEG--2a, LAM, 
ADV, entecavir and best supportive care. None of 
the studies featured PEG--2b. 
 
The economic evaluation reported in Kanwal 
and colleagues (2006),46 based on the evaluation 
by Kanwal and colleagues (2005),38 was strongest 
methodologically. They conducted comprehensive 






Values elicited from 
uninfected/infected  UK 
respondents56 
Values at baseline in 
HBeAg +ve model12 
Values at baseline in 
HBeAg  –ve  model12 
CHB  0.88/0.69  0.89  0.87 
Compensated cirrhosis  0.87/0.68  0.49  0.47 
Decompensated cirrhosis  0.36/0.35  0.39  0.37 
Hepatocellular carcinoma  0.42/0.42  0.39  0.37 
Liver transplant  0.69/0.57  0.38  0.36 
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‘Cured’ state  Not used in Not used in  Not used in UK age‐specific Not used in model  Not used in model Not used in model Not estimated
(HBsAg  –ve)  model model  model population‐based
utility (Kind et al.,
        199957)        
Seroconversion  0.93 0.78  0.90 UK age‐specific UK age‐specific 1.0 1.0h  Not estimated
(HBeAg  –ve,      population‐based population‐based  (Pwu and Chan, 200249) (Wong et al.,19958)
HBsAg +ve)  utility (Kind et al., utility (Kind et al., 
        199957) 199957)      
Chronic  0.89b  0.69c  0.80 0.91–0.04=0.87 0.87f  0.95 0.99i  0.88/0.69
hepatitis B        (Wong et al.,19958)  (Wong et al.,19958)  (Pwu and Chan, 200249)  (Wong et al.,19958)   
Compensated  0.87 0.56  0.50 0.91–0.44=0.47 0.84 0.9 0.8 0.87/0.69
cirrhosis        (Wright et al., 200558)  (Wong et al.,19958)  (Pwu and Chan, 200249)  (Chong et al., 200359)   
Decompensated  0.54 0.15  0.20 0.91–0.54=0.37 0.46 0.54g  0.6 0.36/0.35
cirrhosis        (Wright et al., 200558)  (Wong et al.,19958)8  (Wong et al.,19958)  (Chong et al., 200359)   
Hepatocellular  0.49 0.12  0.20 0.91–0.54=0.37 0.41 0.5g  0.73 0.42/0.42
carcinoma        (Wright et al., 200558)  (Wong et al.,19958)  (Bennett et al., 199755)  (Chong et al., 200359)   
First liver  Not used in Not used in  Not used in 0.91–0.55=0.36 0.42 0.5g  Not used in model 0.69/0.57
transplant  model model  model (Ratcliffe et al., (Bennett et al., (Bennett et al., 199755)
        200260) 199755)      
Post‐liver  Not used in Not used in  Not used in 0.91–0.32=0.59 0.62 0.7g  0.86 0.82/0.66
transplantation  model model  model (Ratcliffe et al., (Bennett et al., (Bennett et al., 199755) (Chong et al., 200359)
        200260) 199755)      
a   Derived utilities based on clinical opinion. 
b  An absolute decrease in utility of 0.13 applied to IFN arm compared with no treatment arm for the duration of IFN treatment (16 weeks).
c    An absolute decrease in utility of 0.23 applied  to IFN arm compared with no treatment arm for the duration of  IFN treatment (16 weeks). An absolute decrease in utility of 0.08
applied to LAM arm compared with no treatment arm.
d   Decrements  in utility values are applied to the cohort of 40‐year‐old patients entering the first cycle of the model. 
e   Utility values reported in Veenstra et al.44  are applied to the cohort of 40‐year‐old patients entering the first cycle of the model.
f     An absolute decrease in utility of 0.05 applied to PEG‐‐2a arm compared with LAM arm (Wong et al.8).
g    In contrast to the utility values reported  in Veenstra et al.44, those reported in Sullivan et al.45 are not adjusted for age‐specific population‐based utilities.
h   Kanwal et al.46  applied the utility value of 1.0 to the health state described as ‘durable virological response’. In Wong et al.,8 the utility value of 1.0 is assigned to HBsAg +ve and
HBeAg –ve patients.





of HBV therapies using a population that was 
representative of the patient mix observed in 
practice. In contrast, Veenstra and colleagues,44 
Sullivan and colleagues45 and Buti and colleagues47 
undertook only a pairwise comparison of treatment 
alternatives in a particular subgroup of patients. 
 
However, the results reported by Kanwal and 
colleagues38,46 are not likely to be fully generalisable 
to the NHS. This is because they were conducted 
from the perspective of the US health-care system 
which differs in prices, structure of resource use 
and economic incentives. The same disadvantage 
applies to the results reported in Sullivan and 
colleagues45 and Buti and colleagues,47 which were 
conducted from the Taiwanese and Spanish health 
system perspectives respectively. The study by 
Buti and colleagues47 is also characterised by the 
number of methodological shortcomings.  
The study by Veenstra and colleagues,44, the only 
one conducted from the UK perspective, reported 
that PEG--2a is associated with higher discounted 
total health-care cost but also with additional 
discounted QALYs compared with long-term (up  
to 4 years) of LAM treatment in HBeAg-positive 
patients. The estimated ICER was £10,444. Our 
original report12  estimated the ICER of PEG- 
-2a versus IFN-in line with the scope of the 
assessment.  
The estimates of utility values reported in Levy 
and colleagues56 were obtained in relation to 
six CHB states: CHB, compensated cirrhosis, 
decompensated cirrhosis, liver transplantation, 
post-liver transplantation and HCC. Although 
utility values for the health states ‘response to 
treatment’ or ‘resistance to treatment’ were not 
assessed, the important contribution of the 
study by Levy and colleagues56 lies in eliciting 
utility estimates directly from patients. Previous 
models, in contrast, derived utility estimates from 
either clinician opinion or patients with hepatitis 
C.12,38,44–46 
 
Update of the Southampton 
Health Technology Assessments 




Our previous report12   presented estimates of the 
cost-effectiveness of PEG--2a and ADV using a 
state-transition model. Development of the model 
was informed by systematic review of the literature 
on natural history, epidemiology and quality of 
life for patients with CHB and on the clinical and 
cost-effectiveness of antiviral treatment. It has not 
been possible to repeat all of the methodological 
detail of the model here. Readers are therefore 
encouraged to consult the original report which  
is freely available to download from the internet 
(www.hta.ac.uk).  
The model included eight health states (CHB, 
HBeAg seroconversion/remission, HBsAg 
seroconversion,  compensated  cirrhosis, 
decompensated  cirrhosis,  HCC,  liver 
transplantation and death) and used ‘tunnel states’ 
to account for previous treatment history (such 
as switching drugs owing to the development of 
resistance). The model was used to extrapolate 
long-term outcomes (in terms of life expectancy 
and quality-adjusted life expectancy) and lifetime 
costs (including costs of managing progressive liver 
disease as well as costs of antiviral treatment) based 
on short-term outcomes included in the clinical 
effectiveness review (HBeAg seroconversion for 
HBeAg-positive patients and ALT normalisation 
for HBeAg-negative patients).  
Published, age-specific quality of life weights for 
healthy populations were used to estimate utility 
values for patients who achieved HBsAg or HBeAg 
seroconversion. Utility values for other health 
states were estimated relative to these values, based 
on the published literature (not all of which were 
specific to patients with CHB).  
The model had a lifetime horizon and the  
analysis adopted the perspective of the NHS and 
Personal Social Services, in accordance with NICE 
methodological guidance. The base-case  results 
reported were for a mixed cohort of patients, with 
70% having HBeAg-positive and the remainder 
HBeAg-negative CHB. The mean age at start of 
treatment was assumed to be 32 years for patients 
with HBeAg-positive CHB and 40 years for those 
with HBeAg-negative CHB. The majority of 
patients in both groups were male. Incremental 
cost-effectiveness ratios were calculated for each 
intervention compared with its closest comparator 
(for PEG--2a this was IFN--2a and for ADV 
it was LAM). The ICERs for individual antiviral 
agents were within the range considered to 
represent good value for money by NHS decision- 
makers:  
• £5994 per QALY gained for IFN-compared 
with best supportive care and £6119 per QALY 















Best supportive care  8555  22.29  17.07   
IFN‐ 12,609  22.98  17.75  5994 
IFN‐followed by LAM  15,159  23.76  18.45  3604a 
IFN‐followed by ADV  27,442  24.81  19.40  8987b 
IFN‐followed by LAM followed by ADV  27,740  25.00  19.56  11,402c 
PEG‐‐2a  15,745  23.51  18.26  6119 
PEG‐‐2a followed by LAM  18,053  24.20  18.88  6766d 
PEG‐‐2a followed by ADV  28,907  25.13  19.71  4649e 
PEG‐‐2a followed by LAM followed by  28,976  25.28  19.83  4452f 




c   Comparing IFN‐‐2a followed by LAM followed by ADV salvage with IFN‐‐2a followed by LAM. 
d  Comparing PEG‐‐2a followed by LAM with IFN‐‐2a followed by LAM.
e   Comparing PEG‐‐2a followed by ADV with IFN‐‐2a followed by ADV.





• £3685 per QALY gained for LAM compared 
with best supportive care and £16,569 per 
QALY gained for ADV compared with LAM.  
In addition, a number of sequential treatment 
scenarios (IFN--2a or PEG -2a as first-line 
treatment followed by LAM or ADV until resistance 
develops) were modelled (Table 30). A similar logic 
to that adopted for individual antiviral agents 
(identifying the closest comparator, for calculating 
ICERs) was applied to the cost-effectiveness 
analysis of sequential treatment strategies:  
• Strategies using IFN- as first-line treatment 
followed by LAM or ADV were compared with 
IFN- alone. 
• The strategy using IFN-as first-line treatment 
followed by LAM, with ADV for patients 
developing LAM resistance was compared with 
IFN-followed by LAM. 
• Strategies using PEG--2a as first-line 
treatment followed by nucleoside/nucleotide 
analogue were compared with the equivalent 
strategy using conventional IFN as first-line 
treatment.  
ICERs derived for these comparisons are reported 
in Table 30. 
To simplify the analysis, Figure 1 shows an optimal 
treatment sequence consisting of IFN-or PEG- 
-2a followed by LAM, with ADV reserved as a 
salvage strategy for patients who develop LAM 
resistance. The dashed line in Figure 1 indicates 
the cost-effectiveness frontier, joining the optimal 
treatment strategies (those which provide a 
given output at minimum cost). Other sequences 
were excluded using the principle of extended 
dominance, i.e. points above the cost-effectiveness 
frontier are non-optimal and can be eliminated, as 
the same output can theoretically be provided at 
lower cost by a combination of strategies that are 
found on the frontier.  
Incremental cost-effectiveness ratios estimated 
using the optimal strategies are: IFN followed by 
LAM (ICER = £4772 per QALY gained relative 
to best supportive care); PEG--2a followed by 
LAM (ICER = £6765 relative to IFN-followed by 
LAM); and PEG--2a followed by LAM followed  
by ADV (ICER = £11,460 relative to PEG--2a 
followed by LAM).  
Deterministic sensitivity analyses showed that 
the results were robust to assumptions about the 
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• efficacy of long-term treatment with ADV 
(whether or not treatment effects observed in 
clinical trials were extrapolated beyond the 
time horizon of the trials) 
• relapse of HBeAg-negative patients following 
treatment with PEG--2a 
• HBeAg seroconversion probability of patients 
with compensated cirrhosis receiving antiviral 




This update has identified:  
• a recently published study of health-related 
quality of life in patients with CHB which 
estimated relevant state-specific utility weights 
using a preference-based method56 suitable for 
updating our model (see earlier in this chapter) 
• RCT evidence on the clinical effectiveness 
of PEG--2b, compared with IFN--2b (see 
Chapter 3, HBeAg loss/seroconversion), which 
can be used in our model to estimate the cost- 
effectiveness of PEG -2b.  
Costs and outcomes in our previous report were 
discounted at different rates (6% for costs and  
1.5% for outcomes) in accordance with NICE 
methodological guidance applicable at the time  
the review was conducted. Since then it has become 
accepted practice (including in updated NICE 
methodological guidance) to discount both costs 
and outcomes at 3.5%. These rates were applied in 
this update. 
 
In addition, while the cost of all drug treatments 
have not changed since our previous report was 
completed, we have updated monitoring and 
health-state costs used in the original report to 
2006–7 prices. This enables an assessment of the 
robustness of the original report’s findings to 
changes in costs as well as to assumptions over 
quality of life for treated patients.  
The update identified no requirement to change 
assumptions regarding disease progression in the 
model. 
 
Estimation of cost-effectiveness 
Specification of  changed  inputs 
 
Health-state utilities applied in the updated 
model are reported in Table 31. The first set of 
values adopted is based on the age- and sex- 
adjusted valuations for UK infected patients 
reported by Levy and colleagues.56 As discussed 
earlier, Levy and colleagues56 did not elicit 
health-state valuations for treatment response or 
seroconversion states. We have assumed, in this 
first set of valuations, that there is a 0.1-point 
increase in health-state utility for patients who 
HBeAg seroconvert or who lose the surface 
antigen (see Table 31, set 1). This was based on the 
difference between the average utility estimated 
for uninfected respondents’ current health (mean 
= 0.87 and median = 0.95) and the average utility 
estimated for CHB in the same group (mean 
= 0.76 and median = 0.85). This utility gain is 
more than double the value of 0.04 applied in  
our original model, based on values estimated by 
Wong and colleagues.8 We assessed the robustness 
of our results to this assumption using two further 
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weights were identical to those in set 1 with the 
following exceptions:  
• In the first sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion or 
losing the surface antigen (i.e. the health-state 
utility value of 0.69, for chronic hepatitis B, 
was also applied to HBeAg-seroconverted and 
HBsAg-seroconverted health states). 
• In a second sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion, but 
it was assumed that patients who lose the 
surface antigen have the same utility as the 
uninfected population (i.e. the 0.10 utility gain 
was applied only to the HBsAg-seroconverted 
health state). 
• In a third sensitivity analysis, the smaller gain 
of 0.04 was applied for both HBeAg- and 
HBsAg-seroconverted health states.  
The utility weights in set 1 were not related to age, 
in contrast to the approach adopted in the model 
developed for our previous report. To examine  
the robustness of the results to this assumption,  
we derived a further set of health-state utility 
weights, based on the valuations reported by Levy 
and colleagues,56 but estimated as state-specific 
utility decrements (see Table 31, set 2). These utility 
decrements were applied to age-specific utility 
values, as in the previous report. As before, we 
assumed a 0.1-point increase in utility for patients 
who HBeAg seroconvert or who lose the surface 
antigen (compared with patients in the chronic 
hepatitis B health state). The robustness of our 
results to this assumption was tested in sensitivity 
analyses:  
• In the first sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion or 
losing the surface antigen (i.e. the –0.10 utility 
decrement for chronic hepatitis B was also 
applied to the age-specific utility values for 
patients in the HBeAg-seroconverted and 
HBsAg-seroconverted health states). 
• In a second sensitivity analysis, no utility gain 
was applied for HBeAg seroconversion, but it 
was assumed that patients who lose the surface 
antigen experience have the same utility as  
the general populations (i.e. the –0.10 utility 
decrement for chronic hepatitis B was also 
applied to the age-specific utility values only 
for patients in the HBeAg-seroconverted health 
state). 
• In a third sensitivity analysis, the smaller gain 




















First year  following  transplant  11,149 









injection of £12.96, a weekly cost of £38.88 and a 










Drug costs for PEG--2b were calculated for a 
dosage of 1.0 mg/kg of PegIntron® (Schering– 
Plough), self-administered by patients once per 
week. Assuming an average body weight of 79 kg, 
this would require one 80 g vial per week. The 
unit cost, from the British National Formulary, is 
Tables 32 and 33 report the inflated costs applied 
in the model. Costs derived for the previous report 
were inflated to 2006–7 prices using the Hospital 
and Community Health Services (HCHS) Pay and 
Prices Index.61  
Table 34 reports treatment responses to PEG-- 
2b included in the model, based on the results of 
the RCT by Zhao and colleagues27  as reported in 
Chapter 3, HBeAg loss/seroconversion.  
The frequency and intensity of monitoring of 
patients being treated with IFN--2b or PEG--2b 
were based on protocols developed for 24 weeks of 
treatment with IFN-, described in our previous 
report.12  Updated costs for monitoring patients 
receiving 24 weeks of IFN-are reported in Table 
32. In this costing we assumed that patients would 
be seen 10 times, during a 24-week treatment 
period, corresponding to weekly visits for the 
first month of treatment, then fortnightly for 
the second month and then monthly visits. The 
protocol stated that full blood counts, liver function 
tests, urea and electrolytes and blood clotting 
tests would be assessed at each consultation, with 
a more detailed assessment undertaken every 3 
months (during which HBeAg and HBsAg serology, 
HBV DNA and thyroid function were assessed). 
The detailed assessments also included screening 
for hepatocellular carcinoma using abdominal 
ultrasound and -fetoprotein tests. Standard 
consultations were assumed to take 30 minutes, 
whereas the detailed assessments were assumed to 
require 1 hour of clinical time. All assessments for 
treated patients were assumed to be performed by 
specialist nurses.  
Drug costs for IFN--2b were calculated for a 
dosage of 3 million units of IntronA® (Schering– 
Plough), self-administered by patients three times 
per week, as used in the trial reported by Zhao 
and colleagues.27  Unit costs of £77.76 for a 1.5- 
ml multidose cartridge (at a concentration of 15 
million units/ml, which delivers six doses of 0.2 ml) 
were taken from the British National Formulary.62 
This corresponds to a cost per 3-million-unit 
£108.00, which includes injection equipment 
and water for injections. This corresponds to a 
total drug cost of £2592 for a 24-week course of 
treatment.  
Results  from updated model 
Applying alternative utility 
sets – base case 
Table 35 reports total cost, discounted life 
expectancy and discounted QALYs for the overall 
cohort of patients with HBeAg-positive and 
HBeAg-negative CHB modelled in our previous 
report, using updated assumptions on health-  
state utility (utility set 1), updated costs and 
applying a discount rate of 3.5% for both costs and 
benefits. Incremental cost-effectiveness ratios are 
substantially higher than for the base case reported 
in our previous report (see Table 30). Total costs are 
between 23% and 45% higher, while discounted 
QALYs are 27–28% lower. However, much of this 
difference arises from the change in discount 
rates, rather than from changes in utility weights 
or inflating costs to current prices. For example, 
for IFN-the same analysis, but using discount 
rates of 6% for costs and 1.5% for QALYs, yields 
total costs of £13,768, total QALYs of 16.96 and  
an ICER of £6981 relative to best supportive care, 
which is broadly comparable to the ICER of £5994 
from our previous report.  
The cost-effectiveness frontier in Figure 2 shows 
that allowable interventions (in cost-effectiveness 
terms) are the same as for the analysis based on 
our previous report (shown in Figure 1). These are: 
IFN- followed by LAM (ICER = £8552 per QALY 
gained relative to best supportive care), PEG-- 
2a followed by LAM (ICER = £12,801 relative to 
IFN-followed by LAM) and PEG--2a followed   
by LAM followed by ADV (ICER = £26,379 relative 
to PEG--2a followed by LAM).  
Again, much of the difference with the results 
based on our previous model (reported earlier in 
this chapter) is due to changes in discount rate. As 
an example, ICERs for these strategies, discounted 





























Best supportive care  12,433  16.42  11.97   
IFN‐ 16,482  16.86  12.35  10,492 
IFN‐followed by LAM  19,376  17.35  12.78  6794a 
IFN‐followed by ADV  34,268  17.97  13.31  18,615b 
IFN‐followed by LAM followed by ADV  35,494  18.08  13.39  26,271c 
PEG‐‐2a  19,564  17.18  12.62  11,459 
PEG‐‐2a followed by LAM  22,228  17.62  13.00  12,800d 
PEG‐‐2a followed by ADV  35,557  18.16  13.47  7833e 




c   Comparing IFN‐‐2a followed by LAM followed by ADV salvage with IFN‐‐2a followed by LAM. 
d  Comparing PEG‐‐2a followed by LAM with IFN‐‐2a followed by LAM.
e   Comparing PEG‐‐2a followed by ADV with IFN‐‐2a followed by ADV.
f   Comparing PEG‐‐2a followed by LAM followed by ADV salvage with IFN‐‐2a followed by LAM followed by ADV 
salvage. 
   
followed by LAM (ICER = £5367 per QALY gained 
relative to best supportive care), PEG--2a followed 
by LAM (ICER = £8192 relative to IFN-followed 
by LAM) and PEG--2a followed by LAM followed 
by ADV (ICER = £12,171 relative to PEG--2a 
followed by LAM).  
Results for separate cohorts of HBeAg-positive and 
HBeAg-negative patients are reported in Appendix 
7. 
Applying alternative utility sets – 
deterministic sensitivity analysis 
A series of one-way sensitivity analyses was 
conducted using the updated model, based on 
the range of values and sources of uncertainty 
reported in sensitivity analyses in our previous 
review.12  These are reported in Table 36. To simplify 
the presentation and interpretation of the cost- 
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Baseline analysis  8552  12,801    26,379 
Structural  assumptions         
Zero transition probability from 8956 11,853 40,833
compensated cirrhosis to HBeAg‐ 
seroconverted  state  
Zero transition probability from 8363 12,605 25,950
HBeAg‐seroconverted state to
HCC   
Zero transition probability to 8636 12,683 27,028
HBsAg‐seroconverted state        
Methodological  uncertainty         
Discount rates (6.0% for costs 5367 8192 12,171
and 1.5% for outcomes)  
Discount rates (0.0% for costs 4362 5672 16,206 16,601
and 0.0% for outcomes)        
Baseline cohort characteristics         
HBeAg‐positive cohort, 50% male  8503  12,758    26,154 
HBeAg‐negative  cohort, 50% 8489 12,544 26,278
male   
Baseline cohort, 50%HBeAg 8406 8933 30,559
positive   
Change age of  –5 years 8135 11,892 24,886
cohort at start  +5years 9117 14,086 28,331
of simulation 

























Parameter uncertainty         
Varying rate of  +0.02 8552 12,801 26,116
ADV resistance  + 0.04  8552  12,801    25,911 
+ 0.06  8552  12,801    25,751 
+ 0.08  8552  12,801    25,626 
No utility gain from 10,425 14,712 31,114
seroconversion   
No utility gain from HBeAg 10,049 14,300 30,107
seroconversion, but 0.1 utility gain 
from HBsAg seroconversion  
Utility gain (+ 0.04) from 9585 13,883 29,030
seroconversion   
Age‐specific utilities (with health‐  8287 12,597 25,883
state decrements based on Levy 
et al.56)   
Age‐specific utilities, as above (no  10,034 14,443 30,426
utility gain from HBeAg or HBsAg 
seroconversion)   
Age‐specific utilities, as above (no  9685 14,046 29,463
gain  from HBeAg, but 0.1 utility
gain from HBsAg seroconversion)   
Double cost for compensated 8062 11,974 26,122
cirrhosis state (to £2683)  
Reduce PEG‐cost by 20%    8241    26,379 
Reduce ADV cost by 20%  8552  12,801  21,981  26,487 
Reduce ADV and PEG‐cost by   8241  21,981  26,487 
20%   
Reduce ADV and PEG‐cost by   7629  18,827  33,354 






we report ICERs only for the optimal strategies in 
each analysis (using the methods for identifying 
the cost-effectiveness frontier and for excluding 
strategies using the principle of extended 
dominance, as described for Figure 1.  
In this sensitivity analysis, the selection of optimal 
strategies is generally robust to changes in 
structural assumptions, baseline characteristics and 
parameter values. As with the base-case analysis, 
the optimal treatment sequence was generally 
identified as IFN-or PEG--2a, followed by LAM, 
reserving ADV as a salvage strategy for patients  
who develop LAM resistance. The estimated ICERs 
are also generally robust to changes applied in 
the sensitivity analysis. However, changes in some 
key assumptions produce less favourable cost- 
effectiveness estimates than the base case adopted 
for this analysis:  
• Assuming that patients with compensated 
cirrhosis cannot achieve HBeAg seroconversion 
produces a significantly less favourable 
ICER for the treatment strategy containing 
ADV as salvage for patients who develop 
LAM resistance. In contrast, the ICERs for 
IFN-or PEG--2a followed by LAM are 
largely insensitive to this changed structural 
assumption. 
• Reducing the proportion of the baseline cohort 
that has HBeAg-positive CHB also produces a 
less favourable ICER for the strategy including 
ADV (relative to PEG--2a followed by LAM), 
while the cost-effectiveness of PEG--2a 
followed by LAM improves (relative to IFN- 
followed by LAM). 
• Cost-effectiveness estimates for all treatment 
strategies are less favourable with increasing 
patient age at start of treatment. QALY gains 
from interventions are reduced by 15–20%, 
whereas incremental costs are reduced by 2–
6%. 
• Reducing the utility gain from seroconversion 
(to either no utility gain or using the lower 
value of 0.04 used in our previous report) gives 
a less favourable ICER than for the base case.  
Reducing drug costs for PEG--2a leads to the 
elimination of ‘IFN-followed by LAM’ from the 
sequence of optimal strategies and leads to an 
improvement in the cost-effectiveness of PEG--2a 
followed by LAM (relative to best supportive care).  
Applying alternative discount rates (6% for costs 
and 1.5% for outcomes, as in our previous report, 
or 0% for both costs and outcomes) produces more 
favourable ICERs than the base case – reducing the 
ICER for PEG--2a followed by LAM with ADV as 
salvage from £26,379 to £12,171 (relative to PEG- 
-2a followed by LAM). 
 
Applying alternative utility sets – 
probabilistic sensitivity analysis 
A probabilistic sensitivity analysis was undertaken 
using utility set 1 (see Table 31), updated costs 
(see Tables 32 and 33) and a discount rate of 3.5% 
for both costs and outcomes. The utilities were 
sampled from beta distributions with parameters 
calculated using the method of moments63 (using 
the reported mean values and standard errors 
derived from 95% CIs reported for UK infected 
patients by Levy and colleagues56) (see Appendix 
6 for full details). Health-state costs were sampled 
from gamma distributions with parameters 
calculated using the method of moments (see 
Appendix 6 for full details).  
Table 37 reports the mean cost and QALYs (with 
percentile-based 95% CIs) and the ICERs for  
the sequential strategies from the probabilistic 
sensitivity analysis. The mean discounted QALYs 
are close to those in the deterministic base-case 
analysis. However, the mean costs are around 
£1500 lower for each strategy. 
 
Figure 3 shows the cost-effectiveness acceptability 
curves (CEACs) for all interventions included in the 
analysis of sequential treatment strategies. As with 
our previous report, this suggests that IFN--2a or 
PEG--2a followed by LAM would be the optimal 
strategy at lower threshold values of willingness to 
pay, but as the threshold increases the sequential 
treatment strategy including ADV salvage is 
increasingly likely to be the optimal intervention.  
In contrast with our previous report,12 this strategy 
(interferon followed by LAM with ADV as salvage) 
becomes optimal only at the upper range of  
ICERs conventionally deemed as cost-effective 
from an NHS decision-making perspective. 
This is reinforced by Figure 4 which shows the 
cost-effectiveness acceptability frontier64 for the 
analysis based on our previous report (Figure 4a) 
and using the updated model (Figure 4b). The 
cost-effectiveness acceptability frontier comprises 
those portions of the CEAC where interventions 
are deemed optimal (using the maximum net 
benefit criterion) over a range of willingness-to-pay 
values. This clearly illustrates that interferon alpha 
followed by LAM is optimal, using the updated 
model, over a wider range of willingness-to-pay 
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and £13,000–£26,000 for PEG-followed by LAM) 
than in the analysis based on the previous report 
(£5000–£6500 for conventional IFN followed by 
LAM and £7000–£11,500 for PEG-followed by 
LAM). As discussed earlier, this arises largely as a 
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expectancy Discounted QALYs 
ICER (£ per QALY 
gained) 
IFN‐‐2b  12,610  18.20  13.57   









Discounted  costs 




(£ per QALY 
gained) 
Best supportive care  11,007 (9079–13,335)  11.99 (11.07–12.77) 
IFN‐ 15,024 (13,164–17,289)  12.38 (11.46–13.16)  10,334 
IFN‐followed by LAM  17,881 (15,881–20,184)  12.80 (11.86–13.61)  6759a 
IFN‐followed by ADV  32,713 (28,737–37,153)  13.32 (12.40–14.11)  18,815b 
IFN‐followed by LAM  33,946 (29,470–39,012)  13.40 (12.47–14.20)  26,762c 
followed by ADV 
PEG‐‐2a  18,128 (16,265–20,309)  12.65 (11.74–13.45)  11,336 
PEG‐‐2a followed by LAM  20,744 (18,745–23,119)  13.03 (12.09–13.86)  12,578d 
PEG‐‐2a followed by ADV  33,966 (29,677–38,788)  13.48 (12.56–14.29)  7412e 
PEG‐‐2a followed by LAM  34,810 (30,068–40,213)  13.55 (12.62–14.33)  5,732f 




c   Comparing IFN‐‐2a followed by LAM followed by ADV salvage with IFN‐‐2a followed by LAM. 
d  Comparing PEG‐‐2a followed by LAM with IFN‐‐2a followed by LAM.
e   Comparing PEG‐‐2a followed by ADV with IFN‐‐2a followed by ADV.
f   Comparing PEG‐‐2a followed by LAM followed by ADV salvage with IFN‐‐2a followed by LAM followed by ADV 
salvage. 
 
Cost-effectiveness of PEG- 
-2b – base case 
Table 38 reports total cost, discounted life 
expectancy and discounted QALYs for a cohort of 
patients with HBeAg-positive CHB receiving 24 
months of PEG--2b compared with 24 months of 
IFN--2b (based on HBeAg seroconversion rates 
reported by Zhao and colleagues27). This is based 
on the clinical effectiveness review (see Chapter 3).  
The results suggest that PEG--2b is a cost-effective 
alternative to IFN--2b for the treatment of  
patients with CHB. In the absence of a comparison 
with best supportive care, this analysis implicitly 
assumes that IFN--2b is a cost-effective option   
and a current standard of care. Supportive care 
has not been included in this analysis as the 
trial reported by Zhao and colleagues27 did not 
include a placebo or no treatment arm. No trials 
comparing IFN--2b with placebo or no treatment 
were included in the clinical effectiveness review 
reported in Chapter 3.  
Cost-effectiveness of PEG--2b – 
deterministic  sensitivity  analysis 
Table 39 reports a series of one-way sensitivity 
analyses based on the range of values and sources 
of uncertainty reported in sensitivity analyses in 
our previous review.12 
 
The ICERs are generally robust to changes in 
structural assumptions, baseline characteristics 
and parameter values. However, changes in some 
key assumptions produce less favourable cost- 
effectiveness estimates than the base case adopted 
























ICER (£ per 
QALY gained) 
Baseline analysis  12,610  13.57  14,067  13.73  9169 
Structural  assumptions           
Zero transition probability from compensated  13,801 12.62 15,222 12.81  7454
cirrhosis to HBeAg‐seroconverted state   
Zero transition probability from HBeAg‐  12,545 13.65 13,998 13.81  8805
seroconverted state to HCC   
Zero transition probability to HBsAg‐  14,853 12.91 16,325 13.08  8935
seroconverted  state   
Discount rates (6% for costs and 1.5% for  10,267 19.08 11,745 19.32  6225
outcomes)   
Discount rates (0% for costs and 0% for  19,124 26.07 20,559 26.41  4218
outcomes)           
Baseline cohort characteristics           
HBeAg‐positive cohort, 50% male  12,646  13.66  14,103  13.82  9090 
Change age of cohort at  –5 years  12,772 14.02 14,230 14.19  8779
start of simulation  + 5 years  12,392  13.03  13,848  13.18  9673 
+ 10 years  12,102  12.38  13,557  12.52  10,340 
Parameter uncertainty           
No utility gain from seroconversion (HBeAg or  12,610 12.45 14,067 12.56  13,415
HBsAg)   
No utility gain from HBeAg seroconversion, but  12,610 12.89 14,067 13.01  12,647
0.1 utility gain from HBsAg seroconversion   
Utility gain (+ 0.04) from seroconversion  12,610  12.90  14,067  13.03  11,311 
Age‐specific utilities  (with health‐state  12,610 14.91 14,067 15.07  8884
decrements based on Levy et al.56)   
Age‐specific utilities, as above (no utility gain  12,610 13.79 14,067 13.91  12,814
from HBeAg or HBsAg seroconversion)   
Age‐specific utilities, as above (no gain from  12,610 14.23 14,067 14.35  12,111
HBeAg but 0.1 utility gain from HBsAg 
seroconversion)   
Double cost for compensated cirrhosis state (to  14,661 13.57 16,056 13.73  8780
£2683)   



























































• Cost-effectiveness estimates for all treatment 
strategies are less favourable with increasing 
patient age at start of treatment. QALY gains 
from interventions are reduced by 5–12%, 
whereas incremental costs reduce by less than 
1%. 
• Reducing the utility gain from HBeAg 
seroconversion (to either no utility gain or 
using the lower value of 0.04 used in our 
previous report) gives a less favourable ICER 
than for the base case.  
Reductions in drug costs for PEG--2b and the use 
of alternative discount rates are associated with 
more favourable cost-effectiveness estimates in the 
sensitivity analysis. Reducing drug costs for PEG- 
-2b by 20% leads to a 4% reduction in total costs 
associated with PEG--2b, reducing the ICER to 
£5906. Using discount rates that applied at the 
time we conducted our previous review (6% for 
costs and 1.5% for outcomes), the ICER reduces 
to £6225. Applying zero discount rates, the ICER 
reduces to £4218.  
In all analyses the ICER is below the threshold 
usually taken to define cost-effectiveness from an 
NHS decision-making perspective. 
 
Cost-effectiveness of PEG--2b – 
probabilistic sensitivity  analysis 
A probabilistic sensitivity analysis was undertaken 
using utility set 1 (see Table 31), updated costs 
(see Tables 32 and 33) and a discount rate of 3.5% 
for both costs and outcomes. The utilities were 
sampled from beta distributions with parameters 
calculated using the method of moments63 (using 
the reported mean values and standard errors 
derived from 95% CIs reported for UK infected 
patients by Levy and colleagues56) (see Appendix 
6 for full details). Health-state costs were sampled 
from gamma distributions with parameters 
calculated using the method of moments (see 
Appendix 6 for full details).  
Table 40 reports the mean discounted cost and 
mean discounted QALYs (with percentile-based 
95% CIs) for IFN--2b and PEG--2b from the 
probabilistic evaluation of the model. Table 40 also 
reports the ICER for PEG--2b compared with 
IFN--2b, based on the mean discounted cost and 
mean discounted QALYs. The results from the 
probabilistic evaluation of the model are similar to 
those in the deterministic base-case analysis.  
Figure 5 shows the CEACs for PEG--2b for 
patients with HBeAg-positive CHB. This suggests 
that PEG--2b is likely to be a cost-effective option 
for the treatment of HBeAg-positive CHB, in 
comparison with IFN--2b. 
 
In the probabilistic sensitivity analysis PEG--2b 
had a probability of being cost-effective (compared 
with IFN--2b) of 79% at a willingness-to-pay 
threshold of £20,000 per QALY, and 86% at a 













Assessment of clinical 
effectiveness 
The trials included in this report were diverse 
in terms of aims, comparators and design 
characteristics. This prohibited quantitative meta- 
analysis and also made it difficult to provide an 
overall narrative summary of outcomes. The 
general finding is that both ADV and PEG--2b are 
associated with benefits across a range of outcomes 
(virological, biochemical and histological), with 
relatively few adverse effects and, in the case of 
ADV, relatively low viral resistance. This finding is 
similar to that of our previous assessment report of 
ADV and PEG--2a.12  
Although both drugs appeared to be superior 
to their comparators, there were no consistent 
statistically significant differences. In many cases, 
no statistical tests were reported to confirm 
superiority, and some trials were small and 
probably underpowered. Uncertainties therefore 
exist regarding comparative efficacy and safety.  
Benefits were not always sustained after treatment 
cessation, suggesting the need for ongoing 
treatment. This report was able to include 
evidence on the durability of effects of continued 
treatment from follow-up studies included in our 
original report. The 5-year follow-up study, based 
on the RCT by Hadziyannis and colleagues,20 
reported that favourable changes in viral load, 
biochemical markers and liver histology were 
generally sustained. After 5 years of ADV, the 
cumulative resistance rate was 29%, lower than 
the 60% rate associated with LAM after 4 years of 
treatment.20  The relatively low rates of resistance 
to ADV are encouraging, particularly as HBeAg- 
negative patients are likely to require maintenance 
treatment over a long period. However, caution is 
required in the interpretation of these results as 
they were derived from an observational cohort 
study arising from an RCT.  
Other RCTs included in our original assessment 
report were ongoing and fully published results 
would have been expected at the time of our 
update search. For example, at the termination of 
the double-blind phase of the RCT of ADV versus 
placebo in HBeAg-positive patients (Marcellin and 
colleagues,65 ADV Study 437, see Appendix 3), all 
patients were assigned to receive ADV for up to 
5 years. This was similar in design to the follow- 
up study in HBeAg-negative patients conducted 
by Hadziyannis and colleagues. Fully published 
results of this study, if and when available, would 
complement those already reported, illustrating 
durability in HBeAg-positive patients. This is a 
group of patients who, in the absence of HBeAg 
seroconversion, are likely to require ongoing 
treatment. 
 
This report identified fully published RCT 
evidence for the effectiveness of adding ADV to 
LAM in LAM-resistant HBeAg-negative patients.18 
Our previous report identified RCTs of this kind 
only in HBeAg-positive patients.66,67  The RCT 
included in this update failed to identify any 
significant differences between treatments in 
clinical outcomes, although there was a statistically 
significant difference between groups favouring 
combination therapy in terms of ADV resistance 
(a zero rate). Caution is advised as the trial 
appeared to be small, underpowered and generally 
methodologically weak, in common with the 
previous trials.66,67  Therefore, the evidence base for 
treatment of LAM-resistant patients is generally 
poor and good quality RCTs are needed.  
PEG--2b is associated with some degree of   
benefit, although the results of the trials were 
inconsistent, which may be partly the result of 
variable methodological quality. In terms of HBeAg 
seroconversion, which expert clinical opinion 
suggests would be one of the goals of IFN-based 
treatment, PEG--2b appears broadly comparable 
to PEG--2a. For example, in the trial by Janssen 
and colleagues,26  the proportion of seroconverted 
patients who received 1 year of PEG--2b and LAM 
was 25% at follow-up, compared to 27% for those 
who received 1 year of PEG--2a and LAM (Lau 
and colleagues50). Caution is advised as no head- 
to-head RCTs have been identified and this is not a 
formal statistical indirect comparison.  
In terms of initiating therapy with a combination 
therapy, the only studies identified by our update 









Such trials have limited applicability as PEG-is 
indicated only in patients with compensated liver 
disease, and may not be tolerated by all patients. 
There has been much interest in the initiation 
of therapy with combined nucleoside/nucleotide 
agents, particularly as a way of minimising the 
risk of drug resistance. No such trials were found 
in our search; however, as this report was being 
finalised, an RCT of LAM in combination with 
ADV, versus ADV and placebo in HBeAg-positive 
treatment-naive patients was published (Sung and 
colleagues68). (Note that a conference abstract 
reporting interim results of this trial was described 
in our previous report.) Combination therapy 
was more effective than monotherapy on some 
measures, including LAM resistance. This trial 
will be fully included in any future updates of this 
report.  
It has been argued that use of sequential 
monotherapies increases the risk of drug resistance 
and may potentially limit treatment options, as 
has been the case in the management of other 
infectious diseases such as HIV.69 Given the 
interest in de novo combination therapy as a 
means of reducing the likelihood of multidrug 
resistance in CHB, there is a need for further 
trials of this modality, particularly of nucleoside/ 
nucleotide analogues. Fortunately, there is 
an increasing number of potential treatment 
options open to clinicians and patients. Newer 
nucleoside analogues are becoming available, 
including entecavir, telbivudine and tenofovir. 
Licensing trials of these drugs have tended  
to assess the efficacy and safety of their use as 
monotherapies.70–73  High-quality RCTs are needed 
to assess appropriate combinations of these and 
other drugs in treatment-naive patients, and these 
should be carefully designed to minimise the risk  
of cross-resistance (e.g. entecavir and telbivudine in 
combination). Trials should be conducted in both 
HBeAg-positive and -negative patients, with long- 
term treatment, particularly for negative patients 
(e.g. at least 5 years).  
Few other systematic reviews have been published 
to which the results of this review can be compared. 
None featuring ADV was identified in the 
production of this report, and only one of PEG- 
was located (Hui and colleagues74). The latter 
included RCTs of both PEG--2a and -2b, and 
its results were comparable with our current and 
previous reports.12  
A limitation of this report is the fact that only 
published evidence was considered for inclusion. 
66 Conference abstracts reporting long-term follow- 
up of some of the RCTs included in our original 
report are available, but have not been included in 
the current report. A more detailed discussion of 
uncertainties and limitations can be found in our 
previous assessment report.12 
  
Assessment of cost- 
effectiveness 
Systematic review of 
economic  evaluations 
The majority of the cost-effectiveness studies 
reviewed in this report were direct evaluations of 
PEG--2a versus LAM (Veenstra and colleagues44 
and Sullivan and colleagues45) or LAM (with or 
without ADV salvage for LAM-resistant patients) 
versus ADV (Buti and colleagues47 and Kanwal 
and colleagues38). There are no published 
economic evaluations of the entire spectrum of 
alternative therapies for CHB (i.e. including the 
new pharmacotherapies entecavir and telbivudine) 
conducted from the NHS perspective, nor any 
evaluations of combinations of nucleotide/ 
nucleoside analogues in LAM-naive patients. 
Evaluation of the new medications was outside  
the scope of this report. Contrary to expectations, 
our searches did not capture studies reporting  
the effectiveness (in terms of drug resistance) 
of nucleoside/nucleotide analogue combination 
therapy in LAM-naive (or non-resistant) patients 
on which to base further modelling.  
The most comprehensive published economic 
evaluation that compares the broader range of 
alternative therapies in the general population 
of CHB patients was conducted in the US,38 
using a mix of health-care resources and prices 
that are unlikely to be applicable in the NHS 
context. The recently published adaptation of the 
unpublished Roche model,44 while adopting an 
NHS perspective, includes only two medications 
(PEG--2a and LAM). There is, therefore, 
uncertainty remaining about the relative costs and 
effects of the entire range of treatment alternatives 
for CHB. A comprehensive economic evaluation of 
alternative antiviral treatments for CHB should be 
undertaken, from an NHS perspective, including 
new treatments [entecavir and telbivudine, which 
have received European marketing authorisation, 
and tenofovir, which has received a positive opinion 
from the Committee for Medicinal Products for 
Human Use (CHMP)].  
The recently published multinational study 
of assessment of quality of life by Levy and 





area. The study employed a preference-based 
method (standard gamble), based on patients’ 
rather than clinicians’ ratings. However, the UK 
sample size was small (about 200 people) and may 
not be representative of the entire population. 
While the results of the study are generally 
consistent with utility estimates used in previously 
published economic evaluations, this is mainly 
because of the large variation between the estimates 
used in previous studies, each of which involved a 
small number of clinicians to evaluate utility weight 
for each of the health states included in the model. 
There is a substantial disparity, in both absolute 
and relative terms, between utility values reported 
by Levy and colleagues56 and those used in our 
previous economic evaluation.12 
 
Update of SHTAC 
economic model 
The model developed for our previous report12 was 
updated to include:  
• utility values based on those reported in Levy 
and colleagues56 
• treatment monitoring and health-state costs 
updated to 2006–7 prices 
• current discounting practice 
• a separate analysis to include PEG--2b. 
 
The ICERs in the updated analysis are generally 
less favourable than in our previous report. 
However, the same optimal treatment sequence 
[IFN (conventional or pegylated) followed by 
LAM with ADV salvage for patients who develop 
resistance] was identified in both analyses. 
Sensitivity analyses indicate that much of the 
difference between the results in the two reports 
arises from the change in discounting practice. 
 
Key uncertainties in the model, identified in the 
sensitivity analyses, that affect the cost-effectiveness 
estimates were:  
• Outcomes for patients with compensated 
cirrhosis who receive treatment – if the 
probability of HBeAg seroconversion is set  
to zero the ICER of strategies including ADV 
increases sharply. 
• The size of utility gain from HBeAg 
seroconversion or loss of the surface antigen 
(HBsAg) – if there is no gain in utility, the 
incremental cost-effectiveness of all strategies 
is poorer.  
While it is relatively common in trials of antiviral 
treatment for hepatitis C to report outcomes by 
stage of disease – identifying cirrhotic and non- 
cirrhotic patients separately – this is less common 
in CHB. Clearer identification of patients’ outcome 
by stage of disease may enable more reliable and 
transparent modelling of the cost-effectiveness of 
antiviral treatments in this group of patients.  
Uncertainty over the existence and size of the 
utility gain associated with response to treatment 
cannot be addressed using studies included in this 
review. The study by Levy and colleagues56 did not 
include utility estimates for patients who HBeAg 
seroconverted or lost the surface antigen, nor did 
it consider quality of life for patients who remain 
chronically infected, but have low viral levels 
(which would characterise response to treatment 
in patients with HBeAg-negative CHB). Further 
research is required to derive utility estimates 
across the full range of health states relevant to 
HBeAg-negative and HBeAg-positive variants of 
CHB, using appropriate preference-based methods 
in a representative sample of the UK population.  
A further source of uncertainty in the model 
concerns the relationship between patients with 
HBeAg-positive and HBeAg-negative CHB. The 
latter group have only recently been included 
in economic models of antiviral treatment and 
have traditionally had a limited evidence base on 
natural history and epidemiology. The two groups 
of patients have typically been enrolled in separate 
clinical trials or have been analysed separately, 
leading to them being included as two separate 
populations in economic models. However, it 
has been suggested that HBeAg-negative CHB 
may represent a late stage of CHB (reflected by  
the older average age for patients with HBeAg- 
negative CHB).75  The implication of this for 
economic models of cohorts of CHB patients is 
that a proportion of patients who begin the model 
with HBeAg-positive CHB should move into the 
HBeAg-negative cohort. Currently, there is limited 
evidence on which to base such transitions. More 
robust evidence on the natural history of CHB and 
development of HBeAg-negative disease is needed 
to improve the robustness of economic models of 
antiviral treatments.  
The absence of reliable evidence on the 
effectiveness (in terms of treatment resistance 
rather than HBeAg seroconversion or viral 
suppression) of combination treatments limits 
the scope for robust modelling of their long- 
term effectiveness and cost-effectiveness. Given 
that patients with HBeAg-negative CHB are 
likely to require long-term maintenance therapy, 







reliable selection of optimal treatment strategies. 
The potential benefits offered by new antiviral 
treatments (in terms of reduced resistance profiles 
in comparison with LAM) may be compromised by 
the use of a well-tolerated, comparatively low-cost 
drug (LAM), with a poor resistance profile which 





rapid development of resistance on switching to 
alternative therapies (such as ADV). However, in 
the absence of evidence of benefit, it is difficult to 
make a case for adopting a combination treatment 





















oth ADV and PEG-are beneficial for patients 
with CHB in terms of suppressing viral load, 
reducing liver damage-associated biochemical 
activity, inducing HBeAg seroconversion, and 
reducing liver fibrosis and necroinflammation. 
Emerging evidence suggests that benefits are 
durable when patients are treated with ADV for up 
to 5 years, with relatively low risk of resistance. 
In terms of cost-effectiveness, the optimal 
treatment strategy is PEG-followed by LAM, 
followed by ADV for patients developing LAM 
resistance. Further research should assess the 
clinical effectiveness and cost-effectiveness of 
newer antiviral agents in relation to existing drugs, 
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Reference and design Intervention Participants Outcome measures 





























































































Compliance: 2/28 patients in Group B had to reduce ADV dose
because of adverse events






Patient characteristics: All LAM resistant, had HBV genotype D







Outcome Group A (ADV) (n=14) Group B (ADV + LAM) (n=28) p-value 
Median HBV DNA at 24 months, copies/ml (range)  1000 (1000–4,957,000)  1000 (1000–58,190)  0.321 
% of patients with HBV DNA 1000 copies/ml at 24 75  82.6  0.670 
months 






Rate of seroconversion  Not reported  Not reported  Not  reported 
Median ALT at 24 months, IU/l (range)  24 (15–55)  24.5 (12–69)   0.863 
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Definitions: Upper  limit of normal  for ALT was 49  IU/l.  Initial virological  response was considered as non‐detectable  serum HBV DNA by PCR and  initial biochemical  response as  the 






















Reference and design Intervention Participants Outcome measures 































Exclusion  criteria: Hepatocellular  carcinoma;  liver 
decompensation; serum creatinine > 1.5 mg/dl (130 mol/L); 
ALT > 10 ULN;  seropositivity  for  hepatitis C or D  virus  or 
HIV;  LAM  therapy within  3 months prior  to  screening;  and ADV 
therapy or any other anti‐HBV  therapy within  the previous 
6 months. Subjects were not permitted to receive systemic 



































































Placebo  Compliance: 45 patients had increased serum HBV DNA of at
Dose: NA  least 1 log10 copies/mL while on ADV, all were compliant 
Duration: 12 weeks  Treatment history: 63% (n = 303) of patients had previously 
takenmedication for CHB, including 32% (n=154) who had
Total ADV duration: 40 receivedLAMand37%(n=176)who received treatment with
weeks  traditionalChinesemedicines
Study design: 12 weeks Patient characteristics: Patients with cirrhosis excluded. 
double‐blind and  Incidence of YMDD‐mutant HBV reported to be similar 











Outcome PAA (n = 120)f AAA (n = 240)f AAP (n = 120)f 
HBV DNA change (log   copies/ml) from baseline week –0.1 –3.4 –3.3
12, median 
Range (25–75%)  –5.2 to 3.1 (–0.7 to 0.3)  –7.7 to 0.5 (–4.6 to 2.6)  –6.8 to –1.0 (–4.3 to –2.7) 
HBV DNA < 105 copies/ml  4/115 (3%)  113/227  (50%)  55/116 (47%) 
HBV DNA undetected1  0/119 (0%)  11/232 (5%)  7/120 (6%) 
continued 
 
 Week 12  2.4 (0.1–14.4)  1.1 (0.3–9.1)  1.1 (0.2–5.9) 
Week 40  0.8 (0.2–4.1)  0.7 (0.1–4.4)  0.9 (0.3–30) 
Week 52  0.7 (0.2–4.0) 0.6 (0.2–5.1) 3.0 (0.2–36.4)
ALT flaresi       
Week 12  5/120 (4%)  1/232 (0.5%)  1/120 (1%) 
Week 40  0/118 (0%)  0/235 (0%)  1/119 (1%) 









Median decrease in serum HBV DNA levels week 12: 3.4 log  copies/ml  in ADV group; 0.1  log  copies/ml in placebo group (p < 0.001) 
HBV DNA change (log 
40, median 
copies/ml) from baseline week  –4.6  –4.2  –4.0 
Range (25%, 75%)  –7.7 to 2.0 (–5.6 to –3.1)  –8.0 to 0.5 (–5.5 to –3.0)  –8.6 to 0.7 (–5.3 to –3.0) 
HBV DNA < 105 copies/ml  75/115 (65%)  147/231 (64%)  68/115 (59%) 
HBV DNA undetectedg  23/119 (19%)  42/236 (18%)  23/119 (19%) 
HBV DNA change (log  copies/ml) from baseline at  –5.0  –4.5  –0.2 
week 52, median 
Range (25%, 75%)  –8.0 to 2.1 (–6.0 to –3.3)  –8.0 to 0.7 (–5.8 to –3.1)  –6.1 to 2.1 (–1.6 to 0.3) 
HBV DNA < 105 copies/ml  81/115 (70%)  155/231 (67%)  13/115 (11%) 
HBV DNA undetectedg  36/119 (30%)  67/236 (28%)  1/119 (1%) 
HBeAg loss at week 52  24/118 (20%)  30/233 (13%)  10/114 (9%) 
HBeAg seroconversion at week 52  21/118 (18%)  19/233 (8%)  8/114  (7%) 
 
ALT normalisation from baselineh 
Week 12  15/108 (14%)  92/220 (42%)  48/110 (44%)
Week 40  69/106 (65%)  163/223  (73%)  81/109 (74%)



























Dose reduction for any adverse event       




Reactivation of hepatitis B  1/120 (< 1%)  1/240 (< 1%)  11/120 (9%) 
Upper respiratory infection  10/120 (8%)  20/240 (8%)  9/120 (8%) 
Fatigue  7/120 (6%)  6/240 (3%)  8/120 (7%) 
Nasopharyngitis  6/120 (5%)  11/240 (5%)  2/120 (2%) 
Viral  resistance at week 52k  PAA (n = 11)  AAA (n = 28)  AAP (n = 6) 






























b Log  reduction  copies/ml. 
c Subjects with elevated serum ALT at baseline. 
d >5 ULN and > 2 baseline (for first 12 weeks) or > 2 nadir for subsequent intervals. 





































Reference and design Intervention Participants Outcome measures 




Number of centres: 32  Duration: 48 weeks  Open‐label phase  score; ranked assessments of necro‐inflammatory 
activity and fibrosis (improved, no change or worse) 

















n = 70  Exclusion criteria: A coexisting serious medical or psychiatric illness;  Open‐label phase end points: immune globulin, interferon or other immune‐ or cytokine‐based  % of patients with undetectable serum HBV DNA 







treatment during the  Histological  improvement  evaluated  by  rank 
second period  assessments: improved, no change or worse; Knodell and  Ishak  fibrosis scores 
Genotypic analysis of entire HBV polymerase at 
baseline and for patients with serum HBV DNA the 
LLQ of the PCR assay weeks 48 96 144 192 and 240
continued 
 
























































Baseline measurements:  Adverse events and  lab  tests 4‐weekly  to week 96; 












































































Male gender, n (%)  46 (84)    57 (81) 
Race, n (%)       
White  38 (69)    49 (70) 
Black  1 (2)    3 (4) 
Asian  16 (29)    18 (26) 
Weight (kg)       
Mean ± SD  74 ± 15.4    75 ± 11.6 
Median  74    76 
HBV DNA levela       
Mean ± SD  6.93 ± 0.96  5.77 ± 1.18  6.87 ± 0.87 
Median  7.16  5.85  7.08 
ALT level, IU/l       
Mean ± SD  156 ± 204  83 ± 70  141 ± 124 
Median  100  62  99 




Knodell score       
Mean ± SD  7.1 ± 2.8  7.3 ± 2.3  7.7 ± 2.7 
Median  7.0  7.0  7.0 
Ishak  fibrosis  score       
Mean ± SD  2.3 ± 1.6  2.6 ± 1.4  2.6 ± 1.4 





















Outcome Group A (ADV) (n = 117) Group B (placebo) (n = 55) p-value 
HBV DNA mean change from baseline at week 48 (log  3.91  1.35  < 0.001 
copies per ml) 
Patients with undetectable HBV DNA levels, n (%)  63/123 (51)  0/61(0)  < 0.001 
Comments: Graphs  in Figure 2 show changes through time at 4‐weekly  intervals, but not data extracted at this stage as treatment end points already taken from tables 
 
% of patients enrolled (open‐label phase)  48 weeks (%)  96 weeks (%)  144 weeks (%)  192 weeks (%)  240 weeks (%)c 
HBV DNA < 1000 copies/mla  72  80  77  73   67 








Long-term response Continued ADV group group Placebo–ADV group 
Long‐term virological response  Week 96 (n = 79)  Week 144 (n = 70)  Week 96 (n = 40)  Week 96 (n = 60) 
No. of patients assessed  70  67  38  49 
 
Change in serum HBV/DNA (log copies/ml) 
Mean ± SD  –3.35 ± 1.18  –3.42 ± 1.27  –1.34 ± 1.24  –3.71 ± 1.05 
Median  –3.47  –3.63  –1.09  –3.85 
IQ range  –4.20 to –2.59  –4.23 to –3.11  –2.19 to –0.40  –4.31 to –3.18 
p‐value compared with continued treatment at week 96  –  NA  < 0.001  0.12 
Serum HBV DNA <1000 copies/ml, n/total (%)  50/70 (71)  53/67(79)  3/38 (8)  37/49 (76) 





















Median decrease  from baseline  (U/l)  55    38  p = 0.01 
ALT normalisation, % of patients enrolled (open‐label phase)  48 weeks (%)  96 weeks (%) 144 weeks (%)  192 weeks (%)  240 weeks (%)c 
ITTa  75  74  71  73  69 
ITTb 
a   ITT, failure for resistance or HCC. 














































Normalisation of ALT, n/total (%)a  47/64 (73)  43/62 (69)  12/38 (32)  40/50 (80) 


































































Ranked assessment, % (open‐label phase)  192 weeks placebo–ADV  240 weeks ADV–ADV   
Improved  necroinflammation  86  83   
Improved fibrosis  73  75   
Median change  in Knodell necroinflammation score  from baseline  –4.5 points  –5.0 points   









Changes from baseline Continued ADV group 
(n = 19) 
ADV–placebo group (n = 8) Placebo–ADV group (n = 20) 
Knodell scores  Week 48  Week 96  Week 48  Week 96  Week 48  Week 96 
Overall             
Baseline  10.02 ± 2.07    12.3 ± 2.25    8.3 ± 3.31   
Change  –4.4 ± 2.39  –4.7 ± 2.7  –4.3 ± 1.49  –1.4 ± 1.92  0.9 ± 4.56  –2.4 ± 4.79 
Inflammation             
Baseline  8.37 ± 1.50    10.0 ± 1.31    6.40 ± 2.76   
Change  –4.2±2.32 –4.3±2.71 –3.8±1.83 –0.9±1.96 0.6±3.78 –2.3±3.93
Fibrosis             
Baseline  1.84 ± 1.17    2.3 ± 1.39    1.9 ± 1.17   
Change  –0.2 ± 0.63  –0.4 ± 1.12  –0.5 ± 0.93  –0.5 ± 0.93  0.3 ± 1.17  –0.15 ± 1.27
 






































Adverse events occurring in at least 10% of patients 
– long-term 
Weeks 49–96 Continued adefovir group 
  Continued ADV ADV‐Placebo group Placebo‐ADV Baseline to Baselinetoweek96(n=70)
group (n=79) (n=40) group (n = 60) week 48
  (n=79)
Any event  58 (73)  32 (80)  41 (68)  67 (85)  60 (86)   
General             
Headache  12 (15)  4 (10)  5 (8)  23 (29)  19 (27)   
Abdominal pain  16 (20)  7 (18)  5 (8)  22 (28)  20 (29)   
Asthenia  8 (10)  6 (15)  3 (5)  15 (19)  15 (21)   
Flu‐like syndrome  6 (8)  4 (10)  5 (8)  14 (18)  14 (20)   
Back pain  4 (5)  5 (12)  3 (5)  9 (11)  9 (13)   
Pain  4 (5)  2 (5)  4 (7)  11 (14)  12 (17)   
Accidental  injury  4 (5)  2 (5)  2 (3)  6 (8)  8 (11)   
Digestive             
Diarrhoea  6 (8)  4 (10)  1 (2)  8 (10)  6 (9)   
Dyspepsia  5 (5)  5 (12)a  1 (2)  7 (9)  7 (10)   
Respiratory             
Pharyngitis  14 (18)  8 (20)  8 (13)  23 (29)  23 (36)   
Increased cough  3 (4)  4 (10)  2 (3)  6 (8)  7 (10)   
Bronchitis  2 (3)  1 (2)  1 (2)  6 (8)  9 (13)   
Metabolic  and  nutritional             
Increased ALT levels  2 (3)b  6 (15)a  1 (2)  3 (4)  3 (4)   
Musculoskeletal             
Arthralgia  6 (8)  5 (13)a  1 (2)  7 (9)  6 (9)   
a  p < 0.05 compared with the placebo–adefovir group. 
b  p < 0.05 compared with the adefovir–placebo group.             










10% of patients  suffered adverse events  in  the 144‐week open‐label phase;  three patients discontinued because of adverse events;  two patients  (1.6%) appeared  to have ADV‐related 
adverse events  (one elevated creatinine, one elevated ALT  in  the  setting of mutations and virological  resistance). Twenty‐four  serious adverse events  (19%) were considered unrelated  to 
ADV 
Three per cent of patients  (6 of 183)  treated with ADV  in  the open‐label phase developed hepatocellular carcinoma. Patients with hepatocellular carcinoma were diagnosed after 112–219 





Cumulative resistance probabilities (open‐label phase)  48 weeks (%)a  96 weeks (%)a  144 weeks (%)a  192 weeks (%)a  240 weeks (%)a 
Mutation  0  3  11  18  29 
Mutation and virological resistance  0  3  8  14  20 
Mutation, virological  resistance and ALT elevation  (clinical 
resistance) 







Long‐term serological response: HBsAg seroconversion occurred  in one patient  in the continued adefovir group at week 72 and one  in the placebo–adefovir group at week 68 (approx 20 
































of  0.05.  Standard  deviations  are  given  for  all  mean  values.  For  the  long‐term  follow‐up  paper,  statistical  analyses  included  all  patients  who  received  at  least  1  dose  of  the  study  drug  in 































Quality assessment for RCTs (quality criteria – CRD report 4) 
1. Was the assignment to the treatment groups really random?  Unknown 
2. Was the treatment allocation concealed?  Adequate 













































Reference and design Intervention Participants Outcome measures 

























































































































Outcome Group A (n = 9) Group B (n = 9) Group C (n = 10) 
Median log HBV DNA reduction   
Week 4a,b  4.21  1.39  2.95 
Week 8a,c  5.46  1.55  3.14 
Week 52d  6.38  3.43  4.44 

















Negative HBV DNA at week 52, n (%)  4 (44) 2 (22)f  1 (10)g 
Negative HBV DNA at week 104, n (%)  3 (33)  5 (56)  4 (40) 










Rate  of  seroconversion   
At week 52, n (%)  6 (67)  3 (33)a  1 (10)b 
At end of treatment (week 104), n (%)  5 (56)  3 (33)c  6 (60)d 
















Histology response at week 104  (n = 9)  (n = 8)  (n = 9) 
Necroinflammatory score, 2‐point improvement, n (%)  8 (89)  6 (75)a  8 (89)b 










Other viral  response outcomes  GroupA(n=10) GroupB(n = 10)  GroupC (n=10)
Adverse events       
Dose reduction for any adverse event  2 0 2
Dose discontinuation  for any adverse eventa  0  1b  0 
Serious adverse events       
Adverse events experienced, n (%)       
Upper respiratory tract symptomsc  5 (50)  1(10)  7 (70) 
Fever  6 (60)  6 (60)  7 (70) 
Alopecia  5 (50)  5 (50)  6 (60) 
Abdominal discomfort  2 (20)  4 (40)  5 (50) 
Malaise  3 (30)  3 (30)  6 (60) 
Headache  4 (40)  6 (60)  3 (30) 
Myalgia  6 (60)  2 (20)  3 (30) 
Reduced  appetite  1 (10)  2 (20)  4 (40) 
Erythema at  injection site  3 (30)  4 (40)  2 (20) 
Allergic rashes  2 (20)  0  0 
Weight  loss >10%  1 (10)  0  0 
Dizziness  4 (40)  1 (10)  2 (20) 
Laboratory toxicity, n (%)       
Increased alanine aminotransferase  0  0  2 (20) 
Increased  creatine  kinase  1 (10)  2 (20)  1 (10) 
Increased  amylase  1 (10)  1 (10)  0 
Low phosphate  0  2 (20)  1 (10) 






Resistance to lamivudine at week 104  Group A (n = 9)  Group B (n = 9)  Group C (n = 10)
rtM204V  1  1  1 
























Allocation concealment: The random numbers were placed  in opaque envelopes by research staff not  involved  in patient management 
Blinding of outcome assessors: Histological specimens were assessed by a single histopathologist who was unaware of the treatment assignments or the times at which the specimens were 






































































Reference and design Intervention Participants Outcome measures 
Chan et al., 200524 and Group A: PEG+LAMa  Total numbers involved: 168  Primary outcomes used: 
Chan et al., 2005 (long- 
term follow-up)28 n = 50  Total randomised: 100  SVR  –  HBeAg  seroconversion  and  HBV  DNA  level < 500,000 copies/ml at 24 weeks after cessation of 
Trial design: phase III, open‐  Drug 1: Pegylated  IFN‐  n in each group: 50  treatment 
label RCT  ‐2bb s.c.  Inclusion criteria:  Follow‐up study: SVR – sustained HBeAg loss and 
Number of centres: 1  Dose: 1.5 g/kg of body  18–65 years with CHB  HBV DNA < 100,000 copies/ml from treatment 





supplied LAM  Drug 2: Lamivudine    response; sustained biochemical response 
(oral)  Exclusion criteria: 
Reduction in HBV DNA levels and normalisation of 
































































































































2‐point   decrease  in   necroinflammatory    score  4 (10%)    4 (9%) 
 2‐point  increase  in  fibrosis  scoresb  6 (15%)    4 (9%) 





LAM‐resistant mutants, EOT, n/N (%)a  10/48 (21)    19/48 (40)
a  Absolute difference 19% points (95% CI 8–37).       
Adverse events, n (%)       
Dose  discontinuation  (PEG)  for  any  adverse  event  4 (8)  0   
Dose reduction (PEG) – any adverse event  5 (10)  0   
Serious adverse events, n (%)  4 (8)  0   
Open‐label LAM for severe post‐treatment biochemical relapse  7  14   
Ascites or hepatic encephalopathy  0  0   
Decompensation  at  post‐treatment  biochemical  relapse  2  4   
Adverse events experienced, n (%)        p‐value 
Upper respiratory tract symptoms  37 (74)  19 (38)    0.001 
Fever  36 (72)  2 (4)    < 0.001 
Alopecia  24 (48)  2 (4)    < 0.001 

















Malaise  22 (44) 7 (14) 0.002
Headache  21 (42)  2 (4)  < 0.001 
Myalgia  13 (26)  2 (4)  0.006 
Arthralgia  12 (24)  2 (4)  0.01 
Reduced  appetite  12 (24)  0 (0)  0.001 
Local erythematous reaction  12 (24)  0 (0)  0.001 
Allergic rashes  9 (18)  1 (2)  0.02 
Dizziness  8 (16)  1 (2)  0.036 
Vomiting or diarrhoea  7 (14)  3 (6)  > 0.2 
Weight loss (> 10%)  7 (14)  1 (2)  0.065 
a  URT symptoms included cough, running nose and sore throat.       
 


































Most AEs were  transient and were  related  to  the use of PEG‐‐2b. No patients died or  required  liver  transplantation 
Serious AEs – one patient  in each of  the  following: bipolar disorder  requiring  antidepressant  therapy  (week 21), pulmonary  tuberculosis  requiring anti‐tuberculosis  treatment  (week 11), 
thyrotoxicosis  requiring propyluracil  treatment (week  17)  and  severe  local  reaction  at  injection sites  (week  8)  that  resolved  spontaneously. PEG was discontinued  in  all  four  cases;  three 






Follow‐up  study: Seven PEG + LAM vs 14 LAM patients  received open‐label LAM  for  severe post‐treatment biochemical  relapse – one patient  (Group A) developed acute duodenal ulcer 
bleeding complicated by  shock and aspiration pneumonia, and died at week 64 after  treatment. No patients developed ascites or hepatic encephalopathy. Two PEG + LAM patients 






Allocation concealment: Research staff, who were not  involved  in patient management, placed the random numbers  in opaque envelopes 
Blinding of outcome assessors: A research nurse prescribed study drugs after receiving the  information about treatment allocation at the baseline visit. One histopathologist, blinded to 
treatment assignments or the times at which the specimens were obtained, assessed all histological specimens. All  lab assays were performed  in‐house.  Investigators assessing adverse 
events were not blinded  to  treatment as  they were able  to  reduce  the PEG dose according  to  the AE experienced. No  information  reported  regarding  the assessment of  the primary or 


























Method of data analysis: Patients  in Group A, who stopped pegylated  interferon prematurely, had assessments of virological and biochemical responses  if  lamivudine treatment was 
continued  to  the end. Continuous variables were expressed as  the median  (range). Hepatitis B virus DNA was  logarithmically transformed  for analysis. Continuous variables, including 
patient age,  liver biochemistry,  log  HBV DNA levels, and histological scores were compared using the Mann–Whitney U‐test. Categorical variables and the proportions of patients with 
virological and biochemical  responses, histological  improvements, lamivudine‐resistant mutants and adverse events were compared using  the Pearson chi‐squared  test or Fisher’s exact 
test, as appropriate. The  timing of HBeAg  seroconversion was compared using Kaplan–Meier survival analysis. A  logistic  regression model was used  to  compare virological  response   





























































Reference and design Intervention Participants Outcome measures 
Janssen et al., 2005,26 van Group A: PEG/LAM  Total numbers involved: 307  Primary outcome: Loss of HBeAg at EOT and end 
Zonneveld et al., 200629 of   follow‐up   (EOF‐U) 
and van Zonneveld et al., n = 130  Total randomised: 307 (Group A, n = 152; Group B n = 155) 
200530 Drug 1: Pegylated  n in each group: Group A 130; Group B 136  Secondary outcomes at EOT and EOF‐U: 
Trial design: Double‐blind  interferon alpha‐2b  n in each group in histology study: Group A 52; Group B 58 (total =  Concentration of HBV DNA < 200,000 copies/ 





Countries: 15 (Netherlands,  Duration: 32 weeks  300)  HBsAg and HBV genotype were also assessed 
Belgium, Germany, Denmark,  Dose 2: 50 g/weeka  Inclusion criteria: Patients with CHB, 16 years. HBsAg positive longer  Baseline liver histology and optional biopsy sample Poland, Spain, Italy, Greece,    than 6 months; positive HBeAg on two occasions within 8 weeks of 
Turkey, Israel, Canada,  Duration: 20 weeks  randomisation; two episodes of raised serum concentrations of ALT (2  at  EOT 
Indonesia, Singapore and  (weeks 32–52)  ULN) within 8 weeks of randomisation 
Malaysia)  Drug 2: Lamivudine    Histological activity  index: Necroinflammatory and Previous liver biopsy if taken < 1 year prior to treatment or  fibrosis scorec 
Funding: Rotterdam  Dose: 100 mg/day  biopsy at start of therapy (second optional biopsy EOT). Biopsy 
Foundation for Liver  samples adequate for evaluation if at least 0.5 cm long, had at least  Adverse events: Research; financial  Duration: 52 weeks  four evaluable portal tracts and not so regimented as to preclude 
support from Schering–  recognition of acinal architecture  Histology study:  liver biopsy overall sample  lengths 





interferon alpha‐2b  or D  virus or HIV; antiviral  therapy or  immunosuppressive  therapy 




Duration:  20  weeks  (100 109/L); radiological or  imaging evidence of          












































































Outcome EOT EOF-U 
  Group A (n = 130) Group B (n= 136) p-value Group A (n = 130) Group B (n=136) p-value 
HBeAg  loss  57 (44%)  40 (29%)  0.01  46 (35%)  49 (36%)  0.91 
HBeAg seroconversion  33 (25%)  30 (22%)  0.52  38 (29%)  39 (29%)  0.92 
HBsAg  loss  9 (7%)  7 (5%)  0.54  9  (7%)  9 (7%)  0.92 
HBsAg seroconversion  8 (6%)  6 (4%)  0.53  9  (7%)  7 (5%)  0.54 
HBV DNA < 200,000 copies/ml  96 (74%)  40 (29%)  < 0.0001  41 (32%)  37 (27%)  0.440.43 
HBV DNA, 400 copies/ml  43 (33%)  13 (10%)  < 0.0001  12 (9%)  9 (7%)   
HBV DNA change from baseline  Not possible to Not possible to 2.3 (estimated from 2.2 (estimated from
calculate as EOT calculate as EOT figure in paper) figure in paper)
on chart is different on chart is different
to that reported in to that reported in
  paper  paper


























































24 discontinued blinded drug
    discontinuation (lamivudine/placebo)
PEG dose reduction for any adverse eventb      37 (54%) Group A  32 (47%) Group B 
Common adverse events experienced, n (%)      Reason for dose reduction, 
n  (%) 
Reason for early dis‐continuation, n (%) 
Flu‐like syndrome  96 (74%)  84 (62%)  7 (10)  3 (11) 
Headache  59 (45%)  55 (40%)     
Fatigue  54 (42%)  59 (43%)  2 (3)   
Myalgia  42 (32%)  41 (30%)  1 (1)   
Abdominal pain  25 (19%)  26 (19%)     
Arthralgia  20 (15%)  22 (16%)     
Loss of > 10% body weight  25 (19%)  28 (21%)     
Anorexia  21 (16%)  22 (16%)     
Diarrhoea  14 (11%)  15 (11%)     
Nausea  14 (11%)  25 (18%)     
Dermatological‐local reaction  38 (29%)  36 (27%)     
Alopecia  35 (27%)  26 (19%)     
Pruritus  18 (14%)  14 (10%)     
Depression  (including mood  changes  and 
irritability) 
28 (22%)  29 (21%)     
Insomnia  20 (15%)  11 (8%)     
Neutropenia (<1.5x 109/L)  34 (26%)  29 (21%)  36 (52)  1 (4) 
Thrombocytopenia (<75 x 109/L)  14 (11%)  17 (13%)  7 (10)  1 (4) 
Leucopenia      2 (3)   
Combined   haematological      6 (8)   





Psychiatric  4 (6)  10 (36)
Local reaction     
Anorexia  1 (1)   









a 266 patients  remained on  treatment and 184  (69%) patients  remained on  full‐dose  treatment. There were no significant differences  in dose  reductions between  the  treatment  




















by automated  techniques at participating centres. Histological samples were scored centrally by a pathologist unaware of  treatment  regimen; assessment of other outcomes was not 





























All p‐values were  two‐sided. Comparisons between groups were made using  the chi‐squared  test  for categorical variables and  the Mann–Whitney  test  for continuous variables. Logistic 
regression was used  for multivariate analysis. Baseline variables  (improvements of necroinflammation and  fibrosis, worsening of  fibrosis: sex, race, age, BMI, transmission route, genotype 
of HBV, ALT,  log HBV DNA, previous  therapy with  LAM or PEG) were  evaluated  as prognostic  factors. A  separate multivariate  analysis  evaluated which  treatment  end points  (ALT 










Of those  included  in  the modified  ITT, 12 patients discontinued because of adverse events, one  for other  reasons and three were  lost  to  follow up  in Group A, while 11 patients 
discontinued as a  result of adverse events and seven were  lost  to  follow‐up  in Group B. Biopsy pairs: n = 151 patients  (40%  response), 41 patients were excluded (= 45 biopsies)  for 























Adverse events were graded according  to  the WHO  recommendations as mild/moderate/severe/life‐threatening, and  reported  in  relation  to  therapy as unrelated/possibly  related/ 
probably related or related to therapy. The effect on study medication was none/dose reduction/treatment discontinuation. Serious adverse events were defined as events resulting 
in death,  life‐threatening, require/prolong patient hospitalisation, events which result  in persistent/significant disability/incapacity, pregnancy, congenital anomaly, cancer or overdose. 
Hepatitis  flares were defined as  increase  in serum ALT at  least 3 baseline  level. Psychiatric side effects  included mood changes,  irritability and depression 
     




























Reference and design Intervention Participants Outcome measures 













































































Outcome Group A Group B 
HBV DNA change from baseline     
HBV DNA  (< 4pg/ml), EOT, n  (%)  12 (63)  23 (79) 















































































9. Were withdrawals  and  drop‐outs  completely  described?  Inadequate 








































Reference and design Intervention Participants Outcome measures 
Zhao et al., 200727 Group A:  Total numbers involved: 412 patients screened  Primary  outcomes: 














































Response at week 48, n (%)a Group A, PEG--2b (n = 115)     Group B, IFN--2b (n = 115) p-value 
Mean reduction of HBV DNA level from baseline, log
10 
copies/ml 
Week 24 (EOT)  2.22  1.66   0.03 
Week 48 (EOF‐U), ± SD  –1.4 ± 2.2  –1.1 ± 2.1   0.34 
HBV DNA level < 5 log   copies/ml  34 (29.6)  22 (19.1)   0.06 
10 
HBV DNA level < 3 log   copies/ml  14 (12.2)  14 (12.2)  1.00 
10 
HBeAg  loss 
Week 24 (EOT)  26 (22.6)  20 (17.4)  Not significant 
Week 48 (EOF‐U)  28 (24.4)  16 (13.9)   0.04 
HBeAg seroconversion  25 (21.7)  16 (13.9)   0.12 
HBsAg seroconversion  0 (0)  2 (1.7)   0.50 
ALT level normalisation  39 (33.9)  40 (34.8)   0.93 











































performed using Pearson’s 2  test, or  if data were sparse, Fisher’s exact  test. Differences between  treatment groups of measurements of efficacy were examined using Cochran– 
Mantel–Haenszel  statistics. A  two‐way analysis of  variance, with  treatment,  centre and  treatment‐by‐centre  interaction as  factors, was used  to  compare changes  in HBV DNA  levels  
from baseline  to weeks 24 and 48 between  the  treatment groups. The  incidence of adverse effects was compared between  treatment groups using Cochran–Mantel–Haenszel  statistics, 
controlling  for centre  (p < 0.05 was considered  to be  significant) 
Power analysis: Not reported 
Attrition/drop‐out: Drop‐outs were  reported at each  stage  in a  flow‐chart. Reasons were given  for  four  (Group B) who discontinued because of adverse events;  two others  (Group B) 
























































Papers excluded on title 
and abstract n = 653: 
• not Hep B (n = 179) 
• not RCT (n = 400) 
• wrong intervention (n = 68) 





n = 17 
(reporting 8 studies) 
• ADV n = 3 studies 
• PEG--2b n = 5* studies 
Papers excluded n = 65: 
• not Hep B (n = 2) 
• not RCT (n = 47) 
• irrelevant intervention (n = 5) 
• irrelevant outcome measure (n = 1) 












No. of participants, 
duration of trial (T ), d 
HBeAg additional follow-up (F ) 
d 
Study status and total duration Arm 1 Arm 2 Arm 3 Arm 4 
ADV studies 
Hadziyannis et al.,  Negative  n = 185  ADV 10 mg/  Placebo 
200321    T = 48 weeksa  day (n = 123)  (n = 62) d 
Study 438  F = 0 weeks d 
Total = 48 weeks 
Marcellin et al.,  Positive  n = 515  ADV 10 mg/  ADV 30 mg/  Placebo 
200365    T = 48 weeksb  day (n = 172)  day (n = 173)  (n = 170) d 
Study 437  F = 0 weeks d 
Total = 48 weeks 
Perrillo et al.,  Positive  n = 95  LAM 100 mg/  LAM 100 mg/ 
200466    T = 52 weeksc  day + ADV  day + 
d 
Study 465  F = 0 weeks  10 mg/day  placebo d  (n = 46)  (n = 49) 
Total = 52 weeks 
Peters et al., 200467  Positive  n = 59  ADV 10 mg/  ADV 10 mg/  LAM 
Study 461    T = 48 weeks  day +  day + LAM  100 mg/ d  placebo  100 mg/day  day + F = 0 weeks 
d  (n = 19)  (n = 20)  placebo 
Total = 48 weeks  (n = 19) 
Sung et al., 200378  Positive  n = 115  LAM 100 mg/  LAM 100 mg/ 












even fully published RCTs were included in our 
original report:  
• Four evaluated ADV. In two studies ADV was 
compared with placebo.21,65 (A publication 
reporting long-term follow-up of one of these 
trials was identified by our update search.20  
In the other two studies, ADV, either as 
monotherapy or in combination with LAM, was 
compared with LAM monotherapy in patients 
with LAM resistance.66,67 
• Three evaluated PEG--2a. In two studies, 
the combination of PEG--2a and LAM was 
compared with both agents separately (the 
difference being that one study included 
HBeAg-positive patients, the other HBeAg- 
negative patients).50,76  The third study 
compared PEG--2a with IFN-.77  
Table 41 provides a general overview of the RCTs 
included in the original systematic review. For 
further detail on the study characteristics and 
results, please consult the original report.12  The 
remainder of the current report focuses on studies 













No. of participants, 
duration of trial (T ), d 
HBeAg additional follow-up (F ) 
d 
Study status and total duration Arm 1 Arm 2 Arm 3 Arm 4 
PEG‐‐2b studies 
Marcellin et al.,  Negative  n = 552 (of whom  PEG 180 g/week +  PEG 180 g/  LAM 
200476    537 were  included  placebo (n = 177)  week + LAM  100 mg/ 





Cooksley et al.,  Positive  n = 194  IFN 4.5 MIU three  PEG 90 g/  PEG  PEG 270 g/ 
200377    T  = 24 weeks  times/week (n = 51)  week (n = 49)     180 g/  week 
d 
Study 037  F = 24 weeks  week  (n = 48) d  (n = 46) 
Total = 48 weeks 
Lau et al., 200550  Positive  n = 814  PEG 180 g/week +  PEG 180 g  LAM 


























Veenstra and colleagues (2007) Cost-effectiveness 
of peginterferon alpha-2a compared with 
lamivudine treatment in patients with HBe- 





What are the stated objectives of the evaluation? 
 
• To assess the net health consequences, costs, 
and cost-effectiveness of peginterferon 
alpha-2a (40 kDa) for treatment of patients 
with HBeAg-positive CHB, compared with 
lamivudine treatment (p. 632). 
 
Study population 
What definition was used for chronic hepatitis B? 
 
• The cohort was defined as those with a 
histological diagnosis of CHB, HBeAg +ve for 
more than 6 months, and detectable HBV DNA 
> 500,000 copies/ml. 
 
What are the characteristics of the baseline cohort 
















Interventions and comparators 









Describe  interventions/strategies: 
 
• Intervention/strategy 1: PEG--2a 180 mg daily 
monotherapy for 48 weeks 
• Intervention/strategy 2: lamivudine 100 mg 
daily monotherapy up to a maximum of 




What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)? 
 
• UK NHS perspective. 
 
Study type 
Cost-effectiveness/cost-utility/cost-benefit     analysis? 
 
• CEA (incremental cost per additional life-year 
saved) 
• CUA (incremental cost per QALY). 
 
Institutional setting 
Where is/are the intervention(s) being evaluated 
usually provided? 
 
• Not identified. PEG--2a is administered 
intravenously, so for some patients the 
treatment may be provided at the institutional 




Has a country setting been provided for the 
evaluation? What currency are costs expressed  
in and does the publication give the base year to 
which those costs relate? 
 











Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 























































Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 






























Bennett WG,  Inoue  Y,  Beck 



















Were the effectiveness data derived from: 
at 6 months after the treatment and the 
subsequent intervals) 
– percentage of lamivudine patients 
developing resistance (used in the scenario 
analysis) 
– percentage of patients with AEs (from Lau 
and colleagues50).  
Give the size of treatment effect used in the 
evaluation.  
• Not applicable. Serocoversion, relapse and 
resistance are composite, qualitative measures 
of outcome. 
 
Include values used for subgroups (if applicable). 








Give the definition of treatment effect used in the 
evaluation.  
• Primary treatment effect (p. 633, also one of 
two primary outcomes in the pivotal clinical 
trial) 
– % of patients achieving seroconversion 
(transitioning from CHB state to 
seroconversion state). This can occur 
spontaneously or as a result of treatment. 
• In addition the following outcomes are used 
– percentage of patients relapsing 
(transitioning from seroconversion state 
back to CHB state). Can occur on an 








Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 






















List the direct intervention costs used in the evaluation – include resource estimates (and sources for these 
estimates, if appropriate) as well as sources for unit costs used. 
 
Resource category Type of resources Unit cost estimate Source 
Drug costs (weekly)  PEG‐‐2a 180 mg  £132  BNF 
  LAM 100 mg  £20   
    
Health state 











Assessments   Centre   (SHTAC);   2005 
Bennett WG,  Inoue  Y,  Beck  JR,Wong  JB, 













  Liver  transplantation  £36,788.00 (27,561–45,985) 











Other direct costs (used 
in scenario analysis) 
 
Were the cost data derived from: 
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used.  
• The cost of ADV used in the LAM arm as a 
salvage therapy for the patients who developed 
resistance (£73.50 per week). 
 
Indicate the source for individual cost values (if 
appropriate). 
 
Indirect costs (due to lost productivity, 
unpaid inputs to patient care) 
Were indirect costs included? 
 
• Not applicable. 
 
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued). 
 
• Not applicable. 
 











Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 
















Bennett WG,  Inoue  Y,  Beck 


















Health-state   valuations/utilities 
(if study uses quality of life 
adjustments  to  outcomes) 














List the utility values used in the evaluation. 
Modelling 
If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation). 
 
• Markov state-transition model. 
 
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original. 
 
• Model structure was similar to previously 
published models by Crowley,42 Crowley and 
colleagues43 and Pwu and Chan,49 except that 
Crowley and colleagues did not include health 
states to account for patients receiving a liver 
transplant.  
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?  
• Not explained, but presumably to estimate 
long-term costs and benefits (expressed 
in terms of final rather than intermediate 
outcomes) beyond the timeframe of the clinical 
trial (48-week treatment).  
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.  
• HBeAg seroconversion, HBeAg-positive 

































































































cirrhosis, HCC, liver transplantation, post-liver 
transplantation, and death.  
Extract transition probabilities for [natural history/ 
disease progression] model and show sources (refer 
to Table 1, p. 634). 
What is the model time horizon? Duration of the 
cycle?  
• 12-month cycle, lifetime duration (not 
specified). 
 
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes? 
 
• All costs were discounted at a 6% annual 
rate and outcomes (e.g. QALYs) at 1.5%, in 




What measure(s) of benefit were reported in the 
evaluation? 
 
• Life-years (LYs), quality-adjusted life years 
(QALYs).  
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation. 
 
• Treatment with PEG--2a compared with 
treatment with LAM is associated with: 
• Additional discounted life expectancy of 0.39 
and additional quality-adjusted life expectancy 
of 0.30 years.  
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.  
• Lifetime (discounted) costs associated with 
treatment 
• PEG--2a £14,900 per patient 
• LAM £11,800 per patient. 
 
Synthesis of costs and benefits –are the costs  
and outcomes reported together (e.g. as cost- 
effectiveness ratios)? If so, provide a summary of 
the results.  
• The comparative performance of alternative 
treatment strategies was measured by the 
ICER, defined as the additional cost of a 
specific strategy, divided by its additional 
clinical benefit, compared with the next least 
expensive strategy. 
• Discounted ICER is equal to £7949 (£8000) per 
LY gained. 
• Discounted ICER is equal to £10,333 (£10,400) 









Give results of any statistical analysis of the results 
of the evaluation.  
• The cost-effectiveness acceptability curve 
generated from the probabilistic sensitivity 
analysis indicated that there was a greater 
than 95% probability that PEG--2a was cost- 
effective compared with lamivudine at the 
£30,000 per QALY threshold (95% central 
range of results, £6000–£26,500 per QALY 
gained).  
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic]?  
• One-way and probabilistic sensitivity analyses 
were  performed. 
• ICERs were most sensitive to variation in the 
probability of: 
– developing compensated cirrhosis from 
CHB 
– PEG--2a seroconversion rate as observed 
in the clinical trial (Lau and colleagues50) 
– relapse after 4 years of lamivudine 
treatment (i.e. from year 5 on) 
– the probability of developing compensated 
cirrhosis from the seroconversion state. 
• The ICER for PEG-2a compared with 
lamivudine monotherapy ranged from 
£8300 to £15,400 per QALY when treatment 
efficacy, drug cost, the health state-transition 
probabilities, utility values and health-state cost 
estimates were varied. 
therapy was obtained from a randomised 
controlled trial of ADV–lamivudine 
combination therapy versus lamivudine 
monotherapy  in  lamivudine-resistant  patients 
(Perrillo and colleagues66) (8% versus 3% 
HBeAg seroconversion at end of 1 year of 
treatment  respectively). 
• Not relevant to structural uncertainty (no new 
state was added) or methodological uncertainty. 
Transition probabilities (parameters of the 
model) were altered.  
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the base-
case analysis. If so, what were the suggested causes?  
• Treatment with PEG--2a compared with 
treatment with LAM and ADV salvage therapy 
is associated with: 
– additional discounted life expectancy of 
0.33 and (versus 0.39 in the base-case 
analysis) 
– additional quality-adjusted life expectancy 
of 0.14 years (versus 0.30 in the base-case 
analysis) 
– the lifetime difference in cost between 
treatments with PEG--2a and LAM has 
decreased from £3100 to £875. 
• The scenario analysis results are: 
– discounted ICER is equal to £2652 per LY 
gained 
– discounted ICER is equal to £6250 not 
(£6100 as reported) per QALY gained. 
                          
140 
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?  
• A scenario analysis in which ADV salvage 
treatment was used for lamivudine-resistant 
patients was provided. 
• Annual seroconversion rates and drug costs 
for lamivudine-treated patients were modified 
based on the proportion of patients (26%, Lok 
and colleagues53), with resistance each year 
rather than explicitly including a resistance 
health state. 
• The increase in the HBeAg seroconversion rate 
for resistant patients who received ADV salvage 
Conclusions/implications 
Give a brief summary of the author’s conclusions 
from their analysis. 
 
• Authors suggest that use of PEG--2a is 
highly likely to be cost-effective, given certain 
assumptions about disease progression 
and the efficacy and cost of therapy. The 
ICERs were most sensitive to variation in 
the probability of developing compensated 
cirrhosis from CHB, PEG--2a seroconversion 
rate, lamivudine treatment durability and 
the probability of developing compensated 
cirrhosis from seroconversion. However, when 
these parameters were varied over a range 
of estimates using one-way and multiway 
sensitivity analyses, the ICER did not exceed 
the £30,000/QALY threshold.  







PEG--2a is likely to be cost-effective in treatment 
of HBeAg +ve patients who do not develop HBeAg 
–ve disease variant. 
 
– Uncertainty in relation to applicability of 
the outcomes to HBeAg –ve patients (a 
shortcoming of the study is an exclusion of 
HBeAg –ve state in disease progression). 
– Uncertainty in relation to generalisability 
of the results to England and Wales 
population (87% Asian in the modelled 
cohort, although UK life tables are used). 
In particular, seroconversion rates used in 
years 2–4 are low in comparison to the rate 
reported elsewhere [27–35% at 2 years and 
40% at 3 years (Shepherd and colleagues12, 
Crowley42)]. 
– Uncertainty associated with terminating 
LAM maintenance (and hence HBV DNA 
suppression) after 4 years. In particular, 
applying transition probabilities beyond  
4 years of lamivudine treatment. A 25% 
annual relapse rate appears to be a 
conservative estimate in comparison with 
the 35% rate reported in the literature; this 
is five times the rate observed in year 4. 
This may bias the result in favour of PEG- 
-2a. 
 
• Although scenario analysis more closely 
approximates the real clinical practice, 
no probabilistic sensitivity analysis was 
performed with respect to parameter estimates 
(seroconversion rates observed in LAM/ADV 
treatment versus LAM monotherapy). 
 
Reference 
Sullivan and colleagues (2007) Cost-effectiveness 
of peginterferon alfa-2a compared to lamivudine 
treatment in patients with hepatitis B e antigen 




What are the stated objectives of the evaluation? 
 
• The objective of our study was to assess the 
net health consequences, costs and cost- 
effectiveness of 48 weeks of peginterferon 
alfa-2a for treatment of patients with HBeAg- 




What definition was used for mild chronic hepatitis 
B? 
• The hypothetical cohort of patients was based 
on the clinical and demographic characteristics 
of patients in the Lau and colleagues (2005) 
clinical trial.50 The cohort was defined as 
those with a histological diagnosis of CHB, 
HBsAg-positive for more than 6 months, and 
detectable HBV DNA > 500,000 copies/ml.  
What are the characteristics of the baseline cohort 















Interventions and comparators 










Describe  interventions/strategies. 
 
• Intervention/strategy 1: PEG--2a 180 mg daily 
monotherapy for 48 weeks 
• Intervention/strategy 2: Lamivudine 100 mg 
daily monotherapy for 48 weeks. 
 
Analytical perspective 
What is the perspective adopted for the evaluation 
[health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)]? 
 
• Taiwan Bureau of National Health Insurance. 
 
Study type 
Cost-effectiveness/cost-utility/cost-benefit     analysis? 
 


























Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 

































• CUA (incremental cost per QALY). 
 
Institutional setting 
Where is/are the intervention(s) being evaluated 
usually provided? 
 
• Not identified. PEG--2a is administered 
intravenously, so for some patients, the 
treatment may be provided at the institutional 




Has a country setting been provided for the 
evaluation? What currency are costs expressed  
in and does the publication give the base year to 
which those costs relate? 
 
• The costs are initially expressed in NTD; the 
outcomes are also converted into US$. The 
base year to which all costs are related is not 
indicated, but unit costs for medical procedures 
and intervention medications were expressed  




Were the effectiveness data derived from: 
Give the definition of treatment effect used in the 
evaluation.  
• Primary treatment effect (p. 633, also one of 
two primary outcomes in the pivotal clinical 
trial) – percentage of patients achieving 
seroconversion (transitioning from CHB 
state to seroconversion state). This can occur 
spontaneously or as a result of treatment. 
• In addition the following outcome is used: 
• percentage of patients relapsing (transitioning 
from seroconversion state back to CHB 
state). Can occur first at year 2 (p. 1495). 
The paper did not report the probability of 
relapsing at year 2. After year 3 all patients 
could experience spontaneous seroconversion 
or relapse on an annual basis (Lok and 
colleagues,83) 
 
Give the size of treatment effect used in the 
evaluation.  
• Not applicable. Seroconversion and relapse are 
composite, qualitative measures of outcome. 
 
Include values used for subgroups (if applicable). 











Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 























Expert opinion   The costs  for  the disease 
states  of  CHB,  compensated 
cirrhosis  and  decompensated 
cirrhosis were based on  the 









Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 














Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 




















List the direct intervention costs used in the evaluation – include resource estimates (and sources for these 






Type of resources 
Cost estimate for the overall 
treatment period of 48 weeks Source 
Drug acquisition costs  PEG‐‐2a 180 mg daily  NTD203,616  BNHI 2004 Reference List 
for Drugs 
  LAM 100 mg daily  NTD30,912   
    
Health state 















  Liver  transplantation  $1,720,632 ($1,290,474–2,150,790) 
  Post‐liver  transplant  $508,901 ($381,676–636,126) 
   
Indicate the source for individual cost values (if 
appropriate). 
 
Other direct costs (incurred 
directly in treating patients) 
Were the cost data derived from: 
Indirect costs (due to lost productivity, 
unpaid inputs to patient care) 
Were indirect costs included? 
 
• Not used. 
 
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued). 
 
Indicate the source for individual cost values (if 
appropriate). 
 
Health-state   valuations/utilities 
(if study uses quality of life 
adjustments  to  outcomes) 
Were the utility data derived from: 
  
 
• Not reported. 
  
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used. 
 























% (range) Source 
Chronic Seroconversion,  32.1 (30.0– Lau et al.,
hepatitisB year 1, 34.0)  200550 
peginterferon  a‐2a 
  Seroconversion,  19.1 (17.0– Lau et al.,










  Hepatocellular  0.83 (0.20– Liaw et al.,
carcinoma 1.00)  198684 
HBeAg Chronic hepatitis  35.0 (30.0– van Nunen
seroconversion B, year 2, 40.0)  et al., 2003,80 
lamivudine Wang et al.,
200454 
  Chronic hepatitis  8.0 (3.0–  van Nunen





























  Liver 1.4 (10.05– Taiwan
transplantation  3.10)  Registry
  Death  39.0 (23.5– Crowley,
40.0)  200042 
Hepatocellular Death  37.2 (37.0– Pwu and
carcinoma 56.0)  Chan, 200249 
  Liver 0.08 (0.02‐ Chen, 200690 
transplantation  0.08) 
Liver Post‐liver 85.0 (79.0– Taiwan



















List the utility values used in the evaluation. Extract transition probabilities for [natural history/ 
disease progression] model and show sources (or 













If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation). 
 
• Markov state-transition model 
 
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original. 
 
• Model structure was similar to previously 
published models by Crowley42 and Pwu 
and Chan,49 except that Crowley did not 
include health states to account for liver 
transplantation.  
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?  
• Not explained, but presumably to estimate 
long-term costs and benefits (expressed 
in terms of final rather than intermediate 
outcomes) beyond the timeframe of the clinical 
trial (48-week treatment).  
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.  
• HBeAg seroconversion, HBeAg-positive 
CHB, compensated cirrhosis, decompensated 
cirrhosis, HCC, liver transplantation, postliver 







What is the model time horizon? 
 
• Not reported, but appears to be life time. 
 
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes? 
 




What measure(s) of benefit were reported in the 
evaluation? 
 
• Life-years (LYs), quality-adjusted life years 
(QALYs)  
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation. 
 
• Treatment with PEG--2a compared with 
treatment with LAM is associated with: 
– additional discounted life expectancy of 
0.33 
– additional quality-adjusted life expectancy 
of 0.41 years.  
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.  
• Lifetime (discounted) costs associated with 
treatment 
• PEG--2a NTD355,932 per patient 
• LAM NTD200,016 per patient. 
 
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost- 
effectiveness ratios)? If so, provide a summary of 
the results. 
 
• The comparative performance of alternative 
treatment strategies was measured by the 
ICER, defined as the additional cost of a 
specific strategy, divided by its additional 
clinical benefit, compared with the next least 
expensive strategy. 
• Discounted ICER is equal to NTD466,936 
(NTD472,475) per LY gained. 
• Discounted ICER is equal to NTD380,619 
(NTD380,250) per QALY gained (US$12,000).  
Give results of any statistical analysis of the results 
of the evaluation. 
• No statistical analysis was reported. 
 
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].  
• Deterministic (one-way) sensitivity analysis was 
performed and the most influential variables 
were identified with a ‘tornado diagram’.  
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?  
• Parameter uncertainty (assumptions over 
values of parameters in the model, such as 
costs, quality of life or disease progression 
rates) were tested.  
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?  
• Estimates of incremental cost-effectiveness were 
most sensitive to variation in the probability of 
developing compensated cirrhosis from CHB, 
the probability of developing compensated 
cirrhosis from the seroconversion state, and the 
peginterferon alfa-2a efficacy rate. 
• The ICER for peginterferon alfa-2a compared 
with lamivudine monotherapy ranged from 
NTD313,819 to NTD485,262 per QALY (i.e. 
did not exceed US$15,000) gained despite 
variation in treatment efficacy, drug cost, the 
health-state transition probabilities, utility 
values and health-state cost estimates. 
 
Conclusions/implications 
Give a brief summary of the authors’ conclusions 
from their analysis. 
 
• The findings suggest that use of peginterferon 
alfa-2a is likely to be cost-effective, given 
certain assumptions about disease progression 
and the efficacy and cost of therapy. The 
cost-effectiveness ratios were most sensitive 









compensated cirrhosis from CHB, the 
probability of developing compensated 
cirrhosis from seroconversion and 
peginterferon alfa-2a efficacy rates. However, 
when these parameters were varied over a 
range of estimates, the ICER did not exceed 
NTD485,000 per QALY. 
 
What are the implications of the evaluation for 
practice?  
• Although 48 weeks of treatment with 
peginterferon alfa-2a (40KD) compared with 
48 weeks of treatment with lamivudine in 
CHB patients who are HBeAgpositive offers 
life expectancy benefits at a favourable cost- 
effectiveness ratio, the implication for clinical 
practice in Taiwan is not clear as the current 
reimbursement guidelines in Taiwan provide 
for 6 months of peginterferon alfa-2a and 12– 
18 months of lamivudine. 
 
Reference 
Kanwal and colleagues (2006) Treatment 
alternatives for hepatitis B cirrhosis: a cost- 




What are the stated objectives of the evaluation? 
 
• An economic analysis is performed to estimate 
the cost-effectiveness of competing strategies 
for the management of cirrhosis as a result of 
chronic HBV with active viral replication. 
 
Study population 
What definition was used for mild chronic hepatitis 
B? 
 
• No definition was provided for chronic HBV; 
however, the cohort of patients with cirrhosis 
was assumed to have active viral replication at 
the baseline. 
What are the characteristics of the baseline cohort 




















Interventions and comparators 










Describe  interventions/strategies. 
 
Strategy 1: no pharmacological treatment of 
chronic HBV (‘do nothing’ strategy).  
Strategy 2: lamivudine monotherapy 100 mg once 
daily for an indefinite period.  
Strategy 3: ADV monotherapy 10 mg once daily for 
an indefinite period. 
 
Strategy 4: lamivudine with crossover to ADV on 
development of resistance (‘ADV salvage’ strategy). 
 
Intervention/strategy 5: entecavir monotherapy 
0.5 mg once daily for an indefinite period. 
 
Intervention/strategy 6: lamivudine with crossover 
to entecavir on development of resistance 










Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 




previous  studies   Yes. A  systematic  review of literature was conducted and 
assessed by three  independent 














What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)?  




Cost-effectiveness/cost–utility/cost–benefit     analysis? 
 
• Cost–utility analysis. The results are reported 
as the incremental cost per QALY gained 
between the competing strategies. 
 
Institutional setting 
Where is/are the intervention(s) being evaluated 
usually provided? 
 
• All pharmacotherapies are administered orally. 
 
Country/currency 
Has a country setting been provided for the 
evaluation? What currency are costs expressed  
in and does the publication give the base year to 
which those costs relate? 
 




Were the effectiveness data derived from: 
Give the definition of treatment effect (outcomes) 
used in the evaluation. 
  
• The following efficacy end points are relevant 
to probability estimates used in the evaluation: 
progression from compensated to 
decompensated cirrhosis 
 
– regression (recompensation) from 
decompensated to compensated cirrhosis 
– decomposition following initial 
recompensation 
– progression from cirrhosis to 
hepatocellular carcinoma (for compensated 
cirrhosis only?) 
– developing resistance to initial 
pharmacotherapy 
– developing severe renal side effects (seems 
to be used in ADV patients only) 
– progression to liver transplantation 
– progression to cirrhosis following liver 
transplantation 
– subsequent complications related to 
recurrent HBV post-liver transplantation. 
 
Give the size of treatment effect used in the 
evaluation.  
• Not applicable. Outcomes are assessed in a 
dichotomous variable (yes/no). 
 
Include values used for subgroups (if applicable). 











Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 





































Were the cost data derived from: 
List the direct intervention costs used in the 
evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well 

























Cost per  subsequent  year  following 
encephalopathy 
3337 




Cost  of  hepatocellular  carcinoma  38,715 
 










Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 
from other published 
studies) 




















Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 























Cost per  subsequent  year  following 
encephalopathy 
$3337 









Other direct costs (incurred 
directly in treating patients) 
Were the cost data derived from: 
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued). 
   
 
Indicate the source for individual cost values (if 
appropriate). 
 
Health-state   valuations/utilities 
(if study uses quality of life 
adjustments  to  outcomes) 





List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used. 
  
 












Indicate the source for individual cost values (if 
appropriate). 
 
Indirect costs (due to lost productivity, 
unpaid inputs to patient care) 
Were indirect costs included? 




If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation). 
 















Kanwal et  al.46 
are presented) 





































































Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original. 
 
• The authors used their previously published 
model (Kanwal and colleagues38) for cost- 
effectiveness analysis of treatment options in 
compensated hepatitis B to develop a current 
version for the subgroup of hepatitis B patients 
with cirrhosis.  
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?  
• To determine whether and under what 
circumstances the greater therapeutic benefits 
of newer antiviral agents, such as adefovir  
and entecavir, offset their greater cost versus 
lamivudine in the management of chronic 
hepatitis B cirrhosis (by extrapolating 
the outcomes of the clinical trial over the 
long term) (p. 2077), and also to permit 
comparisons between different interventions 
in medicine, using QALYs as a final outcome 
to allow for these comparisons to be made (p. 
2080).  
What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.  
• The base-case patient has chronic HBV 
infection, active viral replication and 
clinical cirrhosis (either compensated or 
decompensated) and no previous treatment 
for hepatitis B (see Figure 1, p. 2077, although 
it is a bit confusing, as there is no transition 
from chronic HBV with cirrhosis to either 
decompensated or compensated cirrhosis). 
• The following health states are used in the 
model: 
– compensated cirrhosis 
– decompensated cirrhosis 
– successful liver transplant 
– hepatocellular carcinoma 
– death. 
 
Extract transition probabilities for [natural history/ 
disease progression] model and show sources (or 

























































































































































































































































































What is the model time horizon? 
 
• Lifetime horizon. 
 
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes?  
• All costs and utility estimates were discounted 













Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation. 
 
• Not reported separately. 
 
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation. 
 
• Not reported separately. 
 
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost- 
effectiveness ratios)? If so, provide a summary of 
the results.  
• Adefovir monotherapy versus ‘doing nothing’ 
ICER  is  $19,731($14,342–$24,224). 
• Adefovir monotherapy versus entecavir 
monotherapy ICER is $25,626 ($19,637– 
$31,184). 
• ‘Adefovir salvage’ strategy is dominated. 
• ‘Entecavir salvage’ strategy is dominated. 
• Lamivudine monotherapy is dominated. 
 
Give results of any statistical analysis of the results 
of the evaluation.  
• A probabilistic (Monte Carlo) simulation 
under the assumption that all variables were 
triangular. 
• In distribution was performed to estimate the 
2.5 and 97.5 percentiles for estimated ICERs 
comparing alternative strategies. 
 
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].  
• Base-case probability estimates were varied 
within the plausible range reported in 
the literature or taken as an assumption. 
In particular, proportion of patients with 
decompensated hepatitis B at baseline was 
varied within 0–100% range. In the sensitivity 
analysis the medication prices from the Red 
Book were substituted for the acquisition costs 
of the Veteran’s Administration (VA) used as a 
proxy for the discounts achieved by large third- 
party payers. 
• A multivariable sensitivity analysis (‘tornado 
analysis’) was performed and the most 
influential variables were rank ordered. One- 
way sensitivity analyses on the most influential 
variables were subsequently performed to 
identify the threshold values at which the 
cost-effectiveness order between the strategies 
changes (Table 5, p. 2081).  
What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?  
• Parameter uncertainty was tested (ie. 
assumptions about costs, quality of life and 
disease  progression  rates).  
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?  
• The model outcomes were found to be sensitive 
to the following variables: 
– cost per month of adefovir 
– cost per month of entecavir 
– annual rate of progression from 
compensated to decompensated cirrhosis 
with lamivudine resistance 
– annual rate of progression from 
compensated to decompensated cirrhosis 
with entecavir (no resistance) 
– annual rate of progression from 
compensated to decompensated cirrhosis 
with adefovir (no resistance) 
– annual rate of progression from 
compensated to decompensated cirrhosis 
with adefovir resistance. 
 
Conclusions/implications 
Give a brief summary of the authors’ conclusions 
from their analysis. 
 
The most cost-effective strategy in the management 
of HBV cirrhosis remains unclear. We performed 









most cost-effective therapeutic approach under 
varying clinical and budgetary conditions. Our 
analysis has four key findings: 
 
1. We found that the newer generation of antiviral 
therapies in HBV, including adefovir and 
entecavir, are cost-effective in patients with 
HBV cirrhosis and should be preferred over 
lamivudine  monotherapy. 
2. Of the competing new-generation antiviral 
therapies, entecavir appears to be more 
effective yet more expensive than adefovir. 
Specifically, compared with adefovir, treating 
with upfront entecavir cost an additional 
$25,626 to gain one additional QALY – a 
value that falls well within the range of many 
commonly accepted medical interventions. 
3. Selecting between adefovir and entecavir is 
highly dependent on available budgets and 
‘willingness to pay’. For third-party payers 
willing to pay $50,000 per QALY gained for 
entecavir, most (> 60%) patients receiving 
entecavir will fall within the budget. In 
contrast, entecavir is generally not cost- 
effective for third-party payers willing to pay 
less than $25,000 per QALY gained. 
4. Our analysis found that initiating upfront 
lamivudine with crossover to adefovir or 
entecavir as ‘salvage’ on emergence of viral 
resistance is not cost-effective in HBV patients 
with cirrhosis. However, when faced with a 
patient who has already developed lamivudine 
resistance, using ‘adefovir salvage’ appears 
more effective and less expensive than 
‘entecavir salvage’ on the basis of current viral 
resistance  data.  
What are the implications of the evaluation for 
practice? 
 
1. Both adefovir and entecavir seem to be cost- 
effective in hepatitis B patients with cirrhosis. 
2. Of the new agents, entecavir appears more 
effective yet more expensive than adefovir. 
Selecting between these agents completely 
depends upon the available health care budget 
and willingness to pay. 
3. In patients with pre-existing lamivudine 
resistance, it appears more cost-effective 
to start with adefovir than with entecavir, 
as entecavir is associated with higher viral 
resistance than adefovir in the face of previous 
lamivudine  resistance. 
Critical appraisal 
 
• Whether indirect comparison is used 
appropriately, i.e. only the studies that used the 
‘no treatment’ arm as a common comparator 
were included in obtaining probability 
estimates. 
• Whether homogeneity was addressed in 
calculating probability estimates across the 
studies? 
• Whether assumptions about transitioning from 




Buti and colleagues (2006) Cost-effectiveness 
analysis of lamivudine and adefovir dipivoxil in the 





What are the stated objectives of the evaluation? 
 
• The objective of this study was to analyse the 
cost-effectiveness of long-term therapy (over 4 
years) with adefovir dipivoxil or lamivudine in 
patients with HBeAg-negative CHB in Spain. 
However, the study compared LAM with ADV as a 
salvage therapy treatment algorithm with algorithms 
based on ADV monotherapy. 
 
Study population 
What definition was used for mild chronic HBeAg- 
negative hepatitis B? 
 
• No definition is provided. However from 
Figure 1 (p. 411) it appears that the cohort 
consisted of CHB patients with HBeAg- 
negative disease variant and compensated liver 
function.  
What are the characteristics of the baseline cohort 
for the evaluation?  
• The clinical effectiveness data for 100 
patients with chronic HBeAg-negative CHB 
were obtained from the range of trials that 
enrolled patients with different demographic 





















Has a country setting been provided for the 
evaluation? What currency are costs expressed  
in and does the publication give the base year to 
which those costs relate? 
 





Interventions and comparators 
 









Describe  interventions/strategies. 
 
• Intervention/strategy 1: Lamivudine (100 mg 
daily) followed by adefovir dipivoxil (10 mg 
daily) as a salvage therapy for patients 
developing resistance to LAM treatment. 
• Intervention/strategy 2: Adefovir dipivoxil 
(10 mg daily). 
 
Analytical perspective 
What is the perspective adopted for the evaluation 
(health service, health and personal social services, 
third-party payer, societal (i.e. including costs 
borne by individuals and lost productivity)? 
 
• Spanish Public Health System. 
 
Study type 
Cost-effectiveness/cost–utility/cost–benefit     analysis? 
 
• Cost-effectiveness (incremental cost per 
additional patient with response). 
• Cost-effectiveness ratios were also calculated. 
 
Institutional setting 
Where is/are the intervention(s) being evaluated 
usually provided? 
 










Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 




previous  studies   See transition probabilities in Table 1 (pp. 412–13) 





Give the definition of treatment effect used in the 
evaluation.  
• ‘Response to treatment’ defined as a ‘decrease 
of serum HBV DNA to undetectable levels by 
polymerase chain reaction (PCR) assay’ (p. 
411). 
• In addition, ‘resistance to treatment’ as another 
outcome was used in the model. This was 
defined as as ‘reappearance of HBV DNA in 
serum due to the emergence of drug resistant 
HBV mutants’ (p. 411). 
• Although not stated anywhere, ‘progressing 
to decompensated liver disease’ is an implicit 
outcome that is applied only to patients who 
received no treatment owing to development of 
resistance to LAM and/or ADV. This outcome 
is not associated with a defined health state but 
is associated with additional costs (Table 2, p. 
414).  
Give the size of treatment effect used in the 
evaluation.  
• Not applicable. Outcomes are assessed in a 
dichotomous variable (yes/no). 
 
Include values used for subgroups (if applicable). 


















Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 




















List the direct intervention costs used in the 
evaluation – include resource estimates (and 
sources for these estimates, if appropriate) as well 
as sources for unit costs used. 
  











Pathology  investigation  Analyses   23.66  Not indicated 
Serology   43.73  SOIKOS database 2004 
‐fetoprotein   14.29  Not indicated 
Radiology  investigations  Ultrasound  scan   62.94  SOIKOS database 2004 










Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 














Were the methods for 
deriving these data 
adequately  described? 
(Give sources if using data 

























Indicate the source for individual cost values (if 
appropriate). 
The resources listed in the table above are 
combined in different quantities to obtain the 
aggregated cost of initial assessment, annual 
treatment with LAM, annual treatment with ADV 
and costs incurred when no intervention therapy is 
administered (no active treatment state). See Table 
3, p. 415. 
 
Other direct costs 
Were the cost data derived from: 
Describe how indirect costs were estimated (e.g. 
how days of lost productivity were estimated and 
how those days were valued). 
 
Indicate the source for individual cost values (if 
appropriate). 
 
Health-state   valuations/utilities 
(if study uses quality of life 
adjustments  to  outcomes) 








List the utility values used in the evaluation. 
 




If a model was used, describe the type of model 
used (e.g. Markov state-transition model, discrete 
event simulation). 
 
List the costs used in the evaluation – if quantities 
of resource use are reported separately from cost 
values, show sources for the resource estimates as 
well as sources for unit costs used. 
 
• Decompensation costs  172.50 applied only 
to a percentage of non-treated patients who 
develop decompensation because of cirrhosis 
(7.3%/year), hepatic encephalopathy (0.4%/ 
year), varicose haemorrhage (1.1%/year), 
ascites (2.5%/year), hepatocarcinoma (1.6%/ 
year); the source of these data is not provided. 
 
Indicate the source for individual cost values (if 
appropriate). 
 
Indirect costs (due to lost productivity, 
unpaid inputs to patient care) 
Were indirect costs included? 
 
• Indirect costs were not included. 
• A decision-analytic model. 
 
Was this a newly developed model or was it 
adapted from a previously reported model? If an 
adaptation, give the source of the original. 
 
• Appears to be a newly developed model. 
 
What was the purpose of the model (i.e. why was a 
model required in this evaluation)?  
• Not clearly indicated. Apparently, to help 
decision making in order to optimise resources 
by providing information regarding the costs 
associated with CHB and its progression 
towards more advanced stages, in particular 
with respect to treating HBeAg-negative 
patients with either LAM or AVD (summary of 









What are the main components of the model 
(e.g. health states within a Markov model)? Are 
sources for assumptions over model structure 
(e.g. allowable transitions) reported? List them if 
reported.  
During 4 years the patient may progress through 
the following stages: 
 
• Initial treatment with LAM 
– receiving LAM treatment with response 
– continuing LAM treatment with response 
– developing resistance to LAM treatment 
– receiving ADV treatment and continue with 
response (applies to LAM patients who 
developed resistance) 
– developing resistance and no response to 
ADV treatment 
– no active treatment 
 
Also implicitly assumed is the state of 
decompensated liver disease for the proportion of 
patients who receive no treatment. 
 
• Initial treatment with ADV 
– receiving ADV treatment and continue with 
response 
– developing resistance and no response to 
ADV treatment 
– no active treatment 
 
Also implicitly assumed is the state of 
decompensated liver disease for the proportion of 
patients who receive no treatment.  
Source of data: Expert opinion (not elaborated) 
and published clinical trials.  
Extract transition probabilities for [natural history/ 
disease progression] model and show sources (or 
refer to table in text). 
 
See Table 1, pp. 412–13 
 
Lamivudine as initial treatment 
What is the model time horizon? 
• 4 years. 
 
What, if any, discount rates have been applied in 
the model? Same rate for costs and outcomes? 
 
• A 3% discount rate was applied to costs in the 
base-case scenario. Sensitivity analysis used 
undiscounted costs. No discount rate was 
applied to the efficacy and response results as 




What measure(s) of benefit were reported in the 
evaluation? 
 
• Proportion of patients with response. 
 
Provide a summary of the clinical outcome/benefits 
estimated for each intervention/strategy assessed in 
the evaluation. 
 
• The proportion of patients with response in the 
lamivudine/adefovir arm at the end of year 4 
was 40.4%. 
• The proportion of patients with response in the 
adefovir dipivoxil arm at the end of year 4 was 
78.0%.  
Provide a summary of the costs estimated for each 
intervention/strategy assessed in the evaluation.  
• The estimated discounted total cost of 4 years 
of treatment with lamivudine as an initial 
therapy was  11,457. 
• The estimated discounted total cost of 4 years 
of treatment with adefovir dipivoxil as an initial 
therapy was  21,939.  
Synthesis of costs and benefits – are the costs 
and outcomes reported together (e.g. as cost- 
effectiveness ratios)? If so, provide a summary of 
the results.  
• CER (average cost per patient with successful 
therapy response at year 4) 
–  28,375 for the LAM/ADV arm 
–  28,132 for the ADV arm. 
• ICER (additional cost per patient with response 
in ADV monotherapy arm) 
–  27 872. 
 
Give results of any statistical analysis of the results 
of the evaluation. 
 
• No statistical analysis was performed. 
 
Was any sensitivity analysis performed? If yes, what 
type(s) [i.e. deterministic (one-way, two-way, etc.) or 
probabilistic].  
• Deterministic one-way sensitivity analysis was 












0.73  Tassopoulos NC,  et al.  Efficacy of  lamivudine 
in patients with hepatitis B e antigen‐ 
negative/hepatitis  B  virus  DNA‐positive 




































































What scenarios were tested in the sensitivity 
analysis? How do these relate to structural 
uncertainty (testing assumptions over model 
structure such as relationships between health 
states), methodological uncertainty (such as choices 
of discount rate or inclusion of indirect costs) or 
parameter uncertainty (assumptions over values of 
parameters in the model, such as costs, quality of 
life or disease progression rates)?  
• No sensitivity analysis in relation to structural 
uncertainty was performed. 
Methodological uncertainty was tested by not 
applying a discount rate to the costs (0%), which is 
consistent with the choice of not discounting the 
outcomes.  
The uncertainty in relation to the following 
resource use (but not the associated outcomes) was 
investigated:  
1. the dosage of lamivudine was increased from 









2. decompensation costs were set to be equal to 
zero 
3. the number of visits and laboratory tests 
investigating adefovir resistance was increased 
from two to four times per year to be equal to 
those treated with lamivudine 
4. the cost of the diagnostic test of HBV drug 
resistance was reduced by half.  
In addition a threshold analysis was undertaken by 
varying a single parameter of the model associated 
with clinical effectiveness – the lamivudine arm 
response rate at year 4.  
Give a summary of the results of the sensitivity 
analysis – did they differ substantially from the 
base-case analysis? If so, what were the suggested 
causes?  
• Considering  30,000 a threshold for 
a acceptability of a treatment strategy. 
• CER and ICER were sensitive (i.e. > threshold) 
to the number of consultations in the ADV 
monotherapy arm and to the size of LAM dose 
in the combination therapy arm. 
 
Conclusions/implications 
Give a brief summary of the authors’ conclusions 
from their analysis. 
 
• The results indicate that at the end of  
the 4-year treatment, suppression of viral 
replication is achieved in almost twice the 
number of HBeAg-negative patients treated 
with adefovir dipivoxil (monotherapy) 
compared with patients treated with 
lamivudine (as initial treatment followed by 
adefovir as a salvage therapy in patients who 
developed resistance to LAM). Although the 
costs associated with 4 years of therapy with 
adefovir dipivoxil are moreorless double those 
of lamivudine/(ADV), the cost per responding 
patient with adefovir dipivoxil is slightly 
less than with lamivudine/(ADV). This study 
demonstrates that long-term therapy, over 
a period of 4 years, with adefovir dipivoxil 
as first-line treatment for HBeAg-negative 
patients can be considered a cost-effective 
strategy (p. 417).  
What are the implications of the evaluation for 
practice?  
• Hard to tell considering that the model does 
not adequately describe the natural disease 
progression. 
• In addition to assumptions listed on pp. 411– 
412, many other assumptions were made in the 
model. 
• Meta-analysis of the clinical outcomes across 
the studies using the same end point does not 
seem to have been conducted (simple averages 
are used). This means that the likely sources of 
homogeneity (e.g. differences in the baseline 
characteristics of the patients enrolled in the 
trials that provided inputs in the model) were 
not analysed. 
• Indirect comparison of alternative therapies 
is used inappropriately. Clinical outcomes  
of LAM and ADV that were evaluated 
independently are used in two arms of the 
model. 
• To check whether conditional probabilities 
(i.e. observed in LAM-resistant patients) 





















































































































































































BSC (Veenstra BSC (Sullivan et  BSC (Kanwal et 
From To BSC (SHTAC) et al., 200744) al., 200746) al., 200538)a 
Dead of all causes  Life tables  Life tables  Life tables  Life  tables 
Decompensated  Decompensated  #  #  #  # 
cirrhosis (DC)  cirrhosis 
Liver transplant  0.03 (Bennett et  0.031 (0.01–0.1)  0.014 (0.10–0.3)  0.25 (0.0–0.4) (US
al., 199755)  (Bennett et al.,  (Taiwan Registry)  registry for organ 
1997 55)    sharing) 
Hepatocellular  0.025 (assumed  0.025 (0.02–  0.025 (0.02–0.05) 
carcinoma  the same as CC)  0.078) (assumed  (Crowley,  200042) 
the same as CC) 
Dead (excess  0.39 (Wong et al.,  0.39 (0.3–0.5)  0.39 (0.23–0.4)  0.19 (0.06–0.25) 
mortality risk)  19958)  (Wong et al.,  (Wong et al., 
19958)  19958) 
Dead of all causes  Life tables  Life tables  Life tables  – 
Hepatocellular  Liver transplant  0  0  0  0.3 (0.0–0.4) (US 
carcinoma          registry for organ 
sharing) 
Hepatocellular  #  #  #  # 
carcinoma 
Dead (excess  0.56 (Wong et al.,  0.56 (0.45–0.65)  0.37 (0.37–0.56)  0.433 (0.2–0.6) 
mortality risk)  19958)  (Wong et al.,  (Pwu and Chan, 
19958)  200249) 
Dead of all causes  Life tables  Life tables  Life tables  Life tables 
Liver transplant  Post‐liver  –  0.79  0.85 (Taiwan  Not used 
transplantation  Bureau of National 
state  Health  Insurance) 
Dead  0.21 (Bennett et  0.21 (Bennett et  0.15 (Taiwan 
al., 199755)  al., 199755)  Bureau of National 
Health Insurance) 
Post‐liver  Post‐liver  #  #  #  # 
transplantation  transplantation 
state  state 























PEG--2a  (Veenstra 
et al., 200744) PEG--2a (SHTAC) 
PEG--2a (Sullivan 
et al., 200746) 
‘Cured’ state (HBsAg)  HBsAg  Notused # Not used 
  HCC  0.00005 (Wong et al.,   
    19958)  
  Dead of all causes    Life tables   
Seroconversion  HBsAg  Notused 0.02 (de Franchis et  Not used 
(HBeAg)    al., 20033)  
  HBeAg  #  #  # 
  CHB 0.08 (0.3–0.13) (van 0.09 (as in IFN) (van  0.08 (0.3–0.13) (van
    Nunen et al., 200380) Nunen et al., 200380)  Nunen et al., 200380)
  CC 0.01 (0.5–2.0) 0.01 (Liaw et al., 0.01 (0.5–1.6)
    (Crowley,200042) 198879) (Crowley, 2000)42 
  
  HCC  Not used  0.001 (Wong et al., 
19958) 
Not used 
Dead of all causes  Life tables  Life tables  Life tables 
Chronic hepatitis B 
(CHB) 






























Not used  0.0035  (Shepherd  et 
al., 200612) 
Not used 


















































PEG--2a  (Veenstra 
et al., 200744) PEG--2a (SHTAC) 
PEG--2a (Sullivan 
et al., 200746) 
Decompensated Decompensated # # #
cirrhosis (DC)  cirrhosis     
  Livertransplant  0.031 (0.01–0.1) 0.03 (Bennett et al., 0.014 (0.10–0.3)
    (Bennett et al., 199755) 199755) (Taiwan Registry)
  Hepatocellular  0.025 (0.02–0.078) 0.025 (assumed the 0.025 (0.02–0.05)
carcinoma  (assumed the same as same as CC) (Crowley, 200042)
    CC)  
  Dead (excess mortality  0.39 (0.3–0.5) (Wong 0.39 (Wong et al., 0.39 (0.23–0.4) (Wong
  risk)  et al., 19958) 19958) et al., 19958) 
  Dead of all causes  Life tables  Life tables  Life tables 
Hepatocellular  Livertransplant  0 0 0 
carcinoma       
  Hepatocellular  # # # 
  carcinoma     
  Dead (excess mortality  0.56 (0.45–0.65) 0.56 (Wong et al., 0.37 (0.37–0.56) (Pwu
  risk)  (Wong et al., 19958) 19958) and Chan, 200249)
  Dead of all causes  Life tables  Life tables  Life tables 
Liver transplant  Post‐liver  0.79 – 0.85 (Taiwan Bureau
transplantation state  of National Health
      Insurance) 
  Dead 0.21 (Bennett et al., 0.21 (Bennett et al., 0.15 (Taiwan Bureau
199755) 199755) of National Health
      Insurance) 
Post‐liver  Post‐liver  # # # 
transplantation state  transplantation state     
  Dead 0.057 (Bennett et al., 0.057 (Bennett et al.,  0.015 (Taiwan Bureau
199755) 199755) of National Health



















HBsAg  Not used  #  Not used  Not used 
  HCC    0.00005 (Wong et 
al.,  19958) 
   
























  HCC  Not used  0.001 (Wong et 
al., 19958) 
Not used  Not used 











































































































LAM (Veenstra LAM (Sullivan et  LAM (Kanwal et 
From To et al., 200744) LAM (SHTAC) al., 200746) al., 200538)a 
Decompensated  0.05 (0.038–  0.018 additional  0.046 (0.023–  0.073 (0.035–0.1) 
cirrhosis  0.095) (Fattovich  effect  0.056) (Liaw et al., 
et al., 199185)  198987) 
Hepatocellular  0.025 (0.02–  0.025 (Wong et  0.028 (0.025–  0.034 (0.01–0.12) 
carcinoma  0.078) (Wong et  al., 19958)  0.05) (Liaw et al., 
al., 19958)    198987) 
Dead (excess  0.05 (0.03–0.065)  0.051 (Lau et al.,  0.051 (0.03–  0.049 (0.02–0.14) 
mortality risk)  (Lau et al., 199786)  199786)  0.065) (Lau et al., 
199786) 
Dead of all causes  Life tables  Life tables  Life tables  Life  tables 
Decompensated  Decompensated  #  #  #  # 
cirrhosis (DC)  cirrhosis 
Liver transplant  0.031 (0.01–0.1)  0.03 (Bennett et  0.014 (0.10–0.3)  0.25 (0.0–0.4) (US
(Bennett et al.,  al., 199755)  (Taiwan Registry)  registry for organ 
199755)      sharing) 
Hepatocellular  0.025 (0.02–  0.025 (assumed  0.025 (0.02–0.05) 
carcinoma  0.078) (assumed  the same as CC)  (Crowley,  200047) 
the same as CC) 
Dead (excess  0.39 (0.3–0.5)  0.195  0.39 (0.23–0.4)  0.19 (0.06–0.25) 
mortality risk)  (Wong et al.,  (Wong et al., 
19958)  19958) 
Dead of all causes  Life tables  Life tables  Life  tables 
Hepatocellular  Liver transplant  0  0  0  0.3 (0.0–0.4) (US 
carcinoma          registry for organ 
sharing) 
Hepatocellular  #  #  #  # 
carcinoma 
Dead (excess  0.56 (0.45–0.65)  0.56 (Wong et al.,  0.37 (0.37–0.56)  0.433 (0.2–0.6) 
mortality risk)  (Wong et al.,  19958)  (Pwu and Chan, 
19958)    200249) 
Dead of all causes  Life tables  Life tables  Life tables  Life tables 
Liver transplant  Post‐liver  0.79  –  0.85 (Taiwan  Not used 
transplantation  Bureau of National 
state  Health  Insurance) 
Dead  0.21 (Bennett et  0.021 additional  0.15 (Taiwan  – 
al., 199755)  effect  Bureau of National 
Health Insurance) 
Post‐liver  Post‐liver  #  #  #  # 
transplantation  transplantation 
state  state 



























  Mean SE Distribution Alpha Beta 
HBsAg/HBeAg  seroconverted  0.79  0.0102 Beta 558.6160  148.4929
CHB  0.69  0.0128  Beta  1416.7219  636.4982 
Compensated cirrhosis  0.68  0.0128  Beta  908.7808  427.6615 
Decompensated cirrhosis  0.35  0.0128  Beta  489.0519  908.2392 
Hepatocellular carcinoma  0.42  0.0153  Beta  628.4237  867.8233 
Liver  transplantation  0.57  0.0128  Beta  595.7397  449.4176 




Mean SE Distribution Alpha Beta 
HBsAg seroconverted  0.00  – –  –  – 
HBeAg seroconverted  289.65    57.93  Gamma  25.0000  11.5861 
CHB  583.58    116.72  Gamma  25.0000  23.3433 
Compensated cirrhosis  1341.42    231.17  Gamma  33.6726  39.8372 
Decompensated cirrhosis  10,750.25    1519.47  Gamma  50.0553  214.7674 
Hepatocellular carcinoma  9579.74    1909.83  Gamma  25.1606  380.7444 
Liver  transplantation  32,215.38    2884.79  Gamma  124.7094  258.3237 
  11,148.67    2547.97  Gamma  19.1451  582.3234 
Post‐liver  transplantation  1632.58    355.02  Gamma  21.1461  77.2046 
Standard error (SE) for HBeAg seroconversion and CHB costs assumed to be 20% of mean value.




Parameter Intervention Mean Distribution Parameters 
CHB to HBeAg  IFN‐‐2b  13.9% Beta n = 115; r = 16







Strategy Cost (£) Lifeexpectancy DiscountedQALYs gained) 
Best supportive care  16,532 12.46 8.43  
Conventional IFN‐ 20,799  13.19  8.96  8040 
Conventional IFN‐followed by 
lamivudine 
24,378  13.78  9.40  8172 
Conventional IFN‐followed by adefovir 
dipivoxil 
46,181  14.49  9.92  26,648 
Conventional  IFN‐ followed  by 
lamivudine with adefovir salvage 
50,737  14.75  10.11  37,419 
Pegylated IFN‐ 23,279  13.98  9.55  4251 
Pegylated  IFN‐ followed by  lamivudine  26,323  14.41  9.86  4239 
Pegylated IFN‐followed by adefovir 
dipivoxil 
44,132  14.92  10.24  –6432 
Pegylated  IFN‐ followed by  lamivudine 
with adefovir salvage 














Cost (£) Life expectancy Discounted QALYs 
ICER (£ per QALY 
gained) 
Best supportive care  10,676 18.12 13.48  
Conventional IFN‐ 14,632  18.43  13.80  12,215 
Conventional IFN‐followed by 
lamivudine 
17,232  18.87  14.22  6179 
Conventional IFN‐followed by adefovir 
dipivoxil 
29,163  19.46  14.76  15,186 
Conventional  IFN‐ followed  by 
lamivudine with adefovir salvage 
28,961  19.51  14.80  20,412 
Pegylated IFN‐ 17,972  18.56  13.94  24,873 
Pegylated  IFN‐ followed by  lamivudine  20,473  18.99  14.35  26,647 
Pegylated IFN‐followed by adefovir 
dipivoxil 
31,882  19.55  14.86  27,636 
Pegylated  IFN‐ followed by  lamivudine 
with adefovir salvage 
31,628  19.60  14.89  27,866 
 
Optimal treatment sequence, using the principle of 
extended dominance:  
IFN followed by LAM (ICER = £8804 per QALY 
gained relative to best supportive care), IFN 
followed by LAM followed by ADV (ICER = 
£20,413 relative to IFN followed by LAM) and 
PEG followed by LAM followed by ADV (ICER = 














Optimal treatment sequence, using the principle of 
extended dominance:  
PEG (ICER = £6056 per QALY gained relative to 
best supportive care), PEG followed by LAM (ICER 
= £9714 relative to PEG) and PEG followed by 
LAM followed by ADV (ICER = £41,560 relative to 
PEG followed by LAM). 
 
This contrasts with the ICERs for the optimal 
treatment sequences derived from the original 
model, which were: PEG (ICER = £2950 per  
QALY gained relative to best supportive care), PEG 
followed by LAM (ICER = £4955 relative to PEG) 
and PEG followed by LAM followed by ADV (ICER 
= £18,039 relative to PEG followed by LAM). 
As with the majority of the analyses reported in 
this update, the scale of difference in the ICERs 
(particularly that for the sequence of PEG followed 
by LAM followed by ADV) is largely accounted 
for by the change in discounting practice. Using 
the same discount rates as in our previous report 
(6% for costs and 1.5% for outcomes), the ICERs 
for these sequences (which remain the optimal 
sequences) are: PEG (ICER = £3914 per QALY 
gained relative to best supportive care), PEG 
followed by LAM (ICER = £5715 relative to PEG) 
and PEG followed by LAM followed by ADV (ICER 
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